



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, A61K 31/70, 35/12, 38/13, C07K 16/18, G01N 33/574, C12Q 1/68		A2	(11) International Publication Number: WO 00/20587
			(43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/22873		(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).	
(22) International Filing Date: 4 October 1999 (04.10.99)		(81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 09/166,300 5 October 1998 (05.10.98) US 09/166,350 5 October 1998 (05.10.98) US			
(71) Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(72) Inventors: OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP). GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB). TURECI, Ozlem; Innere Medizin 1, D-66421 Homburg/Saar (DE). SAHIN, Ugar; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFREUNDSCHUH, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US). STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US). CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US). OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).			
(54) Title: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR			
(57) Abstract			
<p>Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, <i>inter alia</i>, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

Field of the Invention

The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with a variety of cancers. The invention also relates to agents which bind the nucleic acids or polypeptides. The nucleic acid molecules, polypeptides coded for by such molecules and peptides derived therefrom, as well as related antibodies and cytolytic T lymphocytes, are useful, *inter alia*, in diagnostic and therapeutic contexts.

Background of the Invention

The mechanism by which T cells recognize foreign materials has been implicated in cancer. A number of cytolytic T lymphocyte (CTL) clones directed against autologous melanoma antigens, testicular antigens, and melanocyte differentiation antigens have been described. In many instances, the antigens recognized by these clones have been characterized.

The use of autologous CTLs for identifying tumor antigens requires that the target cells which express the antigens can be cultured *in vitro* and that stable lines of autologous CTL clones which recognize the antigen-expressing cells can be isolated and propagated. While this approach has worked well for melanoma antigens, other tumor types, such as epithelial cancers including breast and colon cancer, have proved refractory to the approach.

More recently another approach to the problem has been described by Sahin et al. (*Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995). According to this approach, autologous antisera are used to identify immunogenic protein antigens expressed in cancer cells by screening expression libraries constructed from tumor cell cDNA. Antigen-encoding clones so identified have been found to have elicited a high-titer humoral immune response in the patients from which the antisera were obtained. Such a high-titer IgG response implies helper T cell recognition of the detected antigen. These tumor antigens can then be screened for the presence of MHC/HLA class I and class II motifs and reactivity with CTLs.

Presently there is a need for additional cancer antigens for development of therapeutics and diagnosis applicable to a greater number of cancer patients having various cancers.

Summary of the Invention

Autologous antibody screening has now been applied to renal cancer using antisera from cancer patients. Numerous cancer associated antigens have been identified. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and CTLs which recognize the proteins and peptides. Fragments including functional fragments and variants of the foregoing also are provided. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Prior to the present invention, only a handful of cancer associated genes had been identified in the past 20 years. The invention involves the surprising discovery of several genes, some previously known and some previously unknown, which are expressed in individuals who have cancer. These individuals all have serum antibodies against the proteins (or fragments thereof) encoded by these genes. Thus, abnormally expressed genes are recognized by the host's immune system and therefore can form a basis for diagnosis, monitoring and therapy.

The invention involves the use of a single material, a plurality of different materials and even large panels and combinations of materials. For example, a single gene, a single protein encoded by a gene, a single functional fragment thereof, a single antibody thereto, etc. can be used in methods and products of the invention. Likewise, pairs, groups and even panels of these materials and optionally other cancer associated antigen genes and/or gene products can be used for diagnosis, monitoring and therapy. The pairs, groups or panels can involve 2, 3, 4, 5 or more genes, gene products, fragments thereof or agents that recognize such materials. A plurality of such materials are not only useful in monitoring, typing, characterizing and diagnosing cells abnormally expressing such genes, but a plurality of such materials can be used therapeutically. An example of the use of a plurality of such materials for the prevention, delay of onset, amelioration, etc. of cancer cells, which express or will express such genes prophylactically or acutely. Any and all combinations of the genes, gene products, and materials which recognize the genes and gene products can be tested and identified for use according to the invention. It would be far too lengthy to recite all such combinations; those skilled in the art, particularly in view of the teaching contained herein,

will readily be able to determine which combinations are most appropriate for which circumstances.

As will be clear from the following discussion, the invention has *in vivo* and *in vitro* uses, including for therapeutic, diagnostic, monitoring and research purposes. One aspect of the invention is the ability to fingerprint a cell expressing a number of the genes identified according to the invention by, for example, quantifying the expression of such gene products. Such fingerprints will be characteristic, for example, of the stage of the cancer, the type of the cancer, or even the effect in animal models of a therapy on a cancer. Cells also can be screened to determine whether such cells abnormally express the genes identified according to the invention.

The invention, in one aspect, is a method of diagnosing a disorder characterized by expression of a cancer associated antigen precursor coded for by a nucleic acid molecule. The method involves the steps of contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an MHC, preferably an HLA, molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and determining the interaction between the agent and the nucleic acid molecule, the expression product or fragment of the expression product as a determination of the disorder.

In one embodiment the agent is selected from the group consisting of (a) a nucleic acid molecule comprising NA Group 1 nucleic acid molecules or a fragment thereof, (b) a nucleic acid molecule comprising NA Group 3 nucleic acid molecules or a fragment thereof, (c) a nucleic acid molecule comprising NA Group 5 nucleic acid molecules or a fragment thereof, (d) an antibody that binds to an expression product, or a fragment thereof, of NA group 1 nucleic acids, (e) an antibody that binds to an expression product, or a fragment thereof, of NA group 3 nucleic acids, (f) an antibody that binds to an expression product, or a fragment thereof, of NA group 5 nucleic acids, (g) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 1 nucleic acid, (h) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA group 3 nucleic acid, and (i) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 5 nucleic acid.

The disorder may be characterized by expression of a plurality of cancer associated

antigen precursors. Thus the methods of diagnosis may include use of a plurality of agents, each of which is specific for a different human cancer associated antigen precursor (including at least one of the cancer associated antigen precursors disclosed herein), and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 such agents.

In each of the above embodiments the agent may be specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.

In another aspect the invention is a method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method involves the steps of monitoring a sample, from a subject who has or is suspected of having the condition, for a parameter selected from the group consisting of (i) the protein, (ii) a peptide derived from the protein, (iii) an antibody which selectively binds the protein or peptide, and (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, as a determination of regression, progression or onset of said condition. In one embodiment the sample is a body fluid, a body effusion or a tissue.

In another embodiment the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an antibody which selectively binds the protein of (i), or the peptide of (ii), (b) a protein or peptide which binds the antibody of (iii), and (c) a cell which presents the complex of the peptide and MHC molecule of (iv). In a preferred embodiment the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme. The sample in a preferred embodiment is assayed for the peptide.

According to another embodiment the nucleic acid molecule is one of the following: a NA Group 3 molecule or a NA Group 5 molecule. In yet another embodiment the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins. In certain embodiments the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of

proteins.

The invention in another aspect is a pharmaceutical preparation for a human subject. The pharmaceutical preparation includes an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule which comprises a NA Group 1 molecule. In one embodiment the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

The agent in one embodiment comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least two, at least three, at least four or at least 5 different such agents.

In certain embodiments, the agent comprises a plurality of agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

In another embodiment the agent is selected from the group consisting of (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof, (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof, (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and (4) isolated complexes of the polypeptide, or functional variants thereof, and an HLA molecule.

The agent may be a cell expressing an isolated polypeptide. In one embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof. In another embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide. The cell can express one or both of the polypeptide and HLA molecule recombinantly. In preferred embodiments the cell is nonproliferative. In other preferred embodiments, the isolated polypeptide is or includes a kinectin polypeptide. In yet another embodiment the agent is at least two, at least three, at least four or at least five different polypeptides, each representing a different human cancer associated antigen or functional variant thereof.

The agent in one embodiment is a PP Group 2 polypeptide. In other embodiments the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.

In an embodiment each of the pharmaceutical preparations described herein also includes an adjuvant.

According to another aspect the invention, a composition is provided which includes an isolated agent that binds selectively a PP Group 1 polypeptide. In separate embodiments the agent binds selectively to a polypeptide selected from the following: a PP Group 2 polypeptide, a PP Group 3 polypeptide, a PP Group 4 polypeptide, and a PP Group 5 polypeptide. In other embodiments, the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides. In each of the above described embodiments the agent may be an antibody. In a preferred embodiment, at least one of polypeptides is kinectin or a fragment thereof.

In another aspect the invention is a composition of matter composed of a conjugate of the agent of the above-described compositions of the invention and a therapeutic or diagnostic agent. Preferably the conjugate is of the agent and a therapeutic or diagnostic that is an antineoplastic.

The invention in another aspect is a pharmaceutical composition which includes an isolated nucleic acid molecule selected from the group consisting of: (1) NA Group 1 molecules, and (2) NA Group 2 molecules, and a pharmaceutically acceptable carrier. In one embodiment the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule. In another embodiment the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different cancer associated antigen. In preferred embodiments, at least one of the polypeptides is a kinectin polypeptide.

Preferably the pharmaceutical composition also includes an expression vector with a promoter operably linked to the isolated nucleic acid molecule. In another embodiment the pharmaceutical composition also includes a host cell recombinantly expressing the isolated nucleic acid molecule.

According to another aspect of the invention a pharmaceutical composition is provided. The pharmaceutical composition includes an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and a pharmaceutically acceptable carrier. In one embodiment the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.

In another embodiment the isolated polypeptide comprises at least two different polypeptides, each comprising a different cancer associated antigen at least one of which is encoded by a NA group 1 molecule as disclosed herein. In separate embodiments the isolated polypeptides are selected from the following: PP Group 3 polypeptides or HLA binding fragments thereof and PP Group 5 polypeptides or HLA binding fragments thereof.

In an embodiment each of the pharmaceutical compositions described herein also includes an adjuvant.

Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 3 molecule. Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 4 molecule.

The invention in another aspect is an isolated nucleic acid molecule selected from the group consisting of (a) a fragment of a nucleic acid selected from the group of nucleic acid molecules consisting of SEQ ID Nos numbered below and comprising all nucleic acid sequences among SEQ ID NOs 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor, (b) complements of (a), provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of (1) sequences having the GenBank accession numbers of Table 1, (2) complements of (1), and (3) fragments of (1) and (2).

In one embodiment the sequence of contiguous nucleotides is selected from the group consisting of: (1) at least two contiguous nucleotides nonidentical to the sequences in Table 1, (2) at least three contiguous nucleotides nonidentical to the sequences in Table 1, (3) at least four contiguous nucleotides nonidentical to the sequences in Table 1, (4) at least five contiguous nucleotides nonidentical to the sequences in Table 1, (5) at least six contiguous nucleotides nonidentical to the sequences in Table 1, or (6) at least seven contiguous nucleotides nonidentical to the sequences in Table 1.

In another embodiment the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

In yet another embodiment the molecule encodes a polypeptide which, or a fragment

of which, binds a human HLA receptor or a human antibody.

Another aspect of the invention is an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter.

According to one aspect the invention is an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or Group 2 molecule. In another aspect the invention is an expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an MHC, preferably HLA, molecule.

In yet another aspect the invention is a host cell transformed or transfected with an expression vector of the invention described above.

In another aspect the invention is a host cell transformed or transfected with an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter, or an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or 2 molecule and further comprising a nucleic acid encoding HLA.

According to another aspect of the invention an isolated polypeptide encoded by the isolated nucleic acid molecules the invention, described above, is provided. These include PP Group 1-5 polypeptides. The invention also includes a fragment of the polypeptide which is immunogenic. In one embodiment the fragment, or a portion of the fragment, binds HLA or a human antibody. In still another aspect the invention provides as isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.

The invention includes in another aspect an isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule. In one embodiment the fragment is part of a complex with HLA. In another embodiment the fragment is between 8 and 12 amino acids in length. In another embodiment the invention includes an isolated polypeptide comprising a fragment of the polypeptide of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

According to another aspect of the invention a kit for detecting the presence of the expression of a cancer associated antigen precursor is provided. The kit includes a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence

of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping. In one embodiment the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule. Preferably, the pair amplifies a human NA Group 3 molecule.

According to another aspect of the invention a method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor is provided. The method includes the step of administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules, (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules, (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.

In one embodiment the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least 2, at least 3, at least 4, or at least 5 such agents. In a preferred embodiment, at least one of the human cancer associated antigens is kinectin or a fragment thereof.

In another embodiment the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP group 5 polypeptides.

In yet another embodiment the disorder is cancer.

According to another aspect the invention is a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) removing an immunoreactive cell containing sample from the subject, (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor, (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated

nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, NA Group 5.

In one embodiment the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen. In another embodiment the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

The invention includes in another aspect a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c); (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and; (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition. Preferably, the antigen is a human antigen and the subject is a human. In certain preferred embodiments the nucleic acid molecule is a kinectin nucleic acid molecule.

In one embodiment the method also includes the step of (a) identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified in (a) and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

In another embodiment the method also includes the step of treating the host cells to render them non-proliferative.

In yet another embodiment the immune response comprises a B-cell response or a T cell response. Preferably the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

In another embodiment the nucleic acid molecule is a NA Group 3 molecule.

Another aspect of the invention is a method for treating or diagnosing or monitoring a

subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method includes the step of administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

In one embodiment the antibody is a monoclonal antibody. Preferably the monoclonal antibody is a chimeric antibody or a humanized antibody.

In another aspect the invention is a method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method involves the step of administering to a subject at least one of the pharmaceutical compositions of the invention described above in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject. In one embodiment the condition is cancer. In another embodiment the method includes the step of first identifying that the subject expresses in a tissue abnormal amounts of the protein.

The invention in another aspect is a method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the steps of (i) identifying cells from the subject which express abnormal amounts of the protein; (ii) isolating a sample of the cells; (iii) cultivating the cells, and (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

In one embodiment the method includes the step of rendering the cells non-proliferative, prior to introducing them to the subject.

In another aspect the invention is a method for treating a pathological cell condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the step of administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

In one embodiment the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof. In another embodiment the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein. In yet another important embodiment the nucleic acid molecule is a NA Group 3 nucleic acid

molecule. In other preferred embodiments, the nucleic acid molecule is a kinectin nucleic acid molecule.

The invention includes in another aspect a composition of matter useful in stimulating an immune response to a plurality of proteins encoded by nucleic acid molecules that are NA Group 1 molecules. The composition is a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein. In preferred embodiments, at least one of the proteins is kinectin.

In one embodiment at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto. In another embodiment the composition of matter includes an adjuvant. In another embodiment the adjuvant is a saponin, GM-CSF, or an interleukin. In still another embodiment, the compositions also includes at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

According to another aspect the invention is an isolated antibody which selectively binds to a complex of: (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and (ii) an MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

In one embodiment the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof.

The invention also involves the use of the genes, gene products, fragments thereof, agents which bind thereto, and so on in the preparation of medicaments. A particular medicament is for treating cancer and a more particular medicament is for treating breast cancer, lung cancer, renal cancer, colon cancer, prostate cancer or gastric cancer.

Detailed Description of the Invention

In the above summary and in the ensuing description, lists of sequences are provided. The lists are meant to embrace each single sequence separately, two or more sequences together where they form a part of the same gene, any combination of two or more sequences which relate to different genes, including and up to the total number on the list, as if each and every combination were separately and specifically enumerated. Likewise, when mentioning

fragment size, it is intended that a range embrace the smallest fragment mentioned to the full-length of the sequence (less one nucleotide or amino acid so that it is a fragment), each and every fragment length intended as if specifically enumerated. Thus, if a fragment could be between 10 and 15 in length, it is explicitly meant to mean 10, 11, 12, 13, 14, or 15 in length.

The summary and the claims mention antigen precursors and antigens. As used in the summary and in the claims, a precursor is substantially the full-length protein encoded by the coding region of the isolated DNA and the antigen is a peptide which complexes with MHC, preferably HLA, and which participates in the immune response as part of that complex. Such antigens are typically 9 amino acids long, although this may vary slightly.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human cancer antigens and human subjects are preferred.

The present invention in one aspect involves the cloning of cDNAs encoding human cancer associated antigen precursors using autologous antisera of subjects having renal cancer. The sequences of the clones representing genes identified according to the methods described herein are presented in the attached Sequence Listing. Of the foregoing, it can be seen that some of the clones are considered completely novel as no nucleotide or amino acid homologies to coding regions were found in the databases searched. Other clones are novel but have some homology to sequences deposited in databases (mainly EST sequences). Nevertheless, the entire gene sequence was not previously known. In some cases no function was suspected and in other cases, even if a function was suspected, it was not known that the gene was associated with cancer. In all cases, it was not known or suspected that the gene encoded a cancer antigen which reacted with antibody from autologous sera. Analysis of the clone sequences by comparison to nucleic acid and protein databases determined that still other of the clones surprisingly are closely related to other previously-cloned genes. The sequences of these related genes is also presented in the Sequence Listing. The nature of the foregoing genes as encoding antigens recognized by the immune systems of cancer patients is, of course, unexpected.

The invention thus involves in one aspect cancer associated antigen polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

Homologs and alleles of the cancer associated antigen nucleic acids of the invention

can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for cancer associated antigen precursors. Because this application contains so many sequences, the following chart is provided to identify the various groups of sequences discussed in the claims and in the summary:

Nucleic Acid Sequences

NA Group 1. (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences among SEQ ID NOs: 1-11 and 22-46 and which code for a cancer associated antigen precursor,

(b) deletions, additions and substitutions which code for a respective cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 2. Fragments of NA Group 1, which codes for a polypeptide which, or a portion of which, binds an MHC molecule to form a complex recognized by a an autologous antibody or lymphocyte.

NA Group 3. The subset of NA Group 1 where the nucleotide sequence is selected from the group consisting of:

(a) previously unknown human nucleic acids coding for a human cancer associated antigen precursor (i.e. nucleic acid sequences among SEQ ID NOs: 1-11),

(b) deletions, additions and substitutions which code for a respective human cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 4. Fragments of NA Group 3, which code for a polypeptide which, or a portion of which, binds to an MHC molecule to form a complex recognized by an autologous antibody or lymphocyte.

NA Group 5. A subset of NA Group 1, comprising human cancer associated antigens that react with allogeneic cancer antisera.

Polypeptide Sequences

- PP Group 1. Polypeptides encoded by NA Group 1.
- PP Group 2. Polypeptides encoded by NA Group 2.
- PP Group 3. Polypeptides encoded by NA Group 3.
- PP Group 4. Polypeptides encoded by NA Group 4.
- PP Group 5. Polypeptides encoded by NA Group 5.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane upon which the DNA is transferred is washed, for example, in 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of cancer associated antigen nucleic acids of the invention (e.g., by using lower stringency conditions). The skilled artisan also is familiar with the methodology for screening

cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 75% nucleotide identity and/or at least 90% amino acid identity to the sequences of cancer associated antigen nucleic acid and polypeptides, respectively, in some instances will share at least 90% nucleotide identity and/or at least 95% amino acid identity and in still other instances will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>, using default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for cancer associated antigen genes, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. In screening for the expression of cancer associated antigen nucleic acids, Northern blot hybridizations using the foregoing conditions (see also the Examples) can be performed on samples taken from breast cancer patients or subjects suspected of having a condition characterized by expression of breast cancer associated antigen genes. Amplification protocols such as polymerase chain reaction using primers which hybridize to the sequences presented also can be used for detection of the cancer associated antigen genes or expression thereof.

The renal cancer associated genes correspond to SEQ ID NOS. 1-11 and 22-35. Kinectin cancer associated sequences correspond to SEQ ID Nos:36-46. The preferred cancer associated antigens for the methods of diagnosis disclosed herein are those which were found to react with allogeneic cancer antisera (i.e. NA Group 5). Encoded polypeptides (e.g., proteins), peptides and antisera thereto are also preferred for diagnosis.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the

purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating breast cancer associated antigen polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as, antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of peptides by MHC class I and class II molecules, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of

modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated unique fragments of cancer associated antigen nucleic acid sequences or complements thereof. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the cancer associated antigen nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers listed in Table 1 or other previously published sequences as of the filing date of the priority documents for sequences listed in a respective priority document or the filing date of this application for sequences listed for the first time in this application which overlap the sequences of the invention.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the cancer associated antigen polypeptides,

useful, for example, in the preparation of antibodies, and in immunoassays. Unique fragments further can be used as antisense molecules to inhibit the expression of cancer associated antigen nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of cancer associated antigen sequences and complements thereof will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 or more bases long, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide (provided the sequence is unique as described above).

Virtually any segment of the polypeptide coding region of novel cancer associated antigen nucleic acids, or complements thereof, that is 18 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

Especially preferred include nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from a polypeptide having an amino acid sequence encoded by one of the nucleic acid disclosed herein, and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes, can be combined with peptides from one or more other cancer associated antigens (e.g. by preparation of hybrid

nucleic acids or polypeptides) to form "polytopes". The two or more peptides (or nucleic acids encoding the peptides) can be selected from those described herein, or they can include one or more peptides of previously known cancer associated antigens. Exemplary cancer associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-B2, MAGE-B3, MAGE-B4, tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1 MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40) SSX-4, SSX-5, SCP-1 and CT-7. See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art (for example, see Coulie, *Stem Cells* 13:393-403, 1995), and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more peptides and one or more of the foregoing cancer associated peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs.

and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytope can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytope also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytope can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from cancer associated nucleic acids, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for a cancer associated antigen precursor and the HLA molecule which presents it are contained on separate expression vectors, the expression vectors can be cotransfected. The cancer associated antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a cancer associated antigen derived from precursor molecules. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for cancer associated antigen precursor can be used in host cells which do not express a HLA molecule which presents a cancer associated antigen. Further, cell-free transcription systems may be used in lieu of cells.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a cancer associated antigen polypeptide, to reduce the expression of cancer associated antigens. This is desirable in virtually any medical condition wherein a reduction of expression of cancer associated antigens is

desirable, e.g., in the treatment of cancer. This is also useful for *in vitro* or *in vivo* testing of the effects of a reduction of expression of one or more cancer associated antigens.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding breast cancer associated antigen, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although the

listed sequences are cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a cancer associated antigen. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding cancer associated antigens. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as

arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding breast cancer associated antigen polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not

been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds; genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al.,

Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a breast cancer associated antigen polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr Virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant for the expression of an antigen is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996). Additional vectors for delivery of nucleic acid are provided below.

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of a vector and one or more of the previously discussed cancer associated antigen nucleic acid molecules. Other components may be added, as desired, as long as the previously mentioned nucleic acid molecules, which are required, are included. The invention also includes kits for amplification of a cancer associated antigen nucleic acid, including at least one pair of amplification primers which hybridize to a cancer associated antigen nucleic acid. The primers preferably are 12-32 nucleotides in length and are non-overlapping to prevent formation of "primer-dimers". One of the primers will hybridize to one strand of the cancer associated antigen nucleic acid and the second primer will hybridize to the complementary strand of the cancer associated antigen nucleic acid, in an arrangement which permits

amplification of the cancer associated antigen nucleic acid. Selection of appropriate primer pairs is standard in the art. For example, the selection can be made with assistance of a computer program designed for such a purpose, optionally followed by testing the primers for amplification specificity and efficiency.

The invention also permits the construction of cancer associated antigen gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention also provides isolated polypeptides (including whole proteins and partial proteins) encoded by the foregoing cancer associated antigen nucleic acids. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay or diagnostic assay or as therapeutics. Cancer associated antigen polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a cancer associated antigen polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of cancer associated antigens will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 or 12 or more amino acids including each integer up to the full length).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an

immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the cancer associated antigen polypeptides described above. As used herein, a "variant" of a cancer associated antigen polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a cancer associated antigen polypeptide. Modifications which create a cancer associated antigen variant can be made to a cancer associated antigen polypeptide 1) to reduce or eliminate an activity of a cancer associated antigen polypeptide; 2) to enhance a property of a cancer associated antigen polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a cancer associated antigen polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. Modifications to a cancer associated antigen polypeptide are typically made to the nucleic acid which encodes the cancer associated antigen polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the cancer associated antigen amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant cancer associated antigen polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a cancer associated antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

In general, variants include cancer associated antigen polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide

linkages. Similarly, certain amino acids can be changed to enhance expression of a breast cancer associated antigen polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a cancer associated antigen polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant cancer associated antigen polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a cancer associated antigen gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of cancer associated antigen polypeptides can be tested by cloning the gene encoding the variant cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. For example, the variant cancer associated antigen polypeptide can be tested for reaction with autologous or allogeneic sera as disclosed in the Examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in cancer associated antigen polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e, the variants retain the functional capabilities of the cancer associated antigen polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size

characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the cancer associated antigen polypeptides include conservative amino acid substitutions of in the amino acid sequences of proteins disclosed herein. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a cancer associated antigen polypeptide is presented by an MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule. For example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Conservative amino-acid substitutions in the amino acid sequence of cancer associated antigen polypeptides to produce functionally equivalent variants of cancer associated antigen polypeptides typically are made by alteration of a nucleic acid encoding a cancer associated antigen polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a cancer associated antigen polypeptide. Where amino acid substitutions are made to a small unique

fragment of a cancer associated antigen polypeptide, such as an antigenic epitope recognized by autologous or allogeneic sera or cytolytic T lymphocytes, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of cancer associated antigen polypeptides can be tested by cloning the gene encoding the altered cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to antisera recognizing associated antigens.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the cancer associated antigen protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated cancer associated antigen molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating cancer associated antigen polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The isolation and identification of cancer associated antigen genes also makes it possible for the artisan to diagnose a disorder characterized by expression of cancer associated antigens. These methods involve determining expression of one or more cancer associated antigen nucleic acids, and/or encoded cancer associated antigen polypeptides and/or peptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter situation, such determinations can be carried out by screening patient antisera for recognition of the polypeptide.

The invention also makes it possible isolate proteins which bind to cancer associated antigens as disclosed herein, including antibodies and cellular binding partners of the cancer

associated antigens. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from cancer associated antigen polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of renal cancer associated antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the cancer associated antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The invention also involves agents such as polypeptides which bind to cancer associated antigen polypeptides. Such binding agents can be used, for example, in screening assays to detect the presence or absence of cancer associated antigen polypeptides and complexes of cancer associated antigen polypeptides and their binding partners and in purification protocols to isolated cancer associated antigen polypeptides and complexes of

cancer associated antigen polypeptides and their binding partners. Such agents also can be used to inhibit the native activity of the cancer associated antigen polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to cancer associated antigen polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies

while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for $F(ab')_2$, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric $F(ab')_2$ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to cancer associated antigen polypeptides, and complexes of both cancer associated antigen polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the cancer associated antigen

polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the cancer associated antigen polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the cancer associated antigen polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the cancer associated antigen polypeptides. Thus, the cancer associated antigen polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the cancer associated antigen polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of cancer associated antigen and for other purposes that will be apparent to those of ordinary skill in the art.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express cancer associated antigens or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, nuclides for nuclear magnetic resonance such as fluorine and gadolinium. Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art. As used herein, "therapeutically useful agents" include any therapeutic molecule which desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon- α , lomustine, mercaptoperazine,

methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

In the foregoing methods, antibodies prepared according to the invention also preferably are specific for the renal cancer associated antigen/MHC complexes described herein.

When "disorder" is used herein, it refers to any pathological condition where the cancer associated antigens are expressed. An example of such a disorder is cancer, breast, colon, gastric, renal, prostate and lung cancers as particular examples.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation. Thus immunoreactive cells include CD34⁺ hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a cancer associated antigen, the immunoreactive cell is contacted with a cell which expresses a cancer associated antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of antigen presenting cells, such as breast cancer cells which present one or more cancer associated antigens. One such approach is the administration of autologous CTLs specific to a cancer associated antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell

differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex of their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dunbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of β_2 -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J. Immunol.* 21: 1403-1410, 1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex (e.g., dendritic cells) are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/cancer associated antigen complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in

this case a cancer associated antigen sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a cancer associated antigen is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex (i.e. the antigenic peptide and the presenting HLA molecule). Chen et al. (*Proc. Natl. Acad. Sci. USA* 88: 110-114, 1991) exemplifies this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a cancer associated antigen polypeptide or peptide may be operably linked to promoter and enhancer sequences which direct expression of the cancer associated antigen polypeptide or peptide in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding cancer associated antigen, as described elsewhere herein. Nucleic acids encoding a cancer associated antigen also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, pox virus, herpes simplex virus, retrovirus or adenovirus, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate.

A similar effect can be achieved by combining the cancer associated antigen or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into antigen presenting cells *in vivo*. The cancer associated antigen polypeptide is processed to yield the peptide partner of the HLA molecule while a cancer associated antigen peptide may be presented without the need for further processing. Generally, subjects can receive an

intradermal injection of an effective amount of the cancer associated antigen. Initial doses can be followed by booster doses, following immunization protocols standard in the art. Preferred cancer associated antigens include those found to react with allogeneic cancer antisera, shown in the examples below.

The invention involves the use of various materials disclosed herein to "immunize" subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against cancer using a cancer associated antigen nucleic acid. For example, human cancer cells can be introduced into a mouse to create a tumor, and one or more cancer associated antigen nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the cancer associated antigen nucleic acid immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the administration of one or more cancer associated antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.

As part of the immunization compositions, one or more cancer associated antigens or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham), a congener obtained after purification

and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQS21, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQS21/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 μ g to about 100 μ g. Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, *Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (see, e.g., *Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng P., et al. *Proc. Natl. Acad. Sci. USA* 95 (11):6284-6289 (1998)).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12

costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol.*, 154:5637-5648 (1995)). Tumor cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (*J. Immunol.*, 19:1-8 (1986)). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim J., et al. *Nat Biotechnol.*, 15:7:641-646 (1997)) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.*, 4:7:726-735 (1997)). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells *in vitro* and *in vivo* could also be considered. Similarly, the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al., *Nature* 397:263-266, 1999).

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642 (1997), Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)). LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature*, 393:474 (1998), Bennett et al., *Nature*, 393:478 (1998), Schoenberger et al., *Nature*, 393:480 (1998)). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR)

and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor antigens which are normally encountered outside of a inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known TRA precursors.

A cancer associated antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated cancer associated antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner which can interact with cancer associated antigen polypeptides is present in the solution, then it will bind to the substrate-bound cancer associated antigen polypeptide. The binding partner then may be isolated.

It will also be recognized that the invention embraces the use of the cancer associated antigen cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., dendritic cells, B cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also contemplates delivery of nucleic acids, polypeptides or peptides for vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a breast cancer associated antigen, and reintroducing the engineered cell into the subject. One example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a

functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a cancer associated antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 7:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venezuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol.* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus

infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA.

Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO₄ precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a

ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a cancer associated antigen, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

When administered, the therapeutic compositions of the present invention can be administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a cancer associated antigen composition that alone, or together with further doses, produces the desired response, e.g. increases an immune response to the cancer associated antigen. In the case of treating a particular disease or condition

characterized by expression of one or more cancer associated antigens, such as renal cancer, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of cancer associated antigen or nucleic acid encoding cancer associated antigen for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the immune response following administration of the cancer associated antigen composition via a reporter system by measuring downstream effects such as gene expression, or by measuring the physiological effects of the cancer associated antigen composition, such as regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of cancer associated antigen compositions (e.g., polypeptide, peptide, antibody, cell or nucleic acid) administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that

patient tolerance permits.

In general, for treatments for eliciting or increasing an immune response, doses of cancer associated antigen are formulated and administered in doses between 1 ng and 1 mg, and preferably between 10 ng and 100 μ g, according to any standard procedure in the art. Where nucleic acids encoding cancer associated antigen or variants thereof are employed, doses of between 1 ng and 0.1 mg generally will be formulated and administered according to standard procedures. Other protocols for the administration of cancer associated antigen compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumoral) and the like vary from the foregoing. Administration of cancer associated antigen compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

Where cancer associated antigen peptides are used for vaccination, modes of administration which effectively deliver the cancer associated antigen and adjuvant, such that an immune response to the antigen is increased, can be used. For administration of a cancer associated antigen peptide in adjuvant, preferred methods include intradermal, intravenous, intramuscular and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., *Remington's Pharmaceutical Sciences*, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.

Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A renal cancer associated antigen composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of breast cancer associated antigen polypeptides or nucleic acids, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

Examples

Example 1: SEREX screening of renal cancer cell line 1973/10.4

A standard cDNA library was prepared using 5 µg of poly A⁺ RNA derived from the cell line 1973/10.4. A primary (unamplified) cDNA library was immunoscreened (5×10^5 clones per library) by standard SEREX methodology, with absorbed autologous patient serum at 1:200 dilution [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA* 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones represented cDNAs from 22 distinct genes, designated NY-REN-45 through NY-LU-66 (Table A and Sequence Listing (SEQ ID NOS:1-21)). A homology search through the GenBank/EMBO databases revealed that 14 of the 22 genes corresponded to previously known molecules, and 8 others were unknown genes, with sequence identity limited only to short segments of known genes or to expressed sequence tags (ESTs).

Analysis of isolated clones:

I. NY-REN clones which are known gene products

Designation	Gene/Sequence Identity	Accession Number	SEQ ID NO
NY-REN-46	lactate dehydrogenase B	Y00711	22
NY-REN-47	ERK tyrosine kinase	D31661	23
NY-REN-48	PINCH protein	U09284	24
NY-REN-51	BBP/53BP2	U58334	25
NY-REN-52	steroid receptor coactivator	U59302	26
NY-REN-53	KIAA0336 mRNA tag	AB002334	27
NY-REN-54	E6 oncogenic protein-associated protein	X98033	28
NY-REN-55	murine NEK1 protein kinase homologue	S45828	29

NY-REN-56	6-phospho-fructokinase	D49817	30
NY-REN-59	lactate dehydrogenase A	X02152	31
NY-REN-61	KIAA0081 mRNA tag	D42039	32
NY-REN-63	DDB p127-associated protein	AF035950	33
NY-REN-65	HREV107 protein	X92814	34
NY-REN-66	acidic ribosomal phosphoprotein 2	M17887	35

II. Novel gene products

<u>Clone</u>	<u>SEQ ID NO:</u>	<u>Size</u>	<u>Tissue mRNA expression</u>	<u>Protein SEQ ID NO:</u>
NY-REN-45	1	4.0kb	Ubiquitous	12
NY-REN-49	2	1.1kb	Ubiquitous	13
NY-REN-50	3	1.8kb	Ubiquitous	14
NY-REN-57	4,5	2.9kb	Ubiquitous	15, 16
NY-REN-58	6	1.9kb	Ubiquitous	17
NY-REN-60	7	4.0kb	Ubiquitous	18
NY-REN-62	8,9	2.7kb	Ubiquitous	19, 20
NY-REN-64	10,11	3.0kb	Ubiquitous	21

III. Clones which react with autologous sera only:

NY-REN-47

NY-REN-49

NY-REN-50

IV. Clones which react with sera from normal control donors

Frequency of sera reactivity

<u>Clone</u>	<u>normal</u>	<u>cancer patient</u>
NY-REN-46	4/4	6/14
NY-REN-48	14/14	17/17
NY-REN-51	1/12	3/17

- 52 -

NY-REN-52	4/12	7/17
NY-REN-53	4/19	10/31
NY-REN-54	5/8	7/7
NY-REN-55	3/19	6/31
NY-REN-56	3/19	7/31
NY-REN-57	1/19	3/31
NY-REN-58	1/12	2/17
NY-REN-59	1/19	4/31
NY-REN-61	3/19	5/31
NY-REN-62	1/19	4/31
NY-REN-63	2/19	12/31
NY-REN-64	3/19	6/31
NY-REN-65	2/19	2/31

V. Clones which react with sera from cancer patients only (failed to react with 19 normal patient serum samples). These clones are preferred for therapeutic and diagnostic applications.

Frequency of reactivity

NY-REN-32	3/31
NY-REN-45	3/31
NY-REN-57	2/31
NY-REN-60	5/31
NY-REN-66	2/31

VI. Additional allogeneic screening of NY-REN renal SEREX clones

Renal SEREX clones were tested for reactivity with sera from the normal and various cancer patients listed below.

Sera

<u>Clone</u>	<u>normal</u>	<u>colon</u>	<u>renal</u>	<u>lung</u>	<u>breast</u>
NY-REN-3	0/26	7/37	8/32	0/23	1/26
NY-REN-12	0/19	0/16	3/32	0/15	0/16
NY-REN-19	0/19	0/16	2/32	0/15	0/16
NY-REN-21	0/16	3/16	3/32	1/15	0/16
NY-REN-25	0/15	0/16	5/32	0/15	0/16
NY-REN-31	0/14	0/16	5/32	0/15	0/16
NY-REN-32	0/14	2/16	3/32	0/15	0/16
NY-REN-37	0/15	0/16	2/32	0/15	0/16
NY-REN-45	0/14	0/16	3/32	1/15	0/16
NY-REN-57	0/19	0/16	2/32	0/15	0/16
NY-REN-60	0/19	0/16	7/32	0/15	0/16
NY-REN-66	0/19	0/16	2/32	0/15	0/16

Example 2: SEREX screening of tumor cells and testis libraries

Standard cDNA libraries were prepared using poly A⁺ RNA derived from the various cancer sources, as well as testis. The cDNA libraries were immunoscreened by standard SEREX methodology, with absorbed autologous patient serum [Sahin, U. et al., *Proc Natl Acad Sci USA* 92:11810-3 (1995); Chen, Y.T. et al. *Proc Natl Acad Sci USA* 94:1914-8 (1997)]. Excluding false-positive clones encoding immunoglobulin gene fragments, clones were purified and sequence analyzed. Comparisons of the sequences showed that these clones all were substantially identical to the kinectin cDNA (GenBank Accession number L25616).

Table A: Kinectin clones isolated by SEREX

<u>Clone designation</u>	<u>SEQ ID NO</u>	<u>Library</u>	<u>Patient sera for screen</u>
NGO-St-47	36	Gastric tumor	autologous
TS-64-5'	37	Testis	seminoma
HOM-TSOv3-41 (5')	38	Testis	seminoma
HOM-TSOv3-41 (3')	39	Testis	seminoma
HOM-HD2-2(3')	40	Hodgkin's disease	autologous
HOM-HD2-232(3')	41	Hodgkin's disease	autologous
Thy4 (3')	42	Thyroid tumor	autologous

Thy4 (3')	42	Thyroid tumor	autologous
Thy5 (3')	43	Thyroid tumor	autologous
Thy8 (3')	44	Thyroid tumor	autologous
Thy10 (3')	45	Thyroid tumor	autologous
NGO-Br-1	46	Breast cancer	autologous

In addition, a hepatocarcinoma library screened with autologous sera also identified several clones which were sequenced and found to be substantially identical to kinectin.

Allotyping (gastric cancer)

12/12 gastric cancer patient sera recognized kinectin

0/27 normal individual sera recognized kinectin

Therefore it was determined that recognition of kinectin was diagnostic for cancer patients.

Example 3: Preparation of recombinant cancer associated antigens

To facilitate screening of patients' sera for antibodies reactive with cancer associated antigens, for example by ELISA, recombinant proteins are prepared according to standard procedures. In one method, the clones encoding cancer associated antigens are subcloned into a baculovirus expression vector, and the recombinant expression vectors are introduced into appropriate insect cells. Baculovirus/insect cloning systems are preferred because post-translational modifications are carried out in the insect cells. Another preferred eukaryotic system is the *Drosophila* Expression System from Invitrogen. Clones which express high amounts of the recombinant protein are selected and used to produce the recombinant proteins. The recombinant proteins are tested for antibody recognition using serum from the patient which was used to isolate the particular clone, or in the case of cancer associated antigens recognized by allogeneic sera, by the sera from any of the patients used to isolate the clones or sera which recognize the clones' gene products.

Alternatively, the cancer associated antigen clones are inserted into a prokaryotic expression vector for production of recombinant proteins in bacteria. Other systems, including yeast expression systems and mammalian cell culture systems also can be used.

Example 4: Preparation of antibodies to cancer associated antigens

The recombinant cancer associated antigens produced as in Example 4 above are used to generate polyclonal antisera and monoclonal antibodies according to standard procedures. The antisera and antibodies so produced are tested for correct recognition of the cancer associated antigens by using the antisera/antibodies in assays of cell extracts of patients known to express the particular cancer associated antigen (e.g. an ELISA assay). These antibodies can be used for experimental purposes (e.g. localization of the cancer associated antigens, immunoprecipitations, Western blots, etc.) as well as diagnostic purposes (e.g., testing extracts of tissue biopsies, testing for the presence of cancer associated antigens).

Example 5: Expression of cancer associated antigens in cancers of similar and different origin.

The expression of one or more of the cancer associated antigens is tested in a range of tumor samples to determine which, if any, other malignancies should be diagnosed and/or treated by the methods described herein. Tumor cell lines and tumor samples are tested for cancer associated antigen expression, preferably by RT-PCR according to standard procedures. Northern blots also are used to test the expression of the cancer associated antigens. Antibody based assays, such as ELISA and western blot, also can be used to determine protein expression. A preferred method of testing expression of cancer associated antigens (in other cancers and in additional same type cancer patients) is allogeneic serotyping using a modified SEREX protocol (as described above).

In all of the foregoing, extracts from the tumors of patients who provided sera for the initial isolation of the cancer associated antigens are used as positive controls. The cells containing recombinant expression vectors described in the Examples above also can be used as positive controls.

The results generated from the foregoing experiments provide panels of multiple cancer associated nucleic acids and/or polypeptides for use in diagnostic (e.g. determining the existence of cancer, determining the prognosis of a patient undergoing therapy, etc.) and therapeutic methods (e.g., vaccine composition, etc.).

Example 6: HLA typing of patients positive for cancer associated antigens

To determine which HLA molecules present peptides derived from the cancer associated antigens of the invention, cells of the patients which express the cancer associated

antigens are HLA typed. Peripheral blood lymphocytes are taken from the patient and typed for HLA class I or class II, as well as for the particular subtype of class I or class II. Tumor biopsy samples also can be used for typing. HLA typing can be carried out by any of the standard methods in the art of clinical immunology, such as by recognition by specific monoclonal antibodies, or by HLA allele-specific PCR (e.g. as described in WO97/31126).

Example 7: Characterization of cancer associated antigen peptides presented by MHC class I and class II molecules.

Antigens which provoke an antibody response in a subject may also provoke a cell-mediated immune response. Cells process proteins into peptides for presentation on MHC class I or class II molecules on the cell surface for immune surveillance. Peptides presented by certain MHC/HLA molecules generally conform to motifs. These motifs are known in some cases, and can be used to screen the renal cancer associated antigens for the presence of potential class I and/or class II peptides. Summaries of class I and class II motifs have been published (e.g., Rammensee et al., *Immunogenetics* 41:178-228, 1995). Based on the results of experiments such as those described above, the HLA types which present the individual breast cancer associated antigens are known. Motifs of peptides presented by these HLA molecules thus are preferentially searched.

One also can search for class I and class II motifs using computer algorithms. For example, computer programs for predicting potential CTL epitopes based on known class I motifs has been described (see, e.g., Parker et al., *J. Immunol.* 152:163, 1994; D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). Computer programs for predicting potential T cell epitopes based on known class II motifs has also been described (see, e.g. Sturniolo et al., *Nat Biotechnol* 17(6):555-61, 1999). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL <http://bimas.dcrt.nih.gov>. See also the website of: SYFPEITHI: An Internet Database for MHC Ligands and Peptide Motifs (access via <http://www.uni-tuebingen.de/uni/kxi/> or <http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm>). Methods for determining HLA class II peptides and making substitutions thereto are also known (e.g. Strominger and Wucherpfennig (PCT/US96/03182)).

Example 8: Identification of the portion of a cancer associated polypeptide encoding an antigen

To determine if the cancer associated antigens isolated as described above can provoke a cytolytic T lymphocyte response, the following method is performed. CTL clones are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with autologous normal cells transfected with one of the clones encoding a cancer associated antigen polypeptide or with irradiated PBLs loaded with synthetic peptides corresponding to the putative protein and matching the consensus for the appropriate HLA class I molecule (as described above) to localize an antigenic peptide within the cancer associated antigen clone (see, e.g., Knuth et al., *Proc. Natl. Acad. Sci. USA* 81:3511-3515, 1984; van der Bruggen et al., *Eur. J. Immunol.* 24:3038-3043, 1994). These CTL clones are screened for specificity against COS cells transfected with the cancer associated antigen clone and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996). CTL recognition of a cancer associated antigen is determined by measuring release of TNF from the cytolytic T lymphocyte or by ^{51}Cr release assay (Herin et al., *Int. J. Cancer* 39:390-396, 1987). If a CTL clone specifically recognizes a transfected COS cell, then shorter fragments of the cancer associated antigen clone transfected in that COS cell are tested to identify the region of the gene that encodes the peptide. Fragments of the cancer associated antigen clone are prepared by exonuclease III digestion or other standard molecular biology methods. Synthetic peptides are prepared to confirm the exact sequence of the antigen.

Optionally, shorter fragments of cancer associated antigen cDNAs are generated by PCR. Shorter fragments are used to provoke TNF release or ^{51}Cr release as above.

Synthetic peptides corresponding to portions of the shortest fragment of the cancer associated antigen clone which provokes TNF release are prepared. Progressively shorter peptides are synthesized to determine the optimal cancer associated antigen tumor rejection antigen peptides for a given HLA molecule.

A similar method is performed to determine if the cancer associated antigen contains one or more HLA class II peptides recognized by T cells. One can search the sequence of the cancer associated antigen polypeptides for HLA class II motifs as described above. In contrast to class I peptides, class II peptides are presented by a limited number of cell types. Thus for these experiments, dendritic cells or B cell clones which express HLA class II molecules preferably are used.

Table 1: Sequence homologies

SEQ ID NO.: 1

AB002794, U46118RNU46118U19482AF026216AB002739, AB002730, AB002728,
 AF058796, AB002777, AF020187, AF009411, AB015609, AF006627, M95076, U43527,
 AB002741, U25846, AF006628, AF019043, D83352, U10355, M99575, U48288,
 AF090440, AB007504, U82480, Y15794, AJ005572, AF029349, L10111, S80963,
 U38894, L41731, AF022733, AJ225108, Y11879, AF001688, U33214, Z97178,
 AF009413, AF019907, AF016371, X71980, AF001522, M77169, AF023132, D83476,
 AJ009675, U90554, AF069324, AF048691, Z34799, AF004947, U60149, AF022732,
 AF019887, L02937, U55848, AF011331, AF045770, AF043533, X69524, M32882,
 U08214, U50847, AF017364, U35364, Y14339, AJ005969, U90555, U44430, U74296,
 AF001501, AJ223316, D78609, U41060, Z54362, AF034387, U62398, AB005545,
 AB002533, Y13865, AF009959, L02938, U10555, AL010246, AC003041, U37699,
 S75970, AF071010, Z81311, AB003681, X16353, AB002731, X53081, D63450,
 D10911, D90115, X97065, Z82275, AB016891, Y09455, X77990, W58357, W07820,
 AA188593, W81046, AA858164, AI018124, AI139112, AA769634, W00437, D80849,
 AA448160, N98650, T31293, H15307, H51146, N29314, AA770301, AA187822,
 AA978299, T31823, AA936410, AA993194, N41386, W45601, W81099, C05691,
 D60153, AA780119, AA929004, R68608, Z43271, N37024, AA974718, AA928663,
 T30120, AA936583, H51109, N20251, W92917, T36035, AA480197, Z24908, N79450,
 AA872019, AA902275, N59810, R13443, AA740162, AA937759, N72168, AA970708,
 T36257, AA433833, H15700, D51185, AA249138, R37356, W93028, Z28641,
 AA371494, N72757, AA719126, N56164, T31790, D57384, Z41959, N58984,
 AA847848, AA587009, Z39343, AA654834, AA505490, Z38243, D20344, AA252395,
 AA025593, H70133, R09101, AA159862, AI032981, Z28355, C75020, AI139642,
 D82421, AI126922, C75170, AI016032, C18748, C75478, AI129334, C75472,
 AA310765, D63057, C05952, AA357303, C16591, D82132, L48852, D82799, C75176,
 AI124552, AA669404, U30155, C75118, AA374918, C75108, C05853, U30151,
 D57346, AI127548, AA918527, AA317816, AA573490, R21699, AA917928, R36311,
 AA361522, AA701252, AI085492, H44387, AA156256, AA587935, AA976510,
 AA515269, W73374, T27986, N34493, AA737770, N32609, N32612, H64420,
 AA415243, AA413717, AA117350, AA242502, AA117343, AA545256, AA795651,
 AA106372, U31322, AA681967, AA221922, AA600546, AA050610, AU018628, C80932,
 AA920654, AA863834, AI099036, AA183239, AI115182, AA590910, W65628,
 AA162291, AA109440, AI052952, AA999324, AI105714, AI026280, AI072678,
 AA964820, AA754198, AA944557, AI045710, C94989, AA471630, AA933231,
 AA509077, AA257557, AA509328, AA109365, AA963207, AA435473, AA999306,
 AA406684, AI105662, AA509174, AI108597, AA109374, AA925182, AA471671,
 AA088161, AA752812, AA626989, AA406924, AA840999, AA509033, C94899,
 AA406875, AA842672, AA123619, AA072471, AA509339, AA933108, AI110259,
 AA842135, N99262, AA661430, AA842512, AA180648, AI066048, AA559515,
 AA406761, AA109423, AF074736, AA257676, D87312, AA257488, AA114390,
 AI087701, W06665, W32852, AA123649, AA842505, AA509330, AA908025, AA257279,
 AI105717, AA406673, AA627018, AA406850, AA161668, AA114453, AA109372,
 AA257572, AA803997, AA406943, AA257495, AA842019, AA661368, AI082949,
 AA842888, W06539, AA118223, AA406986, AA471717, AI096212, AA257707,
 AA257649, AI053126, AA508950, AA713366, W69049, AA965381, AA208680,
 AI057997, AA161707, AI058071, AA675858, AA257513, AI083337, AA406908,
 AI083256, AA659956, AA842532, AA754036, AA753165, W18199, AI109620,
 AI058022, AI064026, AA471431, AA032116, AA754544, AI108146, C42045,
 AA843025, AI109103, AA509237, AA161620, AA257665, AA471605, W84932,
 AA841358, AA843040, AA471695, AA003471, AA840977, AA509267, AA841711,
 AA471488, AA257699, N98079, AA454318, W04102, AA842874, N99754, AA509307,
 AA751845, AA661358, AA508954, AA406746, AA842720, W23363, AA508951,
 AI068913, AA417420, AI108220, AA508946, AA471497, AA842911, AA842501,
 AA123614, AA509218, AA547812, AA752986, AA752003, AA406839, AA508993,
 AA161747, AA509008, AA180623, AA508986, AA842627, AA753129, AA509214,
 AA406733, AI105737, N74818, AA753300, AA430818, AA417415, AA114426, R46936,
 AA979824, AA246112, AA753138, AI058077, AA842464, AA966639, AA842265,
 AA509025, AA601853, W15128, AA660039, AA842275, AA454424, AA180651,

AA842423, AA257507, AI063375, AA180692, AA051990, W15094, AA180620, W00308,
 AA406729, AA257712, AA257445, AA433148, C48534, AA495533, C08939, AA406845,
 AA933362, AA509242, AA842023, W29144, AI087490, AA842237, AA601823, W06538,
 AI087739, AI087524, AA842164, AA842642, AA471553, AA842419, AI113700,
 AA675813, AI083003, AI021727, AI083274, AI083309, W32823, AA253962,
 AA114520, AA430792, C47230, AA842674, AI053141, D75937, AA843034, W68979,
 AI105681, W91819, AA756971, AA509104, AA111828, AI109720, AI110161,
 AA933311, AA180602, AA842093, R86419, AI058057, AA186285, AA406891,
 AI105725, AA406888, AA649397, N94700, W51718, AA547916, AA840646, U74116,
 AA257756, AI082996, W91818, N74830, AA123585, AA118224, AA454446, AA841367,
 AA509109, AA842387, AI052833, AA751998, AA123634, AA257327, AA803962,
 AA842493, AA471448, AA406716, AA841361, AA840661, AA713447, AA406754,
 AA257695, AA841403, AA751834, AA406947, AI096182, AI105734, W15132, W59918,
 AA089352, AA180566, AA257427, AA257522, AA406980, AA471469, AA509264,
 AA509032, AA749469, AA752028, AA754167, AA754646, AA842335, AA842574,
 AI065957, AI065970, AI096289, AA109379, AA109472, AA114484, AA161689,
 AA430830, AA406948, AA433246, AA454371, AA471492, AA471703, AA752086,
 AA842624, AI096185, R47079, R86415, AA161711, AA161655, AA180549, AA257424,
 AA257437, AA257749, AA433393, AA471419, AA471602, AA430922, AA661401,
 AA752034, AA752066, AA842384, AI082936, AI083329, AI105677, Z33912,
 AA109362, AA109417, AA051807, AA430797, AA406799, AA430806, AA495548,
 AA661116, AI082951, AI105685, AI114069, R47062, W59884, AA109292, AA751829,
 AA754172, AA842257, AI082934, AI082958, AA180706, AA471516, AA508962,
 AA751563, AA751816, AA753137, AA753167, AA840972, AA842079, AA874756,
 AI105522, AI108824, AA180588, AA406676, AA471392, AA509142, AA840909,
 AA842175, AI066854, R47172, AA161565, AA257643, AA753161, AA471447,
 AA680450, AA752897, AA753237, AA842230, AA842544, AA161635, AA454428,
 AA508933, AA509309, C41215, AA842585, D73786, D75990, D75808, AA627049,
 N74809, AA257682, AA257517, AA257668, AA471470, AA509251, AA509051,
 AA990913, C39627, C41200, C42101, C46071, C48450, AA840970, AA842156,
 AA430902, AA842216, AA007706, AA406765, AA180574, AA842310, AI067585,
 AI077003, AA756933, AA114501, AA406690, AA454440, AA661371, AA056797,
 AA114372, AA180676, AI082955, AA406735, AA675746, AA752005, W29142,
 AA109261, AA842401, AA842602, AA246079, AI043420, AA626993, AA123655,
 AA257716, AA406931, AA791379, AI105668, AA842538, R47669, AA088150,
 AA109308, AA738555, AA123638, AA180582, AA123597, AA471535, AA180728,
 AA161741, AA186201, AA430817, AA433170, AA454407, AA471686, AA161596,
 AA509110, AA675874, AA471540, Z26577, AA753093, AI066829, D37716, AA627017,
 N99292, AA508936, AA257656, AA406768, AA471587, H39287, AA842431, AA161715,
 AA509204, AA979935

SEQ ID NO.: 2, AF086243, AE001154, X62889, , W67765, W67764, AA947751,
 AI141491, W76469, AA906091, AA872676, AA349825, H77545, H91001, W72232,
 AA948309, AA361403, R57582, AA337188, AA215714, AA481093, T75310, AA976452,
 , AI120744, AA462558, AI158491, AA014020, AA285990, AA051044, AA473453,
 AA896862, W56907, AA218305, AA020167, W85164, AA017810, W30604, AA541978,
 W20894, AA023164, AA760425, AA024084, AA840044, , AA231755, T20644, C45833,
 T24185, C68940, D37618, AA964657, AI011924

SEQ ID NO.: 3, L08501, Z97205, Z48950, AF010400, AC005162, L08502, D50608,
 , AA707653, AA861639, AA292496, AA702524, AI097367, AI138504, AI147933,
 AI141836, AI075247, N63868, W88668, AA703146, AA625621, AA292247, AI032848,
 AA005331, AA699781, AA427941, D31111, D31113, N92013, AA884207, AA044752,
 R70900, R16693, AA906542, R35112, AA481286, D80100, AA235512, AA960995,
 AA867982, D59403, W88874, AA558590, R10048, AA719917, H43573, R49500,
 AA744780, AA047136, AA789101, AA906332, AA747301, AA830606, AA434559,
 AA236698, AA328889, N98469, W17299, W46605, AA258082, AI078045, R11930,
 W74577, AA703312, AI082727, R45189, N76461, AA010500, W63646, W38891,
 AA490651, AA558805, W87891, AA160849, AA618177, AA776126, AA161281,
 AA822308, AA499768, AA028780, AA183100, AA276783, AA120227, AA200285,
 AA212541, AA116265, AA821616, AA265629, AA108594, W61565, AA030311, W42275,
 AA419903, AA268027, AA028211, AA518504, AA125394, , C92235, C92002, C29917,
 AI145662, C65317, AA901847, AI137443, Z14719, D35515, R90625, H76970,

SEQ ID NO.: 4, AL031178, Y11905, AF031904, M34309, M29366, L33953, L33952,

L33956, L33954, L33957, U41289, X13369, AL022072, AJ223074, AF078695, AC004683, X17267, AF025526, AF071798, AC005274, AB004537, X68248, AF035537, AF056116, AB009052, AL023286, AF058701, L20725, AF001308, U22438, AA211485, AA579574, AI078750, AA568661, AA604128, H49462, AA767424, H97012, AA565823, H49463, AA827171, T87152, F22114, AA748475, T31504, Z42997, T89930, R02581, H75949, T87057, AA322268, R02700, AA005034, AA576177, AI014302, AA348159, T83607, AA322497, AA211532, AA019517, R27657, AA026869, N67589, T83782, AA129383, Z39829, AA814308, AA425564, H67997, AA004420, AA644513, AA007691, T62593, AA333601, H75334, AI057250, T62521, N73865, AA004558, AA004484, AA007690, AA910241, AA456251, AA004568, AA341266, T28757, AA132360, AA781316, AA456942, AA782765, AA662593, AA461351, AA885220, N33840, AA843737, T62232, AA608559, AA643270, R44662, AI074863, AI051088, N63305, W24955, AA085886, W31918, AA047466, AA178965, AA369890, AA515015, N79466, AA768162, AA864694, AA811390, AA834531, AA293263, AA768335, AA749083, T57520, AA292001, AI085512, AA969032, AI027062, AA595663, AA827242, AA744475, AA472485, AA097011, AA959170, AA647546, AA986669, AI006628, W12604, AI122356, AA571721, AA433697, AA880171, AA015463, AA116290, C87721, AA437983, AA990395, AA265925, W14785, W89262, AA059703, AA413613, AI020231, AA667024, AA407526, AA221491, AA222523, C76436, AA409700, W35766, AA859485, H33704, T46512, C25899, T41882, C26586, C92302, AA660448, C94493, C25527, D35045, D33727, F14543, D37473, T45969, AA040979, D68274, T38420, AA228607, AA660541, T38283, AA842575, C71889, T38745, D68465, T46732, AA598393, C23775, C64798, AA042714, F19972, C65873, N97974, AA114425, AA900456

SEQ ID NO.: 5, U29344, S80437, M76767, X62889, M84761, J03514, X62888, X13415, X13135, U05714, AC004013, U58675, S47635, Z81533, AC005250, AC003661, AB008567, Y13444, X96401, AF026487, AF026488, AA781445, AI037943, AI129371, C15883, AI073336, AA904077, AA569042, AI039428, AA568701, AA058907, AA911112, AA234022, N95359, AA565390, AA082427, AA588430, D60358, AA045488, AA084417, N72089, AI143390, R51974, AA081439, AA635907, T47621, AA579930, AA995057, AA827039, AA872490, AA588319, AA069032, AA062768, AA534011, W96404, H06082, AA938900, AA971262, AA836547, AA251544, AA250742, AA830405, AA906492, AA102653, R38286, AA258075, H83302, H38522, R61787, R33742, R24094, AI052406, AA931452, R23634, R39640, AA974568, AI028383, AA312451, AA148800, AI138982, R36172, AA926921, AA472563, AA914598, AA423256, AA476186, AA041992, W84938, AA797706, AA709956, AA544361, AI006075, AA717202, AA008602, AA033399, AA472306, AI037430, AI152943, AA475582, AA471742, AA530292, AA277496, AA718588, AA823112, AA822771, AA710973, AA981780, AA718846, AA797557, AA510746, AI036049, AA543891, AA606513, AA981758, AA822268, AA413161, AA472201, AA646527, AA213036, AA168254, AA718549, AA458342, AA119418, AA879925, AA050917, AA718814, AA793638, AA177849, AA575627, AA537367, AI121788, AA203946, AA413157, AA517432, AA867736, AI037420, W30436, Z71851, AA957415, AI112847, AA955881, AA963915, AI043663, C95061, AI009894, AA957229, AI044678

SEQ ID NO.: 6, AC002426, AC004674, AC004675, AC004006, L12157, U20839, U46028, U20835, AC004058, X67115, X76266, M25485, U59759, AC005172, U70848, AF042274, X14724, L31840, L41679, W52480, AA863014, W56770, AA286755, AA164604, W52777, AA814246, AA765427, AA873647, AA360577, AI139274, AA770312, AA732557, AA568651, AA164603, W56724, AA194905, AA865009, R16884, R08110, F07672, AA577790, T11467, AA502489, AA366688, AA480628, AA516318, AA090005, AA081908, F01265, AA780686, AA466811, AA465808, AA197646, AI157174, AA153086, AA197667, AA066612, AA058086, AA024186, AA110104, AA880419, AA870161, AA153880, AA072995, AI031052, AI043934, AA849320, D15181, U95093, AI096188, T09655, C62926, AA996434, AA925202, AA817271, AA901051, R03660, AA948980, AA658709, AA899446, AA957150, AA800160, T76196, AA891787

SEQ ID NO.: 7, X63547, X63546, AF017306, U44839, U20657, AF017305, AJ001589, L21998, D21270, Z48245, U63834, Z68006, L04573, D63819, AC005266, AF025468, M94131, AI056961, C15588, AA373847, AA887911, N87070, R39133, AA226825, AA353972, AA325352, R88378, AA490675, AA456219, AA701415, AA046611, AA456224, AA065652, AA221447, AA710221, AA717401, AA254049,

AA041745, AA510261, AA170745, AA656404, AA572506, AA174539, AA217630, ,
AI134284, C58457, C11202, AA413362, AA728532

SE ID NO.: 8, AB016886, Z92811, AL021481, U52078, L46702, U23515, AC005555,
Z84814, Z93016, D21138, X57513, L07144, D83711, M28488, U15974, U52513,
AF026939, L19120, J05258, Z13985, Z70691, U59227, , AA190526, AA764854,
AI014655, H88220, AA622877, N32046, H89609, AA682362, AA464420, AA375477,
AA284905, AA257109, N80276, H89373, N92393, AA884334, AA778708, AA766209,
AA535677, W46414, AA770266, AA983635, AA721113, H88219, R87349, AA628091, ,
AI116513, AA183589, AI035517, AA209952, AA184622, AI097904, AA016440,
AA162370, AA939521, AA162376, AA718152, AA048154, AA253815, AA795350, ,
AA996981, C44448, C41783, C44695, C44039, C62421, C47063, C45014, D36613,
C60872, C50136, C69177, AI055708, D27648, C65648, AI114022, AI064663,
AI107213, AA395461, AA800126, AA891487, T01611, C27943, AI113482, C83830

SEQ ID NO.: 9, L43510, U71249, L11275, X73541, Z28317, AB008270, X75652,
U05987, U85262, U24189, Z46676, X70823, AC004981, D11079, X56121, M58053,
U33636, Z92773, U23168, D31662, , R15557, F01629, N71722, AA252548,
AA806751, T59557, AA612671, AA329585, AA295675, AA166990, AA128100, H46363,
AA125810, , AA396888, AA408999, AA270873, AA144722, AA863954, W10303, ,
C38016, N96746, Z37622, AA395862, C38756, F15295, N99294, W68877, C44749,
C24349, F15569, AA113611, AA689147, N96676, C73598, F15564, L46559, W06235,
T09718, H77154, T14151, AI082914, AA650815, AA728021, AA072559, C92112,
T46743, C61743, AA550223, C12798, AA275531, AA681003, T75878, AI100047,
T75882, AA848187, T44109, AA542686, H21339

SEQ ID NO.: 10, Z81595, U41372, U01317, AE000696, AC002057, X66250, L11665,
D13438, U29377, Z50028, U40953, AA114228, AI025080, R80188, W28745,
AA381819, AA381991, Z44165, H75915, AI124743, H08139, AA375957, AA381750,
AA166751, R42511, T26985, , AA471592, AA661387, AA606231, D35147

SEQ ID NO.: 11, X76498, Z97632, AC004232, AC005184, AC002545, AC003991.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

We claim:

Claims

1. A method of diagnosing a disorder characterized by expression of a human cancer associated antigen precursor coded for by a nucleic acid molecule, comprising:
 - contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and
 - determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder.
2. The method of claim 1, wherein the agent is selected from the group consisting of
 - (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules or a fragment thereof,
 - (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules or a fragment thereof,
 - (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules or a fragment thereof,
 - (d) an antibody that binds to an expression product of NA group 1 nucleic acids,
 - (e) an antibody that binds to an expression product of NA group 3 nucleic acids,
 - (f) an antibody that binds to an expression product of NA group 5 nucleic acids,
 - (g) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 1 nucleic acid,
 - (h) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 3 nucleic acid, and
 - (i) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 5 nucleic acid.
3. The method of claim 1, wherein the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which is specific for a different human cancer associated antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 4, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

4. The method of claims 1-3, wherein the agent is specific for a human cancer associated antigen precursor that is selected from the group consisting of breast, gastric, lung, prostate, renal, colon, thyroid, Hodgkin's disease, and hepatocarcinoma cancer associated antigen precursors.
5. A method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising
 - monitoring a sample, from a patient who has or is suspected of having the condition, for a parameter selected from the group consisting of
 - (i) the protein,
 - (ii) a peptide derived from the protein,
 - (iii) an antibody which selectively binds the protein or peptide, and
 - (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule,
 - as a determination of regression, progression or onset of said condition.
6. The method of claim 5, wherein the sample is a body fluid, a body effusion or a tissue.
7. The method of claim 5, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of
 - (a) an antibody which selectively binds the protein of (i), or the peptide of (ii),
 - (b) a protein or peptide which binds the antibody of (iii), and
 - (c) a cell which presents the complex of the peptide and MHC molecule of (iv).
8. The method of claim 7, wherein the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme.
9. The method of claim 5, comprising assaying the sample for the peptide.
10. The method of claim 5, wherein the nucleic acid molecule is a NA Group 3 molecule.

11. The method of claim 5, wherein the nucleic acid molecule is a NA Group 5 molecule.
12. The method of claim 5, wherein the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a cancer associated protein encoded by a NA Group 1 molecule.
13. The method of claim 5, wherein the protein is a plurality of proteins, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and wherein the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins.
14. A pharmaceutical preparation for a human subject comprising
an agent which when administered to the subject enriches selectively the presence of
complexes of an HLA molecule and a human cancer associated antigen, and
a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is
a fragment of a human cancer associated antigen precursor encoded by a nucleic acid
molecule comprises a NA Group 1 molecule.
15. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of
agents, each of which enriches selectively in the subject complexes of an HLA molecule and a
different human cancer associated antigen, wherein at least one of the human cancer
associated antigens is encoded by a NA Group 1 molecule.
16. The pharmaceutical preparation of claim 15, wherein the plurality is at least two, at
least three, at least four or at least 5 different such agents.
17. The pharmaceutical preparation of claim 14, wherein the nucleic acid molecule is a
NA Group 3 nucleic acid molecule.
18. The pharmaceutical preparation of claim 14, wherein the agent comprises a plurality of

agents, at least one of which is kinectin, the remainder of which are non-kinectin cancer associated proteins, and each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen.

19. The pharmaceutical preparation of claim 14, wherein the agent is selected from the group consisting of

- (1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof,
- (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof,
- (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and
- (4) isolated complexes of the polypeptide, or functional variant thereof, and an HLA molecule.

20. The pharmaceutical preparation of claims 14-19, further comprising an adjuvant.

21. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell is nonproliferative.

22. The pharmaceutical preparation of claim 14, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide.

23. The pharmaceutical preparation of claim 21 or 22, wherein the isolated polypeptide comprises a kinectin polypeptide.

24. The pharmaceutical preparation of claim 14, wherein the agent is at least two, at least three, at least four or at least five different polypeptides, each coding for a different human cancer associated antigen or functional variant thereof, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

25. The pharmaceutical preparation of claim 24, wherein the at least one of the human cancer associated antigens is kinectin or a fragment thereof.
26. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 2 polypeptide.
27. The pharmaceutical preparation of claim 14, wherein the agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.
28. The pharmaceutical preparation of claim 22, wherein the cell expresses one or both of the polypeptide and HLA molecule recombinantly.
29. The pharmaceutical preparation of claim 22, wherein the cell is nonproliferative.
30. A composition comprising
an isolated agent that binds selectively a PP Group 1 polypeptide.
31. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 2 polypeptide.
32. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 3 polypeptide.
33. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 4 polypeptide.
34. The composition of matter of claim 30, wherein the agent binds selectively a PP Group 5 polypeptide.
35. The composition of claims 30-34, wherein the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides.

36. The composition of claim 35, wherein the at least one of polypeptides is kinectin or a fragment thereof.
37. The composition of claims 30-34, wherein the agent is an antibody.
38. The composition of claim 315 wherein the agent is an antibody.
39. A composition of matter comprising
a conjugate of the agent of claims 30-34 and a therapeutic or diagnostic agent.
40. A composition of matter comprising
a conjugate of the agent of claim 35 and a therapeutic or diagnostic agent.
41. The composition of matter of claim 39, wherein the conjugate is of the agent and a therapeutic or diagnostic that is a toxin.
42. A pharmaceutical composition comprising an isolated nucleic acid molecule selected from the group consisting of NA Group 1 molecules and NA Group 2 molecules, and a pharmaceutically acceptable carrier.
43. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule.
44. The pharmaceutical composition of claim 42, wherein the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different human cancer associated antigen.
45. The pharmaceutical composition of claim 44, wherein at least one of the polypeptides is a kinectin polypeptide.
46. The pharmaceutical composition of claims 42-45 further comprising an expression

vector with a promoter operably linked to the isolated nucleic acid molecule.

47. The pharmaceutical composition of claims 42-45 further comprising a host cell recombinantly expressing the isolated nucleic acid molecule.
48. A pharmaceutical composition comprising an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and a pharmaceutically acceptable carrier.
49. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.
50. The pharmaceutical composition of claim 48, wherein the isolated polypeptide comprises at least two different polypeptides, each comprising a different human cancer associated antigen.
51. The pharmaceutical composition of claim 50, wherein at least one human cancer associated antigen is kinectin.
52. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 11 polypeptides or HLA binding fragments thereof.
53. The pharmaceutical composition of claim 48, wherein the isolated polypeptides are PP Group 12 polypeptides or HLA binding fragments thereof.
54. The pharmaceutical composition of claims 48-53, further comprising an adjuvant.
55. An isolated nucleic acid molecule comprising a NA Group 3 molecule.
56. An isolated nucleic acid molecule comprising a NA Group 4 molecule.
57. An isolated nucleic acid molecule selected from the group consisting of

(a) a fragment of a nucleic acid molecule having a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs. 1-11 and 22-46, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor,

(b) complements of (a),

provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of

- (1) sequences having the GenBank accession numbers of Table 1,
- (2) complements of (1), and
- (3) fragments of (1) and (2).

58. The isolated nucleic acid molecule of claim 50, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

59. The isolated nucleic acid molecule of claim 57, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20 nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

60. The isolated nucleic acid molecule of claim 57, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

61. An expression vector comprising an isolated nucleic acid molecule of any of claims 55-60 operably linked to a promoter.

62. An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.
63. An expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an HLA molecule.
64. A host cell transformed or transfected with an expression vector of claim 61.
65. A host cell transformed or transfected with an expression vector of claims 62 or 63.
66. A host cell transformed or transfected with an expression vector of claim 61 and further comprising a nucleic acid encoding HLA.
67. A host cell transformed or transfected with an expression vector of claim 62 and further comprising a nucleic acid encoding HLA.
68. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 55 or claim 56.
69. A fragment of the polypeptide of claim 68 which is immunogenic.
70. An isolated polypeptide comprising a fragment of a kinectin polypeptide which is immunogenic.
71. The fragment of claims 69 or 70, wherein the fragment, or a portion of the fragment, binds HLA or a human antibody.
72. An isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule.

73. The fragment of claim 72, wherein the fragment is part of a complex with HLA.

74. The fragment of claim 73, wherein the fragment is between 8 and 12 amino acids in length.

75. An isolated polypeptide comprising a fragment of the polypeptide of claim 68 of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

76. A kit for detecting the presence of the expression of a human cancer associated antigen precursor comprising
a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping.

77. The kit of claim 76, wherein the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule.

78. A method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor, comprising
administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of
(a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules,
(b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules,
(c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.

79. The method of claim 78, wherein the disorder is characterized by expression of a

plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

80. The method of claim 79, wherein at least one of the human cancer associated antigens is kinectin or a fragment thereof.
81. The method of claim 79, wherein the plurality is at least 2, at least 3, at least 4, or at least 5 such agents.
82. The method of claims 78-81, wherein the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP Group 5.
83. The method of claims 78-81, wherein the disorder is cancer.
84. The method of claims 82, wherein the disorder is cancer.
85. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:
 - (i) removing an immunoreactive cell containing sample from the subject,
 - (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor,
 - (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, and NA Group 5.

86. The method of claim 85, wherein the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen.

87. The method of claim 85, wherein the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

88. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:

- (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule;
- (ii) transfected a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c);
- (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and;
- (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.

89. The method of claim 88, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.

90. The method of claim 88, further comprising identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

91. The method of claim 88, wherein the immune response comprises a B-cell response or a T cell response.

92. The method of claim 91, wherein the response is a T-cell response which comprises

generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

93. The method of claim 88, wherein the nucleic acid molecule is a NA Group 3 molecule.

94. The method of claims 88 or 90, further comprising treating the host cells to render them non-proliferative.

95. A method for treating or diagnosing or monitoring a subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising

administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

96. The method of claim 95, wherein the antibody is a monoclonal antibody.

97. The method of claim 96, wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.

98. A method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

administering to a subject a pharmaceutical composition of any one of claims 14-29 and 42-547 in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.

99. The method of claim 98, wherein the condition is cancer.

100. The method of claim 98, further comprising first identifying that the subject expresses

in a tissue abnormal amounts of the protein.

101. The method of claim 99, further comprising first identifying that the subject expresses in a tissue abnormal amounts of the protein.

102. A method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

- (i) identifying cells from the subject which express abnormal amounts of the protein;
- (ii) isolating a sample of the cells;
- (iii) cultivating the cells, and
- (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

103. The method of claim 102, further comprising rendering the cells non-proliferative, prior to introducing them to the subject.

104. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

105. The method of claim 104, wherein the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or an antibody fragment.

106. The method of claim 104, wherein the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

107. The method of claim 104, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

108. The method of claim 104, wherein the nucleic acid molecule is a kinectin nucleic acid molecule.

109. A composition of matter useful in stimulating an immune response to a plurality of a proteins encoded by nucleic acid molecules that are NA Group 1 molecules, comprising a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

110. The composition of matter of claim 109, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

111. The composition of matter of claim 109, wherein at least one of the proteins is kinectin.

112. The composition of matter of claim 110, further comprising an adjuvant.

113. The composition of matter of claim 112, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

114. The composition of matter of claim 109, further comprising at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

115. An isolated antibody which selectively binds to a complex of:

- (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and
- (ii) and an MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

116. The antibody of claim 115, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a fragment thereof.

SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

5 <120> Cancer Associated Antigens
and Uses Therefor

<130> L0461/7050wo

10 <140> US 09/166,300
<141> 1997-10-05

<140> US 09/166,350
<141> 1997-10-05

15

<170> FastSEO for Windows Version 3.0

20 1310 1

<210> 1

<211> 442.

<212> DNA
<213> *Homo sapiens*

25 <400> 1

gattattctg	gaggaagatg	acttcattt	tatggttatg	tgtgtgtgc	tgtgtgtctt	160
tggaaaaata	tatataattt	tttcaaata	gaagccaaca	tatcaagtga	tgaattaaag	120
tatgctgcag	aatatatattt	ctaaaactac	aaaaaaagtca	ctgaatata	aatgataca	180
gcttatacat	atagttactg	tgacaagtga	cagactgcta	gttcagaatt	aaaaatcct	240
ttcctagtt	gtgagataat	gggctaaattt	ccttctgcct	gccactgggg	caaagcaat	300
tgcttagtt	ttttagatgaga	gttcttagaa	gtttaggtgt	attccttcat	ccacagcatc	360
cattgttga	ataaccattt	tcagttgtga	tgccttaact	aagaagccaa	ttgttagcct	420
gaaatgcaat	cttggtagcc	agttcaatg	aagctagaga	ttagtcagaa	aaagtttagt	480
gttgggc	agaaaggat	tttgagtcct	gncaattct	cttggagca	tttggagca	540
gattaagctt	tcagtataaa	aacaagtggc	tacctgtatgg	aaactttct	tacccttata	600
gggaaactga	gcacaagctg	aatgatattt	tcgtctgcaaa	aaaaaaacaa	acaaaaaaaaa	660
aacaaaacaa	aaaacaaaaaa	aaaaaaaaaa	aaaacctcgat	gccgaattcg	gcacgagggg	720
aaggccccgt	caccccccgc	cctccggcc	cccccgc	gttggccctg	cagecgctgc	780
cgctgcctcg	ggctacagcc	ccgggctcg	cgttccggc	tgggaaagga	ggccggcgcag	840
cgcgcccgga	gccgcccggag	atggcgggag	ggcactgcgg	cagttcccc	gcccggcgg	900
ccggcagcgg	cgagatcg	caactgaacg	taggggggac	cagatttagt	acctcaagac	960
aaactcttat	gtgatttca	gattctttt	tttccagttt	gtcgagtgg	agaatttcaa	1020
cacttcgaga	tgaaaactgg	gtatatttta	ttgatagaga	tccagcagca	tttgcaccca	1080
ttttaaattt	tcttcggaca	aaagaactag	acttaagggg	agtgagtatt	aatgttctca	1140
ggcatgaagc	agaattttac	ggatcactc	cattagtaag	aaggcttctc	ttatgtgaag	1200
aattggagcg	ttcctcttgt	ggcagtg	ttttcatgg	ttacttgc	ccaccaggta	1260
ttcctagtcg	taaaataaaac	aacacagtca	gatctgctga	ttcttaggaat	ggtctaaatt	1320
ctcagaaagg	tgaagcccg	ggaaatggta	cacagcctgt	tctctctgga	acgggagaag	1380
aaactgttag	gctaggattt	cctgtgatc	cacgaaaggat	gctaata	gtggccatc	1440
acaactggat	tgtagctca	tatgcccatt	ttgctgngt	gtacagaatc	aaagaatctt	1500
caggatggca	gcaagtgtt	acgaccat	attggattt	gactatcgaa	cgagtagctt	1560
taaatgcaaa	ggtgggttgg	gggcacat	gagacaaaga	aaaatgg	gtctgtgc	1620
cagagagtag	catcatctt	tggagtg	agatgggg	aagtgg	gaaattggag	1680
tgttcagct	gggtgttcc	gtagatg	tcttctttat	tggtaaccag	ttggtgccca	1740
cgagtcat	aggaaaagt	ggagtgt	atgctgtc	tcagcact	cagggtcaag	1800
atgttgttcc	tataactagt	tatgacact	ctggatcatt	ccttctgtt	ggatgtaa	1860
atggatcaat	atattacata	gatatgc	aggatccc	gcaatgaaa	gataatgatc	1920
ttcttgtta	actgtatgtat	catgatc	caa	tattactg	ctgagtg	1980
acctcacacc	caaaacaagt	gtcagtg	actggatc	gatcgctt	ggtacgag	2040
ctggagcagt	acgagtatt	gtacaacacc	cagagac	tgggtcag	cctcagctt	2100
ttcagactt	cacagtcc	cgaa	taacaaaat	catgctatc	gagaagc	2160
ttgtatcgt	ctgtcgat	aataatcat	tcggacgt	gacagtaac	cgattcngag	2220
gaatgatctc	tactcagcc	ggttctact	ctttagcgt	attcaagata	ctatccctgg	2280
aggagacaga	aagtcatgtt	agtatcc	cttggaaat	cataggac	tttggagag	2340
gagacgatca	acaggtgtt	atccagaa	tttgcctat	caccaaaaa	ctattgtaa	2400
gactctcatc	gactggaaaa	agaatatgt	atgatccagg	tgttgact	actacaat	2460
cctcatttac	agtqagggat	ccqatqagg	ggqctcaaga	ccaaaggcc	ccaaaggcc	2520

acttgttcac	aggccataca	aatggcagta	ttcaaatgtg	ggatctgacc	actgctatgg	2580
atatggtaa	caaaaagtgaa	gataaggatg	taggtggtcc	aaccgaagaa	gagctactca	2640
aattactcga	tcaatgtat	ttgagcacat	ctcgctgtgc	tactcctaac	atcagtcac	2700
caacttccgt	agttcagcat	agccacttac	gagaatcaaa	ttcttagcctt	cagcttcagc	2760
accatgatac	cacccatgaa	gcagctactt	acggttccat	gaggccttac	agagaaaagtc	2820
ctttttagc	aaggggcaaga	aggactgaga	gttttcacag	ttataggac	ttccagacta	2880
ttaatttga	cagaaatgtt	gaaagagctg	tccctgaaaaa	tggtaactt	ggtccaatac	2940
aagctgaagt	gaaagggggca	acaggggaat	gtaatataatc	tgagagaaaag	tctcctggag	3000
tagaaataaa	aagtttgaga	gaattggata	gtggatttgg	agtgcataaa	atagctgaag	3060
gtttttcaga	atccaaagaaa	aggtcatcg	aagatgaaaaa	tgaaaataaa	atagagttt	3120
ggaagaaaagg	aggatttggaa	ggggggaggat	tccttggaa	aaagaaaagtt	ccctatctgg	3180
catcatacc	aagtacttcc	gatggggagaa	ctgactcacc	tggtactcg	tccccatctc	3240
ctacaagac	tactccatc	cctcggcata	aaaaaaagt	ttcttcagg	caggagtaca	3300
gcttgtgaaa	actcaccaaa	atgaatagtt	gtttcggta	catttagat	aaagttaaac	3360
tttactgaat	ttcagttacat	tagttttac	actaaaactt	tacaagataa	aattggactt	3420
catttagtat	cttttaaca	gaattactt	gaataatgag	atacaatataat	catactctt	3480
ttgacatttt	gaaaattttt	ttaattttac	aagtacattt	aacagatcat	ttataaaagca	3540
ggagtccatt	ttaacactta	ccgacttttt	ttgggttgg	aacatattac	cacgtcttaa	3600
taggatggtg	cccatatagg	tgagcatccc	tttagatcat	gggaaccagc	agactgcatt	3660
cctaattttc	attatgcctg	agacttgtct	tacaatgtt	cctttaaagt	aatcacataa	3720
ttgtctttgg	aacttggct	cccaacactt	attgtgattt	caaagtgtt	accagatatt	3780
tgtgaggtg	ctatgtttgt	aaaaaacata	tcatgtattt	aaaaaacact	attgatattt	3840
aataccagat	accactatgt	agtaagtctt	tttaggtat	ttaattttag	tcgtgcgtca	3900
ttttctgtatt	ctccatcattt	ggagatctt	aatcttagca	agcatttagca	atattaaatg	3960
ccaaaattttc	attggaaactt	tcaagttgg	gcaatttgtt	gtgtttggaa	agatgaaata	4020
aaaataataaa	tcaagggcaa	agctttgtt	gcccagaagg	gaaagctgt	ccagttgtt	4080
acctgtctt	tttcaggagc	caccatgtt	ttttttcagt	gttancaaca	atcatgataa	4140
ttaaaataaa	acncttagtt	gttcaactt	aggactgcag	ttctgtat	tgggttaaaag	4200
gttttggctg	ctgttagaat	gtgaatttga	atgtat	aattgtt	gaaaagaaac	4260
gtttttgtac	aatttttttt	catttaattt	gaatgtat	cagggttctt	caaataaggt	4320
aattgttaaaat	ttaaaggcatt	agcatttatt	ggttataat	gtatataatcc	ccattccaag	4380
aaatataatgt	gagtgaagtt	gaaataaaaat	ctttaaaatt	ta		4422

35 <210> 2
<211> 502
<212> DNA
<213> *Homo sapiens*

		<400> 2							
40		gctagcttcg	gcgcggatcc	ctgggcgtcc	gtacgtcgga	gtccttcgtc	ctccagggtc		60
		cctgttctt	gcgcggatcc	gaaccactat	ctctgcactc	ctgggggttt	gttacatggc		120
		tgctttccctc	aaaatgagtg	ttatgtgtca	tttcttcaga	ccttcacca	ggttttttgt		180
		gccatttacc	cttcataatgg	agagaaataa	cttacaat	ttgcagagat	acatgtcttc		240
45		aaaaataccca	gctgttactt	atcctaaaaat	tgagagtaca	cgccttctgt	aagagctaga		300
		gttggataaag	tggaaaaacta	ccatgaaatc	tagtgtgcaa	gagaatgtg	tttcaacaat		360
		ctcaaggcgt	aaggatgaag	atcctcttagc	tgcaccacaga	gagttcattt	agatgtggag		420
		attgttttgc	agagaagttac	cagaacacat	cactgaagaa	gagctcaaaa	cccttatggaa		480
		atgtgtttct	aacacagcata	aa					502

50 <210> 3
<211> 1948
<212> DNA
<213> *Homo sapiens*

5	gctgctctt	catcccgaa	tgtcagtgg	ctgcctgtt	atgctcagtc	aggagagcct	780
	aggaggctga	cccaggcaca	ggtggcagcg	tttcctggag	agaatcttt	ggaacactct	840
	tcagaccagg	acacctggaa	cagcctgagg	agcccggtt	tctgcagccc	tttgtcatct	900
	ggtggtggag	cagagtccct	ggcccttggg	gggcctggac	atgcagaggc	aggacaccc	960
	ggcaagggtt	gtgacttcca	cctgaaccac	cagcagccca	gccccaccag	cgtccgtcct	1020
	acagagggtgg	cagccctcc	gtttgagaaa	attttgtctg	tggatagcgt	gcaagtggac	1080
	tgtgcctaca	ggactgtgcc	caagccaggg	cctcagcctg	gccccatgg	atcactatgg	1140
	actgaagggt	gtctcagaag	ccttccggg	gacttgaaaa	ggttccctg	ttggatggag	1200
	gtgcactctg	gccagagaga	actggagagc	gtgggtgtc	tcggcgaagc	catggcttg	1260
	aaatttccaa	tgggagccat	gagttactgt	ctcagggaca	gaagcagatt	tttattcaga	1320
	cttccgatgg	gcttatcttg	tccctccag	gtacaatagt	gtctcaggag	gaggacattg	1380
	tcacagtgac	tgtatgcagag	gggcgtgcct	gcccgtgggc	ccgctagaag	gagttccctt	1440
	agaagctgtg	gagtcggctcg	tcaccgcgag	agccctcaca	gtgaagtgg	gtcagatct	1500
	agattcgct	gattttatcc	agagaaggc	tatggcaagc	aatgtatatt	tttctaatgt	1560
	gaatattgca	catatgaacc	tttttattat	aaagaataat	gtcttctgc	cctgctgtct	1620
	acattttct	atggagcttg	tcataataat	agcagatatt	acctgtatcg	gaatccctgt	1680
	ggcgcgtctg	acgctcatga	gtttttcatg	atggatgtat	gtagcactgc	actgtcacct	1740
	gatgattggc	cctgctccgt	ttcccttctc	tcctgggaga	tatgctgctt	ttccaccaga	1800
	cttgctccat	actagaagct	tctttgggt	tcaattaaaa	agaaaataag	ctagtcattc	1860
	tgcccagcat	tttattgata	gaagggggaa	aaagtcat	ctacttgcatt	gatttttaa	1920
	attaaat	attaaat	tttaaaaa				1948

25 <210> 4
<211> 1486
<212> DNA
<213> Homo sapiens

<400> 4		60
30	ccgcggccgc gtccggggtc tccagtaggg ctgacgctcc ggtgctcgca caatcccccg	120
	cctcggtctgg caacgggcgt ccctccactc cccgagtcgg cggcagccgc cgccacccca	180
	gchgcccccg atctggcccc ctgcccccg aagatggctg ccgtacgccc gccccgcagt	240
	tattgcccgt gcctgggtcg cttctccgac cgagaactct gctaagctcc gtcgcagaga	300
	caggcaggag tagacaccccg gacaccggc accccctcctc cggggggccgg tgcagagggg	360
35	gcacggagag cccctcgagc gcagcaggcc gccccggccag catggcagaa gctgaggaag	420
	atttgtatcc tgatactgtc agagcagatg atgatgaaga aaatgaaat cctgtctgaaa	480
	cagatctgca ggcacaactc catggatgtcc gagctcagt gatgttcaa cttgtctccag	540
	gtgtaaatgc tagcaattta aaaaatcgac cttcgagac agcaagaggg ctctccaga	600
	aaacatcgcc agataccaaa gaaaaacaag aacaggcaaa agaagaaaaag gctcgagaac	660
40	tcttccttaaa agcagtagaa gaagaacaaa atggagctct ctatgaagcc atcaagttt	720
	atcgttagggc tatgcaactt gtacctgata tagagttcaa gattacttat acccggtctc	780
	cagatggta tggcggttggc aacagctaca ttgaagataa tgatgatgac agcaaaatgg	840
	cagatcttt gtcctacttc cagcagcaac tcacattca ggagtctgtg cttaaactgt	900
	gtcagcctga gcttgagagc agtcagattc acatatcagt gctgccaatg gaggtctga	960
45	tgtacatctt ccgatgggtg gtgtcttagt acttggacct cagatcattt gagcagttgt	1020
	cgctgggtgtg cagaggattc tacatctgtg ccagagaccc taaaatatgg cgtctggcct	1080
	gcttggaaatg ttggggcaga agctgttata aacttggtcc gtacacgtcc tggagagaga	1140
	tgttttttaga acggcctgt gttcggtttt atggcgtgtg tatacgtaaa accacatata	1200
	ttcgtcaagg ggaacagtct cttgatgtt tctatagagc ctggcaccaa gtggatatt	1260
	acaggatcat aagattctt cctgtatggc atgtatgtat gttgacaacc cctgaagagc	1320
50	ctcagtcctat tgttccacgt ttaagaacta gggatataa ggactgtatgc caatttctact	1380
	gggtcactat cgcttggcac aagacacaga ccatcagacc caaatgtt tgctgtataata	1440
	actaagaaaa aaaggaagaa aaaccactt gactataaat acccgatatt ttctgtcgcccc	1486
	ttccctgtacc aaagaqccg aatcagaagt ttcatqnnq qqqctn	

55 <210> 5
<211> 774
<212> DNA
<213> *Homo sapiens*

60	<400> 5	
	tgcgccaccc caccggccccc caccggccccc atgcaacggg attgaagggt cctggccggtg	60
	gacccctgtc cggcccgatgt ccactggccc ccgaggctgc tagacgtagg tgtaggcatt	120
	gtccccaccca cccggccgcct cccacggcac ctcggggaca ccagagctgc cgacttggag	180
65	actctctggtc tgtgaagagc cggtggtgcc cgtgcccgcga ggaactggc tgggccttgt	240
	gcgcccgtgg ggtctgcgcgt tggctttct gtgcttggat ttgcattttt attgcattgc	300
	tggtagagac ccccaaggccgt gtccacccctg ccaagactcc tcaggcagcg tggggtccc	360
	gcactctgtcc cccattttccc cgatgtcccc tgcggccgcgc ggcagccacc caagcctgt	420

ggctgcggcc	ccctctcgcc	caggcattgg	ctcagccccgc	tgagtggggg	gtcgtggcc	480
agtccccgag	gagctggcc	cctgcacagg	cacacaggc	ccggccacac	ccagcggccc	540
cccgcacagc	caccctgtgg	gtgctgcct	tatgcccgc	gccgggcacc	aactccatgt	600
ttggtgtttt	tctgttttgc	ttttcaaga	aatgattcaa	attgctgctt	ggatttgaa	660
5 atttactgt	actgtcagt	tacacgtctg	gaccggcgtt	cattttaca	ccaatttggt	720
aaaaatgctg	ctctcagcct	cccacaatta	aaccgcgt	gatctccaaa	aaaa	774

<210> 6
<211> 2936

10 <212> DNA
<213> Homo sapiens

<400> 6

cgtaaccctt	agtcccaatg	cctccgttaag	cgaggatgttag	tgggtgcctg	tgggtggagc	60
15 tggggaggtt	ccccgggtgg	cgagcgcggc	cagaactgcg	gtcacttaag	tttccgtgt	120
gccccgtca	aggagcgtgc	gtgcgtctgg	tatagggagg	acacctctgg	attgaggatc	180
ttatgaccta	cttttagagga	aggtataatt	tggcttcctg	agattctgcc	ttagcaagaa	240
aggagtggga	aatacccttg	gaaagaaaaac	taaaacagta	agaaagccaa	aaccttatttt	300
20 tacatggttt	tcagcacatt	taccgatatg	gacactttc	ccaaaaattt	tcctccgtgt	360
ggagacagtg	gattgacagg	ttctcagtcg	gagttccaga	aaatgttaat	tgtgaaaagg	420
ttacatgtgt	agcatcataa	agctaattat	cagacactga	aggctgaaca	cacaagggtt	480
cagaatgaac	atgttaaagt	aaaaaaatgaa	ctcaagcacc	tgtttaatga	aaagcaaaact	540
caggagaaa	aacttcagct	cctgcttgg	gaactaagag	gagaatttagt	agagaaaact	600
25 aaagatttag	aagaatgaa	actgcagata	ttaactccca	aaaattgaa	ttgctaagag	660
coccaataca	acaagaattt	gaaactccaa	tgagagaacg	ttttaggaat	ctagatgaag	720
aggttagaaaa	gtataagact	gtatataata	agctcgcta	tgaacatata	tttctcaagt	780
cagaatttga	acaccagaag	gaagagtatg	cacgtatttt	agatgaagga	aaaataaaaat	840
atgaatcaga	gattgcaaga	ctggaggaag	ataaagaaga	actacgtaa	cagtcgttta	900
30 atgttgcatt	cacaaaagac	agcaaaacgag	tggacaact	tgctcgagaa	aaagtctatt	960
tgtgtcaaaa	attaaaaggt	ttagaggctg	aagtagcgg	attaaagct	gaaaaggaga	1020
attctgaggc	tcaggtggaa	aatgcccataa	gaatacaggt	gccccgttgc	gctgagatgc	1080
aggctacagt	cagatccctg	ggggctgaaa	aacaatcage	taatttacgg	gcagaacgcct	1140
tggaaaaaga	gctacaatca	gcgatgtgg	aaaatccctt	ttttaattaaat	aaattgcata	1200
35 aagctgaaac	agaaaaataat	acattgtcc	gtaaatggaa	agaacttaaa	cattcaaaca	1260
aactggaaat	aacagacatc	aaactggaga	cagcaagagc	taagagttag	ctagaaagag	1320
aaaggaataa	gcttcaaagt	gaactggatg	gattacagtc	agacaatgaa	attctcaaag	1380
cagctgttga	acatcacaaa	gtgctcttag	tagaaaagga	tcgtgaatta	atacgtaaag	1440
tacaagctgc	caaagaagaa	ggttatcaaa	aacttgttgg	attacaagat	gaaaagttag	1500
40 aactcgagaa	cagatttagca	gatttggaga	aaatggaaat	ggaacatgtat	gtctggaggc	1560
aatctgaaaa	ggatcagttat	gaagagaaaat	tgcggccttc	acagatggca	gaagagatca	1620
ccaggaagga	gcttcaagat	tttaggtttaa	aacttcagca	acaaatttgc	actattgaaa	1680
atgcagagaa	ggaaaaaaat	gaaaattctg	acctaaaaca	gcaaatcagt	agtttgcaga	1740
tccaagtgtac	ttcacttgca	cagtcagaga	atgacttgct	gaatttcaac	caaatgtca	1800
45 agggaaatgg	ggagagatca	aaacaagaat	gcccggat	ttagaagccaa	gtgtaaaaag	1860
cgcactaga	agtcggaaat	acattggaaag	agaaaaagat	acagtgggtt	gaagaaaaagc	1920
ataagctca	tgaccgtatc	acagacagag	aagaaaaatg	caatcaagct	aggagaaaaac	1980
tgcagcgagc	tgcaatttgcc	cagaaaaaaa	gaaaatctct	tcatgaaaac	aaatttggaaa	2040
gactacaaga	gaaagttagaa	gtcttggagg	caaagaaaag	agaatttggaa	acagaaatca	2100
50 ggtcttaat	agacaaaatg	ttcctttgaa	gactataca	ggcttcaaaa	aagactaaaa	2160
gatatacaga	gaagacataa	tgaatttgc	agtctaattt	tgggtccaa	catgcctcca	2220
acagcatcta	tcaatccctgt	tagctttcg	tcatcagcc	tgggtccaa	catggaaacta	2280
ccatttcctc	ctcatatgca	ggagggacaa	catcaaagg	aactctctt	acttcgcata	2340
agactagaag	aactggaaac	aacacaaaaga	aaacaactag	aggaacttgg	atcttccgga	2400
55 gaatgtatgt	cttggagaac	aggcagatca	aaagggatgt	agtttgggtac	tcgtaaaaac	2460
ttgacatttt	aacctgtggc	atttagat	ttttactgt	ttgccaaaac	acttgaatgt	2520
gcctcaagaa	aaggtaacta	ctacatgtcg	tattgtatga	ctgtcaggat	tttaagat	2580
tacaagtgt	gcattaaaag	agaaaattctc	agagatattt	agaatatttgc	acaatgttt	2640
55 gagaatgtaa	aacaaaagg	aacttagtt	agtcagttt	taaaattttgc	actttgttgc	2700
atttttttt	ttggcatttt	gagtgttata	taactatcat	taattctctc	ttcatcttgc	2760
60 agatgcttgg	ccataaacagg	gtccatacac	atcttctgtt	ttactatata	caaaaactgt	2820
agttgaaaaaa	agatgacaat	ttaaaagtca	gcctaaagaa	tgtaaagta	tctatataca	2880
aaaggctacc	ttttctaaaa	tctgtgtgc	cataattaaa	gagcttaatt	ttttaaa	2936

65 <210> 7
<211> 1387
<212> DNA
<213> Homo sapiens

<400> 7

aaaggctaca	tcattaacac	tagaaggagg	acgattaaaa	cgaactccac	agctgattca	60
tggaaagagac	tatgaaatgg	tcccagaacc	tgtgtggaga	gcactttatc	actggatgg	120
agcaaacctg	gccttaccta	gaccagttat	caagaacagc	aagacagaca	tcccagact	180
ggaatttattt	ccccgctatc	ttcttcttct	gagacagcg	cctgcccactc	ggacacagca	240
gtctaacatc	tgggtgaata	tggaaatgt	accttctccg	aatgcacctt	taaagcgggt	300
attagcctat	acaggctgtt	ttagtcgaat	gcagaccatc	aaggaaattc	acgaatatct	360
atctcaaagg	ctgcccatta	aagaggaaga	tatgcccctg	tggctataca	acagtgagaa	420
ctaccttact	cttctggatg	atgaggatca	taaattggaa	tatttggaaa	tccaggatga	480
acaacacctg	gtaattgaag	ttcgcaacaa	agatatgagt	tggcctgagg	agatgtctt	540
tatagcaaat	agtagtaaaa	tagatagaca	caaggtccc	acagaaaagg	gagccacagg	600
tctaagcaat	ctggaaacaa	catgctcat	gaactcaagc	atccagtgt	ttagtaacac	660
acagccactg	acacagtatt	ttatctcagg	gagacatctt	tatgaactca	acaggacaaa	720
tcccatttgt	atgaaggggc	atatggctaa	atgctatgtt	hatttagtgc	aggaacttgc	780
gagtggaact	cagaagaatg	ttgccccatt	aaagcttcgg	tggaccatag	aaaaatatgc	840
tcccagggtt	aatgggtttc	agcaacagga	cttccaagaa	cttctggctt	ttctcttgc	900
tggtcttcat	gaagatctt	atcgagtcca	tggaaaagcca	tatgtggAAC	tgaaggacag	960
tgtatggcga	ccagactggg	aagtagctgc	agaggcctgg	gacaaccatc	taagaagaaa	1020
tagatcaatt	gttggatt	tggtccatgg	gcagctaaga	tctcaagtaa	aatgcaagac	1080
atgtggccat	ataagtgtcc	gatttgaccc	tttcaatttt	ttgtctttgc	cactaccaat	1140
ggacagcttat	atgcacttag	aaataacagt	gattaagttt	gatggacta	ccctgtacg	1200
gtatggacta	agactgataa	tggatggaaa	gtacacaggt	ttaaaaaaac	agctgagtga	1260
tctctgttgg	ctttaatttag	aacaaatctt	tettagcagaa	gtacatggtt	ccaacataaa	1320
gaactttctt	caggacaacc	caaaaatgtac	cgaacttctc	agtgaagtgg	gatttttttgg	1380
tgtgcca						1387

<210> 8

<211> 749

<212> DNA

<213> Homo sapiens

<400> 8

gccccaaatcg	gctggagcgc	ggcgagggtg	agccggccgc	ccgccccgcag	acgccccagc	60
ctactgcgcc	cgagtcccgc	ggccccagtg	gcccctcagc	tctgcgggtgc	cgaggcccaa	120
cggctcgatc	gctgcccgc	gccagcatgt	ttgggcgcggc	ggacgagagc	tccgtgcggg	180
tggctgtcag	aataagacca	cagcttgcca	aagagaagat	tgaaggatgc	catatttgta	240
catctgtcac	accaggagag	cctcaaggct	tccttagggaa	agataaggct	tttacttttg	300
actatgtatt	tgacatttgac	tcccagcaag	agcagatcta	cattcaatgt	atagaaaaac	360
taattgaagg	ttgctttgaa	ggataacaatg	ctacagttt	tgcttatgga	caaactggag	420
ctggtaaaac	atacacaaatg	ggaacaggat	ttgatgttaa	cattgttgag	gaagaactgg	480
gtattatttc	tcgagctgtt	aaacacctt	ttaagagtt	tgaaaaaaa	aaacacatag	540
caattaaaaa	tggccttcct	gctccagatt	ttaaagtgaa	tgcccaattc	ttagagctct	600
ataatgaaga	ggtccttgac	ttatttgata	ccactcgtga	tattgtatca	aaaagtaaaa	660
aatcaaatat	aagaattcat	gaagattcaa	ctggaggggaa	tttatactgt	gggcgtttcc	720
aacacqtact	qtqaatacag	aatcnagq				749

<210> 9

<211> 686

<212> DNA

<213> Homo sapiens

<400> 9

tggaaattat	agacctagca	aaaaaaagatt	tagagaaggt	tgnaaaagaaa	agaaaaagagg	60
aagnaaaaaaaa	gtgtggctgg	taaagaggat	aatacagaca	ctgaccaaga	gaagaaaagaa	120
aaaaaggggtg	tttcggaaag	agaaacccaa	tgaatttagaa	gtggaaagaaa	gtcaagaagt	180
gagtgtatcat	gaggatgaag	aagaggagga	ggaggaggag	gaagatgaca	ttgatggggg	240
tgaaaaggttct	gatgaatcag	attctgaatc	agatgaaaaa	gccnattatc	aagcagactt	300
ggcaaaacatt	acttgtgaaa	ttgcaattaa	gcaaaagctg	attgtatgaac	tagaaaacag	360
ccagaaaaaga	ctgcagactc	tgaaaaagca	gtatgaagag	aagntaatga	tgctgcAACa	420
taaaatttcgg	gatactcagc	ttgaaagaga	ccaggtgttt	caaaaacttag	gctcggtaga	480
atcttactca	gaagaaaaaaag	caaaaaaagt	taggtctgaa	tatgaaaaga	aactccaagc	540
catgaacaaa	gaactgcaga	gacttcaagc	agctcaaaaa	gaacatgca	ggttgcttaa	600
aaatcagtct	cagtatgaaa	agcnattgaa	gaaattgcag	caggatgtga	tggaaatgaa	660
aaaaacaaaq	qttcqccctaa	tqaaaa				686

<210> 10

<211> 833
<212> DNA
<213> *Homo sapiens*

5	<400> 10	gttcttctgt	cggccggcttc	agcagccccgc	gcccgccggcag	gaatagaaga	tgaacaaacc	60
		cataaacacca	tcaacatatg	tgcgctggct	caatgttgg	ctaatttagga	agctgtcaga	120
		tttttattgtat	cctcaagaag	gatggaaagaa	gttagctgt	gctattaaaa	aaccatctgg	180
		tgatgtataga	tacaatcagt	ttcacataag	gagatttga	gcattacttc	aaactggaaa	240
10	aagtcccact	tctgaattac	tggttgactg	gggcaccacac	aattgcacag	ttggtgatct	300	
	tgtggatctt	ttgatccaaa	atgaattttt	tgctcctgcg	agtctttgc	tcccagatgc	360	
	tgttccaaa	actgctaata	cactaccc	taaagaagct	ataacagttc	agcaaaaaaca	420	
	gatgccttc	tgtgacaaaag	acaggacat	gatgacacct	gtgcagaatc	ttgaacaaag	480	
	ctatatgc	cctgactcct	caagtccaga	aaataaaaagt	ttagaagtt	gtgatacacg	540	
15	tttcacagt	ttttcatttt	atgtatggaa	gaatgtcaca	aataacttgc	atgaacgacc	600	
	catttctgtt	ggtggtaata	aaatggggaga	ggggaggattt	ggatgttat	ataaagggtc	660	
	acgttaataa	cacaactgtg	gcagtggaa	aagcttgcag	caatgggtga	cattactact	720	
	gaaggaaactg	aaaccagcag	tttgatccaa	gaaaataaaa	gtaatgggc	aaagtggtca	780	
	accatggaaa	aactttagta	ggAACCTACT	TGGGTTTCT	caagtggatg	gga	833	

20 <210> 11
<211> 799
<212> DNA
<213> *Homo sapiens*

25	<400> 11	
	taaaaatatac cccttngatg atacacctgcca ataatgatata gtcggcattat tagattatgt	60
	tacatgccaa agtttaaagg aatttgggca gatccagttt aggttcctta aacaacntca	120
	cttggagact gttggaaaggg cctgacccaa tccaaatgtt gcccggccaa gaagaattct	180
30	ccttggtaaagc cttggaaaggag tatgtgagag ggccacattt gctaaaaccc aaagggtggcc	240
	tctaggagat gagacccatcc ttccagttt cagcaaggag gaaaaaaaaa ttggggacctc	300
	agttggcaacc acaaggaact gaattctgaa aaaaatntga gtcagcttag aagagtaactc	360
	caaggttccat atgataaccat cagggccggc tgacacccgg atttagctt gcatgatccct	420
	cagtatgaga atctatctgt tctgtgtctgg acttcttaata tataagaactg tgagataatg	480
35	ggtcacatgg gctggatgtg gtggctcatc cctgtttttt ccagcactt gggaggccga	540
	ggcaggccaga tcacccgttgg tcaagagttt aagaccggcc tggccaaatcat ggtggaaacc	600
	cgtctntact aaaaatacaa aaatttagacg agcgtgttgg tggacacccctg tagtcccacg	660
	tgcttgggag gctgaggcag gagactagctt ggaaccaggg aggttagaggt tgcaatgttggc	720
40	tgagatcgatccactt ccactgttggg tgacagatgtt agactccatc ataaataat	780
	aaataaaatataa atgggttcnc	799

45 <210> 12
<211> 812
<212> PRT
<213> *Homo sapiens*

<400> 12
 Met Ala Gly Gly His Cys Gly Ser Phe Pro Ala Ala Ala Ala Gly Ser
 1 5 10 15
 Gly Glu Ile Val Gln Leu Asn Val Gly Gly Thr Arg Phe Ser Thr Ser
 20 25 30
 Arg Gln Thr Leu Met Trp Ile Pro Asp Ser Phe Phe Ser Ser Leu Leu
 35 40 45
 Ser Gly Arg Ile Ser Thr Leu Arg Asp Glu Thr Gly Ala Ile Phe Ile
 50 55 60
 Asp Arg Asp Pro Ala Ala Phe Ala Pro Ile Leu Asn Phe Leu Arg Thr
 65 70 75 80
 Lys Glu Leu Asp Leu Arg Gly Val Ser Ile Asn Val Leu Arg His Glu
 85 90 95
 Ala Glu Phe Tyr Gly Ile Thr Pro Leu Val Arg Arg Leu Leu Leu Cys
 100 105 110
 Glu Glu Leu Glu Arg Ser Ser Cys Gly Ser Val Leu Phe His Gly Tyr
 115 120 125
 Leu Pro Pro Pro Gly Ile Pro Ser Arg Lys Ile Asn Asn Thr Val Arg
 130 135 140
 Ser Ala Asp Ser Arg Asn Gly Leu Asn Ser Thr Glu Gly Glu Ala Arg
 145 150 155 160

Gly Asn Gly Thr Gln Pro Val Leu Ser Gly Thr Gly Glu Glu Thr Val
 165 170 175
 Arg Leu Gly Phe Pro Val Asp Pro Arg Lys Val Leu Ile Val Ala Gly
 180 185 190
 5 His His Asn Trp Ile Val Ala Ala Tyr Ala His Phe Ala Tyr Arg Ile
 195 200 205
 Lys Glu Ser Ser Gly Trp Gln Gln Val Phe Thr Ser Pro Tyr Leu Asp
 210 215 220
 Trp Thr Ile Glu Arg Val Ala Leu Asn Ala Lys Val Val Gly Gly Pro
 225 230 235 240
 His Gly Asp Lys Asp Lys Met Val Ala Val Ala Ser Glu Ser Ser Ile
 245 250 255
 Ile Leu Trp Ser Val Gln Asp Gly Gly Ser Gly Ser Glu Ile Gly Val
 260 265 270
 15 Phe Ser Leu Gly Val Pro Val Asp Ala Leu Phe Phe Ile Gly Asn Gln
 275 280 285
 Leu Val Ala Thr Ser His Thr Gly Lys Val Gly Val Trp Asn Ala Val
 290 295 300
 Thr Gln His Trp Gln Val Gln Asp Val Val Pro Ile Thr Ser Tyr Asp
 20 305 310 315 320
 Thr Ala Gly Ser Phe Leu Leu Leu Gly Cys Asn Asn Gly Ser Ile Tyr
 325 330 335
 Tyr Ile Asp Met Gln Lys Phe Pro Leu Arg Met Lys Asp Asn Asp Leu
 340 345 350
 25 Leu Val Thr Glu Leu Tyr His Asp Pro Ser Asn Asp Ala Ile Thr Ala
 355 360 365
 Leu Ser Val Tyr Leu Thr Pro Lys Thr Ser Val Ser Gly Asn Trp Ile
 370 375 380
 Glu Ile Ala Tyr Gly Thr Ser Ser Gly Ala Val Arg Val Ile Val Gln
 30 385 390 395 400
 His Pro Glu Thr Val Gly Ser Gly Pro Gln Leu Phe Gln Thr Phe Thr
 405 410 415
 Val His Arg Ser Pro Val Thr Lys Ile Met Leu Ser Glu Lys His Leu
 420 425 430
 35 Val Ser Val Cys Ala Asp Asn Asn His Val Arg Thr Trp Thr Val Thr
 435 440 445
 Arg Phe Gly Met Ile Ser Thr Gln Pro Gly Ser Thr Pro Leu Ala Ser
 450 455 460
 Phe Lys Ile Leu Ser Leu Glu Glu Thr Glu Ser His Gly Ser Tyr Ser
 465 470 475 480
 40 Ser Gly Asn Asp Ile Gly Pro Phe Gly Glu Arg Asp Asp Gln Gln Val
 485 490 495
 Phe Ile Gln Lys Val Val Pro Ile Thr Asn Lys Leu Phe Val Arg Leu
 500 505 510
 45 Ser Ser Thr Gly Lys Arg Ile Cys Glu Ile Gln Ala Val Asp Cys Thr
 515 520 525
 Thr Ile Ser Ser Phe Thr Val Arg Glu Cys Glu Gly Ser Ser Arg Met
 530 535 540
 Gly Ser Arg Pro Arg Arg Tyr Leu Phe Thr Gly His Thr Asn Gly Ser
 545 550 555 560
 Ile Gln Met Trp Asp Leu Thr Thr Ala Met Asp Met Val Asn Lys Ser
 565 570 575
 Glu Asp Lys Asp Val Gly Gly Pro Thr Glu Glu Leu Leu Lys Leu
 580 585 590
 55 Leu Asp Gln Cys Asp Leu Ser Thr Ser Arg Cys Ala Thr Pro Asn Ile
 595 600 605
 Ser Pro Ala Thr Ser Val Val Gln His Ser His Leu Arg Glu Ser Asn
 610 615 620
 60 Ser Ser Leu Gln Leu Gln His His Asp Thr Thr His Glu Ala Ala Thr
 625 630 635 640
 Tyr Gly Ser Met Arg Pro Tyr Arg Glu Ser Pro Leu Leu Ala Arg Ala
 645 650 655
 Arg Arg Thr Glu Ser Phe His Ser Tyr Arg Asp Phe Gln Thr Ile Asn
 660 665 670
 65 Leu Asn Arg Asn Val Glu Arg Ala Val Pro Glu Asn Gly Asn Leu Gly
 675 680 685
 Pro Ile Gln Ala Glu Val Lys Gly Ala Thr Gly Glu Cys Asn Ile Ser

	690		695		700												
	Glu	Arg	Lys	Ser	Pro	Gly	Val	Glu	Ile	Lys	Ser	Leu	Arg	Glu	Leu	Asp	
5	705					710				715						720	
	Ser	Gly	Leu	Glu	Val	His	Lys	Ile	Ala	Glu	Gly	Phe	Ser	Glu	Ser	Lys	
						725				730						735	
	Lys	Arg	Ser	Ser	Glu	Asp	Glu	Asn	Glu	Asn	Lys	Ile	Glu	Phe	Arg	Lys	
					740				745							750	
10	Lys	Gly	Gly	Phe	Glu	Gly	Gly	Gly	Phe	Leu	Gly	Arg	Lys	Lys	Val	Pro	
					755				760							765	
	Tyr	Leu	Ala	Ser	Ser	Pro	Ser	Thr	Ser	Asp	Gly	Gly	Thr	Asp	Ser	Pro	
					770			775					780				
	Gly	Thr	Ala	Ser	Pro	Ser	Pro	Thr	Lys	Thr	Thr	Pro	Ser	Pro	Arg	His	
15	785						790				795						800
	Lys	Lys	Ser	Asp	Ser	Ser	Gly	Gln	Glu	Tyr	Ser	Leu					
						805				810							

20 <210> 13
<211> 167
<212> PRT
<213> *Homo sapiens*

<400> 13
 Leu Ala Ser Ala Arg Ile Pro Gly Arg Pro Tyr Val Gly Val Leu Arg
 1 5 10 15
 Pro Pro Gly Ser Leu Phe Phe Ala Pro Ala Gly Thr Thr Ile Ser Ala
 20 25 30
 Leu Leu Gly Phe Cys Tyr Met Ala Ala Phe Leu Lys Met Ser Val Ser
 35 40 45
 Val Asn Phe Phe Arg Pro Phe Thr Arg Phe Leu Val Pro Phe Thr Leu
 50 55 60
 His Arg Lys Arg Asn Asn Leu Thr Ile Leu Gln Arg Tyr Met Ser Ser
 65 70 75 80
 Lys Ile Pro Ala Val Thr Tyr Pro Lys Asn Glu Ser Thr Arg Pro Ser
 85 90 95
 Glu Glu Leu Glu Leu Asp Lys Trp Lys Thr Thr Met Lys Ser Ser Val
 100 105 110
 Gln Glu Glu Cys Val Ser Thr Ile Ser Ser Ser Lys Asp Glu Asp Pro
 115 120 125
 Leu Ala Ala Thr Arg Glu Phe Ile Glu Met Trp Arg Leu Leu Gly Arg
 130 135 140
 Glu Val Pro Glu His Ile Thr Glu Glu Glu Leu Lys Thr Leu Met Glu
 145 150 155 160
 Cys Val Ser Asn Thr Ala Lys
 165

Arg Asp Met Asp Gly Glu Gln Leu Glu Gly Ala Ser Ser Glu Lys Arg
 130 135 140
 Glu Arg Glu Ala Ala Glu Glu Gly Leu Ala Ser Val Lys Arg Pro Arg
 145 150 155 160
 5 Arg Glu Ala Leu Ser Asn Asp Thr Thr Glu Ser Leu Ala Ala Asn Ser
 165 170 175
 Arg Gly Arg Glu Lys Pro Arg Pro Leu His Ala Leu Pro Ala Gly Phe
 180 185 190
 10 Ser Pro Pro Val Asn Val Thr Val Ser Pro Arg Ser Glu Glu Ser His
 195 200 205
 Thr Thr Thr Val Ser Gly Gly Asn Gly Ser Val Phe Gln Ala Gly Pro
 210 215 220
 Gln Leu Gln Ala Leu Ala Asn Leu Glu Ala Arg Arg Gly Ser Ile Gly
 225 230 235 240
 15 Ala Ala Leu Ser Ser Arg Asp Val Ser Gly Leu Pro Val Tyr Ala Gln
 245 250 255
 Ser Gly Glu Pro Arg Arg Leu Thr Gln Ala Gln Val Ala Ala Phe Pro
 260 265 270
 20 Gly Glu Asn Ala Leu Glu His Ser Ser Asp Gln Asp Thr Trp Asp Ser
 275 280 285
 Leu Arg Ser Pro Gly Phe Cys Ser Pro Leu Ser Ser Gly Gly Gly Ala
 290 295 300
 Glu Ser Leu Pro Pro Gly Gly Pro Gly His Ala Glu Ala Gly His Leu
 305 310 315 320
 25 Gly Lys Val Cys Asp Phe His Leu Asn His Gln Gln Pro Ser Pro Thr
 325 330 335
 Ser Val Leu Pro Thr Glu Val Ala Ala Pro Pro Leu Glu Lys Ile Leu
 340 345 350
 30 Ser Val Asp Ser Val Ala Val Asp Cys Ala Tyr Arg Thr Val Pro Lys
 355 360 365
 Pro Gly Pro Gln Pro Gly Pro His Gly Ser Leu Leu Thr Glu Gly Cys
 370 375 380
 Leu Arg Ser Leu Ser Gly Asp Leu Asn Arg Phe Pro Cys Gly Met Glu
 385 390 395 400
 35 Val His Ser Gly Gln Arg Glu Leu Glu Ser Val Val Ala Val Gly Glu
 405 410 415
 Ala Met Ala Leu Lys Phe Pro Met Gly Ala Met Ser Tyr Cys Leu Arg
 420 425 430
 40 Asp Arg Ser Arg Phe Leu Phe Arg Leu Pro Met Gly Leu Ser Cys Pro
 435 440 445
 Leu Gln Val Gln
 450

45 <210> 15
 <211> 321
 <212> PRT
 <213> Homo sapiens

50 <400> 15
 Met Ala Glu Ala Glu Glu Asp Cys His Ser Asp Thr Val Arg Ala Asp
 1 5 10 15
 Asp Asp Glu Glu Asn Glu Ser Pro Ala Glu Thr Asp Leu Gln Ala Gln
 20 25 30
 55 Leu Gln Met Phe Arg Ala Gln Trp Met Phe Glu Leu Ala Pro Gly Val
 35 40 45
 Ser Ser Ser Asn Leu Glu Asn Arg Pro Cys Arg Ala Ala Arg Gly Ser
 50 55 60
 Leu Gln Lys Thr Ser Ala Asp Thr Lys Gly Lys Gln Glu Gln Ala Lys
 65 70 75 80
 60 Glu Glu Lys Ala Arg Glu Leu Phe Leu Lys Ala Val Glu Glu Gln
 85 90 95
 Asn Gly Ala Leu Tyr Glu Ala Ile Lys Phe Tyr Arg Arg Ala Met Gln
 100 105 110
 65 Leu Val Pro Asp Ile Glu Phe Lys Ile Thr Tyr Thr Arg Ser Pro Asp
 115 120 125
 Gly Asp Gly Val Gly Asn Ser Tyr Ile Glu Asp Asn Asp Asp Ser
 130 135 140

Lys Met Ala Asp Leu Leu Ser Tyr Phe Gln Gln Gln Leu Thr Phe Gln
 145 150 155 160
 Glu Ser Val Leu Lys Leu Cys Gln Pro Glu Leu Glu Ser Ser Gln Ile
 165 170 175
 5 His Ile Ser Val Leu Pro Met Glu Val Leu Met Tyr Ile Phe Arg Trp
 180 185 190
 Val Val Ser Ser Asp Leu Asp Leu Arg Ser Leu Glu Gln Leu Ser Leu
 195 200 205
 10 Val Cys Arg Gly Phe Tyr Ile Cys Ala Arg Asp Pro Glu Ile Trp Arg
 210 215 220
 Leu Ala Cys Leu Lys Val Trp Gly Arg Ser Cys Ile Lys Leu Val Pro
 225 230 235 240
 Tyr Thr Ser Trp Arg Glu Met Phe Leu Glu Arg Pro Arg Val Arg Phe
 245 250 255
 15 Asp Gly Val Tyr Ile Ser Lys Thr Thr Tyr Ile Arg Gln Gly Glu Gln
 260 265 270
 Ser Leu Asp Gly Phe Tyr Arg Ala Trp His Gln Val Glu Tyr Tyr Arg
 275 280 285
 Tyr Ile Arg Phe Phe Pro Asp Gly His Val Met Met Leu Thr Thr Pro
 290 295 300
 20 Glu Glu Pro Gln Ser Ile Val Pro Arg Leu Arg Thr Arg Glu Tyr Gln
 305 310 315 320
 Asp

25 <210> 16
 <211> 172
 <212> PRT
 <213> Homo sapiens

30 <400> 16
 Ala Cys Pro Thr His Pro Pro Pro Pro Thr Ala Pro Arg Gly His Gln
 1 5 10 15
 Ser Cys Arg Leu Gly Asp Ser Trp Ser Val Lys Ser Arg Trp Cys Pro
 20 25 30
 35 Cys Pro Gln Glu Leu Gly Trp Ala Ser Cys Ala Arg Gly Val Cys Ala
 35 40 45
 Trp Ser Phe Cys Ala Trp Ile Cys Ile Phe Ile Ala Leu Leu Val Glu
 50 55 60
 40 Thr Pro Arg Pro Val His Pro Ala Lys Thr Pro Gln Ala Ala Cys Gly
 65 70 75 80
 Ser Arg Thr Leu Pro Pro Phe Pro Arg Cys Pro Leu Arg Ala Arg Ala
 85 90 95
 Ala Thr Gln Ala Cys Trp Leu Arg Pro Pro Leu Gly Gln Ala Leu Ala
 100 105 110
 45 Gln Pro Ala Glu Trp Gly Val Val Gly Gln Ser Pro Arg Ser Trp Ala
 115 120 125
 Pro Ala Gln Ala His Arg Ala Arg Pro His Pro Ala Ala Pro Arg Thr
 130 135 140
 50 Ala Thr Arg Gly Val Leu Pro Leu Cys Pro Ala Pro Gly Thr Asn Ser
 145 150 155 160
 Met Phe Gly Val Cys Leu Cys Leu Phe Phe Lys Lys
 165 170

55 <210> 17
 <211> 472
 <212> PRT
 <213> Homo sapiens

60 <400> 17
 Met Arg Glu Arg Phe Arg Asn Leu Asp Glu Glu Val Glu Lys Tyr Arg
 1 5 10 15
 Ala Val Tyr Asn Lys Leu Arg Tyr Glu His Thr Phe Leu Lys Ser Glu
 20 25 30
 65 Phe Glu His Gln Lys Glu Glu Tyr Ala Arg Ile Leu Asp Glu Gly Lys
 35 40 45
 Ile Lys Tyr Glu Ser Glu Ile Ala Arg Leu Glu Glu Asp Lys Glu

50	55	60	
Leu Arg Asn Gln Leu Leu Asn Val Asp Leu Thr Lys Asp Ser Lys Arg			
65	70	75	80
Val Glu Gln Leu Ala Arg Glu Lys Val Tyr Leu Cys Gln Lys Leu Lys			
5	85	90	95
Gly Leu Glu Ala Glu Val Ala Glu Leu Lys Ala Glu Lys Glu Asn Ser			
100	105	110	
Glu Ala Gln Val Glu Asn Ala Gln Arg Ile Gln Val Arg Gln Leu Ala			
115	120	125	
10	130	135	140
Glu Met Gln Ala Thr Val Arg Ser Leu Gly Ala Glu Lys Gln Ser Ala			
145	150	155	160
Asn Leu Arg Ala Glu Arg Leu Glu Lys Glu Leu Gln Ser Ser Ser Glu			
15	165	170	175
Gln Asn Thr Phe Leu Ile Asn Lys Leu His Lys Ala Glu Arg Glu Ile			
180	185	190	
Asn Thr Leu Ser Ser Lys Val Lys Glu Leu Lys His Ser Asn Lys Leu			
20	195	200	205
Glu Ile Thr Asp Ile Lys Leu Glu Thr Ala Arg Ala Lys Ser Glu Leu			
210	215	220	
Asp Asn Glu Ile Leu Lys Ala Ala Val Glu His His Lys Val Leu Leu			
225	230	235	240
Val Glu Lys Asp Arg Glu Leu Ile Arg Lys Val Gln Ala Ala Lys Glu			
25	245	250	255
Glu Gly Tyr Gln Lys Leu Val Val Leu Gln Asp Glu Lys Leu Glu Leu			
260	265	270	
Glu Asn Arg Leu Ala Asp Leu Glu Lys Met Lys Val Glu His Asp Val			
275	280	285	
30	290	295	300
Trp Arg Gln Ser Glu Lys Asp Gln Tyr Glu Glu Lys Leu Arg Ala Ser			
Gln Met Ala Glu Glu Ile Thr Arg Lys Glu Leu Gln Ser Val Arg Leu			
305	310	315	320
Lys Leu Gln Gln Ile Val Thr Ile Glu Asn Ala Glu Lys Glu Lys			
35	325	330	335
Asn Glu Asn Ser Asp Leu Lys Gln Gln Ile Ser Ser Leu Gln Ile Gln			
340	345	350	
Val Thr Ser Leu Ala Gln Ser Glu Asn Asp Leu Leu Asn Ser Asn Gln			
355	360	365	
40	370	375	380
Met Leu Lys Glu Met Val Glu Arg Leu Lys Gln Glu Cys Arg Asn Phe			
Arg Ser Gln Ala Glu Lys Ala Gln Leu Glu Ala Glu Lys Thr Leu Glu			
385	390	395	400
Glu Lys Gln Ile Gln Trp Leu Glu Glu Lys His Lys Leu His Asp Arg			
405	410	415	
45	420	425	430
Ile Thr Asp Arg Glu Glu Lys Tyr Asn Gln Ala Lys Glu Lys Leu Gln			
Arg Ala Ala Ile Ala Gln Lys Lys Arg Lys Ser Leu His Glu Asn Lys			
435	440	445	
50	450	455	460
Leu Lys Arg Leu Gln Glu Lys Val Glu Val Leu Glu Ala Lys Lys Glu			
Glu Leu Glu Thr Glu Ile Arg Ser			
465	470		

55 <210> 18
 <211> 462
 <212> PRT
 <213> Homo sapiens

60	65	70	75	80	
Lys Ala Thr Ser Leu Thr Leu Glu Gly Gly Arg Leu Lys Arg Thr Pro					
1	5	10	15		
Gln Leu Ile His Gly Arg Asp Tyr Glu Met Val Pro Glu Pro Val Trp					
20	25	30			
65	35	40	45		
Arg Ala Leu Tyr His Trp Tyr Gly Ala Asn Leu Ala Leu Pro Arg Pro					
Val Ile Lys Asn Ser Lys Thr Asp Ile Pro Glu Leu Glu Leu Phe Pro					

	50	55	60	
	Arg Tyr Leu Leu Phe Leu Arg Gln Gln Pro Ala Thr Arg Thr Gln Gln			
5	65	70	75	80
	Ser Asn Ile Trp Val Asn Met Gly Asn Val Pro Ser Pro Asn Ala Pro			
	85	90	95	
	Leu Lys Arg Val Leu Ala Tyr Thr Gly Cys Phe Ser Arg Met Gln Thr			
	100	105	110	
	Ile Lys Glu Ile His Glu Tyr Leu Ser Gln Arg Leu Arg Ile Lys Glu			
10	115	120	125	
	Glu Asp Met Arg Leu Trp Leu Tyr Asn Ser Glu Asn Tyr Leu Thr Leu			
	130	135	140	
	Leu Asp Asp Glu Asp His Lys Leu Glu Tyr Leu Lys Ile Gln Asp Glu			
15	145	150	155	160
	Gln His Leu Val Ile Glu Val Arg Asn Lys Asp Met Ser Trp Pro Glu			
	165	170	175	
	Glu Met Ser Phe Ile Ala Asn Ser Ser Lys Ile Asp Arg His Lys Val			
	180	185	190	
	Pro Thr Glu Lys Gly Ala Thr Gly Leu Ser Asn Leu Gly Asn Thr Cys			
	195	200	205	
20	Phe Met Asn Ser Ser Ile Gln Cys Val Ser Asn Thr Gln Pro Leu Thr			
	210	215	220	
	Gln Tyr Phe Ile Ser Gly Arg His Leu Tyr Glu Leu Asn Arg Thr Asn			
	225	230	235	240
25	Pro Ile Gly Met Lys Gly His Met Ala Lys Cys Tyr Gly Asp Leu Val			
	245	250	255	
	Gln Glu Leu Trp Ser Gly Thr Gln Lys Asn Val Ala Pro Leu Lys Leu			
	260	265	270	
	Arg Trp Thr Ile Ala Lys Tyr Ala Pro Arg Phe Asn Gly Phe Gln Gln			
	275	280	285	
30	Gln Asp Ser Gln Glu Leu Leu Ala Phe Leu Leu Asp Gly Leu His Glu			
	290	295	300	
	Asp Leu Asn Arg Val His Glu Lys Pro Tyr Val Glu Leu Lys Asp Ser			
	305	310	315	320
35	Asp Gly Arg Pro Asp Trp Glu Val Ala Ala Glu Ala Trp Asp Asn His			
	325	330	335	
	Leu Arg Arg Asn Arg Ser Ile Val Val Asp Leu Phe His Gly Gln Leu			
	340	345	350	
	Arg Ser Gln Val Lys Cys Lys Thr Cys Gly His Ile Ser Val Arg Phe			
	355	360	365	
40	Asp Pro Phe Asn Phe Leu Ser Leu Pro Leu Pro Met Asp Ser Tyr Met			
	370	375	380	
	His Leu Glu Ile Thr Val Ile Lys Leu Asp Gly Thr Thr Pro Val Arg			
	385	390	395	400
45	Tyr Gly Leu Arg Leu Asn Met Asp Glu Lys Tyr Thr Gly Leu Lys Lys			
	405	410	415	
	Gln Leu Ser Asp Leu Cys Gly Leu Asn Ser Glu Gln Ile Leu Leu Ala			
	420	425	430	
	Glu Val His Gly Ser Asn Ile Lys Asn Phe Pro Gln Asp Asn Pro Lys			
	435	440	445	
50	Ser Thr Glu Leu Leu Ser Glu Val Gly Phe Phe Gly Val Pro			
	450	455	460	

<210> 19

<211> 243

<212> PRT

<213> Homo sapiens

<400> 19

60	Pro Thr Trp Leu Glu Arg Gly Gly Glu Pro Ala Ala Arg Pro Gln			
	1	5	10	15
	Thr Pro Gln Pro Thr Ala Pro Glu Ser Arg Gly Pro Ser Gly Ala Ser			
	20	25	30	
	Ala Leu Arg Cys Arg Gly Pro Thr Ala Arg Ser Leu Pro Ala Ala Ser			
	35	40	45	
65	Met Leu Gly Ala Pro Asp Glu Ser Ser Val Arg Val Ala Val Arg Ile			
	50	55	60	
	Arg Pro Gln Leu Ala Lys Glu Lys Ile Glu Gly Cys His Ile Cys Thr			

65	70	75	80
Ser Val Thr Pro Gly Glu Pro Gln Val Phe Leu Gly Lys Asp Lys Ala			
85	90	95	
Phe Thr Phe Asp Tyr Val Phe Asp Ile Asp Ser Gln Gln Glu Gln Ile			
100	105	110	
Tyr Ile Gln Cys Ile Glu Lys Leu Ile Glu Gly Cys Phe Glu Gly Tyr			
115	120	125	
Asn Ala Thr Val Phe Ala Tyr Gly Gln Thr Gly Ala Gly Lys Thr Tyr			
130	135	140	
10	Thr Met Gly Thr Gly Phe Asp Val Asn Ile Val Glu Glu Glu Leu Gly		
145	150	155	160
Ile Ile Ser Arg Ala Val Lys His Leu Phe Lys Ser Ile Glu Glu Lys			
165	170	175	
15	Lys His Ile Ala Ile Lys Asn Gly Leu Pro Ala Pro Asp Phe Lys Val		
180	185	190	
Asn Ala Gln Phe Leu Glu Leu Tyr Asn Glu Glu Val Leu Asp Leu Phe			
195	200	205	
Asp Thr Thr Arg Asp Ile Asp Ala Lys Ser Lys Lys Ser Asn Ile Arg			
210	215	220	
20	Ile His Glu Asp Ser Thr Gly Gly Asn Leu Tyr Cys Gly Arg Phe Gln		
225	230	235	240
His Val Leu			

25 <210> 20
 <211> 223
 <212> PRT
 <213> Homo sapiens
 30 <400> 20
 Gly Asn Tyr Arg Pro Ser Lys Lys Arg Phe Arg Glu Gly Lys Glu Lys
 1 5 10 15
 Lys Arg Gly Lys Lys Val Trp Leu Val Lys Arg Ile Ile Gln Thr Leu
 20 25 30
 35 Thr Lys Arg Arg Lys Lys Lys Arg Val Phe Arg Lys Glu Lys Pro Asn
 35 40 45
 Glu Leu Glu Val Glu Glu Ser Gln Glu Val Ser Asp His Glu Asp Glu
 50 55 60
 40 Glu Glu Glu Glu Glu Glu Asp Asp Ile Asp Gly Gly Glu Ser
 65 70 75 80
 Ser Asp Glu Ser Asp Ser Glu Ser Asp Glu Lys Ala Tyr Gln Ala Asp
 85 90 95
 Leu Ala Asn Ile Thr Cys Glu Ile Ala Ile Lys Gln Lys Leu Ile Asp
 100 105 110
 45 Glu Leu Glu Asn Ser Gln Lys Arg Leu Gln Thr Leu Lys Lys Gln Tyr
 115 120 125
 Glu Glu Lys Met Met Leu Gln His Lys Ile Arg Asp Thr Gln Leu Glu
 130 135 140
 50 Arg Asp Gln Val Leu Gln Asn Leu Gly Ser Val Glu Ser Tyr Ser Glu
 145 150 155 160
 Glu Lys Ala Lys Lys Val Arg Ser Glu Tyr Glu Lys Lys Leu Gln Ala
 165 170 175
 Met Asn Lys Glu Leu Gln Arg Leu Gln Ala Ala Gln Lys Glu His Ala
 180 185 190
 55 Arg Leu Leu Lys Asn Gln Ser Gln Tyr Glu Lys Leu Lys Lys Leu Gln
 195 200 205
 Gln Asp Val Met Glu Met Lys Lys Thr Lys Val Arg Leu Met Lys
 210 215 220
 60 <210> 21
 <211> 206

65 <400> 21
Met Asn Lys Pro Ile Thr Pro Ser Thr Tyr Val Arg Cys Leu Asn Val
1 5 10 15

Gly Leu Ile Arg Lys Leu Ser Asp Phe Ile Asp Pro Gln Glu Gly Trp
 20 25 30
 Lys Lys Leu Ala Val Ala Ile Lys Lys Pro Ser Gly Asp Asp Arg Tyr
 35 40 45
 5 Asn Gln Phe His Ile Arg Arg Phe Glu Ala Leu Leu Gln Thr Gly Lys
 50 55 60
 Ser Pro Thr Ser Glu Leu Leu Phe Asp Trp Gly Thr Thr Asn Cys Thr
 65 70 75 80
 10 Val Gly Asp Leu Val Asp Leu Leu Ile Gln Asn Glu Phe Phe Ala Pro
 85 90 95
 Ala Ser Leu Leu Pro Asp Ala Val Pro Lys Thr Ala Asn Thr Leu
 100 105 110
 Pro Ser Lys Glu Ala Ile Thr Val Gln Gln Lys Gln Met Pro Phe Cys
 115 120 125
 15 Asp Lys Asp Arg Thr Leu Met Thr Pro Val Gln Asn Leu Glu Gln Ser
 130 135 140
 Tyr Met Pro Pro Asp Ser Ser Pro Glu Asn Lys Ser Leu Glu Val
 145 150 155 160
 20 Ser Asp Thr Arg Phe His Ser Phe Ser Phe Tyr Glu Leu Lys Asn Val
 165 170 175
 Thr Asn Asn Phe Asp Glu Arg Pro Ile Ser Val Gly Gly Asn Lys Met
 180 185 190
 Gly Glu Gly Phe Gly Val Val Tyr Lys Gly Leu Arg Lys
 195 200 205
 25
 <210> 22
 <211> 1260
 <212> DNA
 <213> Homo sapiens
 30
 <400> 22
 cttctccgca cgactgttac agaggtctcc agagccttct ctctcctgtg caaaatggca 60
 actcttaagg aaaaactcat tgccacca gccaagaag aggcaacagt tccaaacaat 120
 aagatcaactg tagtgggtgt tggacaagtt ggtatggcgt gtgctatcag cattctggaa 180
 35 aagtctctgg ctgtatgaaact tgctcttgcgat gatgtttgg aagataagct taaaggagaa 240
 atgatggatc tgcacatggcggattattctgtgacatggccaa 300
 gattattctgtgacatggccaa 360
 gaagggggaga gtcggctcaatgggtgcag agaaatgtta atgtcttcaa attcattatt 420
 cctcagatcg tcaagatcag tctgtatgc atcataatttgc 480
 40 attcttacgt atgttacatgttgcgatggatc tggattctgc 540
 gatgttacatgttgcgatggatc tggattctgc 600
 cccagcagct gccatggatg 660
 agtgggtgtga atgtggcagg 720
 aatgatagtg aaaattggaa 780
 atcaagctaa aaggatatac 840
 45 tccatgttga aaaaatctatc 900
 ggcattgttga atgaagtctt 960
 agcgttatac accagaagct 1020
 accctgtggg acatcccgaa 1080
 50 aaatttaaaa actacaatgt 1140
 cacagtttgc ttgtatctt 1200
 cttggtttaa tgcttgcatt 1260
 <210> 23
 <211> 3151
 <212> DNA
 <213> Homo spaiens
 55
 <400> 23
 taacacagggttggatgttgcgttccatggccctgtcc tgggtgtgcact 60
 tatgcagaaa cgttccatgttgcgttccatggccctgtcc 120
 cctccatgttgcgttccatggccctgtcc 180
 taccagggtgttgcgttccatggccctgtcc 240
 cggcgccgttgcgttccatggccctgtcc 300
 60 agcatccccca cgttccatgttgcgttccatggccctgtcc 360
 gacttttgact cggccaccaatggatggccatggccctgtcc 420
 gataccatttgcgttccatggccctgtcc 480

	atcaaacaccc	aggtgcggag	cttcggacct	gtgtcccgca	gcggcttcta	cctggccttc	540
	caggactatg	gcggctgcat	gtccctcatc	gccgtgcgtg	tcttcttaccg	caagtgcggcc	600
5	cgcatcatcc	agaatggcgc	catcttccag	gaaaccctgt	cgggggctga	gagcacatcg	660
	ctggtggctg	cccgccccag	ctgcatcgcc	aatgcggaaag	aggtggatgt	accatcaag	720
	ctctactgt	acggggacgg	cgagtggctg	gtgcccattcg	ggcgctgcat	gtgaaagca	780
	ggcttcgagg	ccgttggaaa	ttgcaccgtc	tgccgagggtt	gtccatctgg	gacttcaag	840
	gccaaccaag	gggatgaggg	ctgtaccac	tgtcccatca	acagccggac	cacttctgaa	900
10	ggggccacca	actgtgtctg	ccgcaatgac	tactacagag	cagacctgga	ccccctggac	960
	atgcctgca	caaccatccc	ctccgcgccc	caggctgtga	tttccatgt	caatgagacc	1020
	tcctcatgc	tggagtggac	ccctccccgc	gactccggag	gccgagagga	cctcgcttac	1080
	aacatcatct	gcaagagct	tggctcgggc	cggggtgcct	gcaccgcgt	cggggacaat	1140
	gtacagtacg	caccacgca	cttgcggctg	accgagccac	gcatttacat	cagtgcacgt	1200
15	ctggccca	cccgatcac	cttcgagatc	caggctgtga	acggcgttac	tgaccagagc	1260
	cccttctcgc	ctcagttcgc	ctctgtgaac	ataccacca	accaggcgc	tccatcgca	1320
	gtgtccatca	tgcatacggt	gagccgcacc	gtggacagca	taccctgtc	gtggcccccag	1380
	ccagaccacg	ccaatggcgt	gatcctggac	tatgagctgc	agtactatga	aaagcaggag	1440
	ctcagtgagt	acaacgccc	agccataaaa	agccccacca	acacggtcac	cgtgcagggc	1500
	ctcaaagccg	gcccacatca	tgtctccag	gtgcgggac	gcaccgtggc	aggctacggg	1560
20	cgctacagcg	gcaagatgt	cttccagacc	atgacagaag	ccgattacca	gacaagcatc	1620
	caggagaagt	tgccactcat	catcggtc	tcggccgt	gcctggctt	cctcattgt	1680
	gtgggtgtca	tcgcccattgt	gtgtacaga	cgggggttt	agcgtgt	ctcgaggatc	1740
	acggacaagg	tgcaacacta	caccagtggc	cacatgaccc	caggcatgaa	gatctacatc	1800
	gatccttca	cctacgagga	ccccaaacgg	gcagtgccgg	agtttgccaa	ggaaattgac	1860
25	atccctgt	tcaaaaatgt	gcaggtgtac	ggagcagggg	attttggcga	ggtctgcgt	1920
	ggccacctga	agctgcccagg	caagagagag	atctttgtgg	ccatcaagac	gctcaagtcg	1980
	ggctacacgg	agaagcagcg	ccgggacttc	ctgagcga	cctccatcat	gggcagttc	2040
	gaccatccca	acgtcatcca	cctggaggg	gtcgtgacca	agagcacacc	tgtatgtac	2100
	atcaccgagt	tcatggagaa	ttgtccctgt	gactccattc	tccggcaaaa	cgatggcag	2160
30	ttcacagtca	tccagctgtt	gggcattgtt	cggggcatcg	cagctggcat	gaagttacgt	2220
	gcagacatga	actatgttca	ccgtgacctg	gtgtcccgca	acatcctgt	caacagcaac	2280
	ctgtctgca	aggtgtcgga	cttgggctt	tcacgttcc	tagaggacga	tacccatcgac	2340
	cccacctaca	ccagtgcct	ggcgccggaaag	atccccatcc	gctggacacg	cccggaaagcc	2400
	atccatgtacc	ggaagttcac	ctcggccagt	gatgtgtgg	gctacggcat	tgtcatgtgg	2460
35	gagggtatgt	cctatggg	ggggccctac	ttggacatga	ccaaccagg	tgtatcaat	2520
	gcccattgagc	aggactatcg	gtgtccaccg	cccatggact	gcccagctgc	cctgcaccaa	2580
	ctcatgtctgg	actgttggca	gaaggaccgc	aaccacccgc	ccaaggctgg	ccaaattgtc	2640
	aacacgctag	acaagatgt	ccgcaatccc	aacaggctca	aagccatgac	gcccccttcc	2700
	tctggcatca	acctgcgc	gttggaccgc	acgatcccc	actacaccag	ctttaacacg	2760
40	gtggacgagt	ggctgaaggc	catcaagatg	gggcagttaca	aggagagatc	cgccaaatgcc	2820
	ggcttcaccc	ccttgcacgt	cgtgtctcg	atgatgtgg	aggacattt	ccgggttggg	2880
	gtcaacttgg	ctggccacca	aaaaaaaatc	ctgaacagta	tccaggtat	gccccggcag	2940
	atgaaccaga	ttcagttctgt	ggagggttga	cattcacctg	cctcccttc	ctctttcc	3000
	caagccccgc	ccctctgca	ccacgtgccc	gcccctctgg	tgctctatcc	actgcaggc	3060
45	cagccactcg	ccaggaggcc	acgggcacgg	gaagaacaa	gcccgtccag	ccacgagacg	3120
	tcaccaagaa	aacatgcaac	tcaaaccgac	g			3151

<210> 24

<211> 1234

<212> DNA

50 <213> Homo sapiens

<400> 24

	tagttcaaga	caacagagac	aaagctaaga	tgaggaagtt	ctgtacagtt	tagaaatag	60
	aggcttcaa	agataattcg	cagtgtatgt	aaacttgcct	cccaagccct	gataacaaca	120
55	tggccaaacgc	cctggccacgc	gccacttgcg	agcgctgca	gggcggctt	gcgcggcgt	180
	agaagatcg	gaacagtaat	ggggagctgt	accatgagca	gtgtttcg	tgcgtctagt	240
	gttcccgca	gttcccgaaa	ggactcttct	atgagttga	aggaagaaag	tactgtgaac	300
	atgatcttca	gatgtcttt	gccccctgt	gtcatacgat	tggtaattc	atcattggcc	360
	gagttatcaa	agccatgtat	aaacgtgtgc	atccggatgt	cttccgtgt	gacccctgtcc	420
	aggaagttct	ggcagatatac	gggtttgtca	agaatgtcg	gagacaccc	tgtcgcccc	480
	gtcataatcg	tgagaaagcc	agaggccttgc	ggaaatacat	ctgcccggaaa	tgccatgtca	540
	tcatacgat	gcagccctcg	atattcaaga	acgaccccta	ccatccggac	catttcaact	600
	gcgcctactg	cgggaaaggag	ctgactgccc	atgcacggga	gctgaaagg	gagctatact	660
65	gcctccatg	ccatgtat	atgggggtcc	ccatctgtgg	tgcttgcg	cgcccatcg	720
	aaggcgcgt	gttgaacgct	atgggcaagc	agtggatgt	ggagcatttt	gtttgtgcca	780
	agtgtgagaa	accctttctt	ggacatcgcc	attatgagag	gaaaggcctg	gcatattgt	840
	aaactcaacta	taaccagacta	tttggatgt	tttgcattca	ctgcaatcg	gttatagaag	900

gtgatgtgg	ctctgctctt	aataaggcct	ggtcgtgaa	ctgcttgcc	tgttctacct	960
gcaacactaa	attaacactc	aagaataagt	tttgtggagtt	tgacatgaag	ccagtctgt	1020
agaagtgtca	ttagatttcc	attggagctg	aagaaaagac	ttaagaaaact	agctgagacc	1080
tttaggaagga	aataagtcc	tttatttttt	cttttctatg	caagataaga	gattaccaac	1140
attacttgtc	tttgatctacc	catatttaaa	gctatatctc	aaagcagttg	agagaagagg	1200
acctatata	atggtttat	gtcatttttt	taaa			1234

<210> 25
<211> 4534
212

<212> DNA
<213> *Homo sapiens*

<400> 25

gtcacgagcg	tgcgatgttt	aaagccgcgt	cagggggccc	ggccggggcg	ggggagcccg	120
gggcttgtt	gtgcggcc	ccgcggag	ggcccttcgg	accgcgcgc	cggcgtgcc	180
ccgcgcgc	cctcgcaaca	ggtcgggcg	gcctcgctc	ccgccccct	cccccgcatc	240
ccgcacctc	cggggcacct	cagctcggcc	ggggccgcag	tctggccacc	cgcttccatg	300
cggttcggt	ccaagatgtat	gccgatgtt	cttaccgtgt	atctcagtaa	aatgagcag	360
cacttcacag	aagtccagt	tactccagaa	acaatatgc	gagacgttgt	ggatctgtgc	420
aaagaacccg	gcgagagtga	ttgcatttgc	gtgaagtgt	gtgtggctc	tgttagagata	480
gagtttcatc	atgtggccca	ggatggctc	gatctcctga	ccttgtgatc	cgccgcctc	540
ggcctccaa	agtgtggat	tacagggtg	agccaccac	atcaggctct	agtgttaaa	600
aaagaacgtc	cagttgcgga	taatgagcga	atgtttgtat	tttccaac	atttggaaat	660
cagaggaacg	aagttcgctt	cttcctcg	catgaacgc	ccccctggcag	ggacatgttg	720
agtggaccaa	gatctcagga	tccaagttt	aaaagaatag	gtgtaaatgt	tcctgggtgaa	780
tatcgaagaa	aggagaacgg	tgtaatagt	cctaggatgg	atctgactct	tgctgaactt	840
caggaaatgg	catctcgcca	gcagcaacag	attgaagccc	agcaacaatt	gtctggcaact	900
aaggaacacg	gcttaaagt	tttgaacaa	caagatcagc	gacaacagca	acaagttgt	960
gagcaggaga	aacttaaaag	gctaaaagaa	atagctgaga	atcagaagc	taagctaaaa	1020
aaagtggag	cacttaaagg	ccacgtggaa	cagaagagac	taagcaatgg	gaaacttgg	1080
gaggaaattt	aacagatgaa	taatttggtc	cagcaaaaac	agaggagct	cgtcctgg	1140
gtgtcaaaa	tagaagaact	gaccaggcag	ctagagatgc	tcaagaacgg	caggatcgac	1200
agccaccatg	acaatcagtc	tgcagtggct	gagcttgc	gcctctataa	ggagctgcag	1260
ctaagaaaca	aattgaatca	agagcagaat	gccaagctac	aacaacagag	ggagtgttt	1320
aataagcgta	attcagaatgt	ggcagtcatg	gataaggcgt	ttaatgatgt	gagggaccgg	1380
ctgtggaaaga	agaaggcagc	tctacagcaa	aaagaaaatc	taccagttc	atctgtatgg	1440
aatctccccc	ageaagccgc	gtcagcccc	agccgtgtgg	ctgcagtagg	tccctatatac	1500
cagtcatcta	ctatgcctcg	gatgcctca	aggcctgaat	tgctggtggaa	gccagccctg	1560
ccggatgtt	ccttggtcat	tcaggctca	gagggggccga	tgaaaataca	gacactgccc	1620
aacatgagat	ctggggctgc	ttcacaaact	aaaggctcta	aaatccatcc	agttggccct	1680
gattggagtc	cttcataatgc	agatctttc	ccaagccaag	gctctgc	tgtacctcaa	1740
agcaactgg	atgtctgtt	tcaagttgtat	gatggagagg	ttccgcgtgag	ggagaaagag	1800
aagaaatgc	gtccgttctc	aatgtttgtat	gcagtagacc	agtccaaatgc	cccaccccttcc	1860
tttggtactc	tgagggagaa	ccagagcagt	gaagatatact	tgccggatgc	tcaggttgca	1920
aataaaaatg	tggctaaatgt	accacccct	gttccctacaa	aaccaaaaaca	gattaatttt	1980
ccttattttt	gacaaaactaa	ttagccacct	tcagacatta	agccagacgg	aaatcttcag	2040
caagttgtcaa	cagttgttcc	gtccatggga	actaaaccaa	aaccagcagg	gagcagcccg	2100
agagtgtcgc	tatctcccg	catacctcg	gttggccaag	accagaccct	tttcccggt	2160
tctaagcaag	aaagtccacc	tgctgtgcc	gtccggccct	ttactccca	gccttccaaa	2220
gacacccattac	ttccaccctt	cagaaaaccc	cagaccgtgg	cagcaagttc	aatatattcc	2280
atgtatacgc	aacagcaggg	gccagggaaa	aacttccagc	aggctgtgca	gagcgcgttg	2340
accaagactc	ataccagagg	gccacactt	tcaagtgtat	atggtaagcc	tgttaattgt	2400
gtgtcccgaga	atcaacagca	gcacccagag	aacattttt	ccaatagcca	ggcaagcc	2460
ggcagtcag	aacctgaaac	agagcctgtt	tcttcagttc	aggagaacca	tgaaaacgaa	2520
agaatttctc	ggccactctcg	cccaactaaa	ttactgcctt	tcttatctaa	tccttaccga	2580
aaccagagtg	atgtgcacct	agaagccta	cgaaaagaaaac	tgtctaacgc	accaaggcc	2640
ctaaagaaac	gtagttctat	tacagagcga	gaggggtccta	atggggccaaa	tattcagaag	2700
cttttataatc	agaggaccac	catagcgcc	atggagacca	tctctgtccc	atcataccacca	2760
cccaagtcag	cttctgtgac	tgccagtc	gaaagcccg	tagaaatcca	gaatccatata	2820
ttacatgtgg	agccccggaaa	ggaggtggc	tctctgtgtt	ctgaatcatt	gtccccccagag	2880
gatgtgggaa	atgccagttac	agagaacagt	gacatggccag	ctcttctcc	aggccttgc	2940
atgagcctg	agggagtccc	agacaacagc	ccaaatctcc	agaataaccc	agaagaaccca	3000
aatccagagg	ctccacatgt	gcttgcgtgt	tacccgtgggg	ataccctcc	atacccaccc	3060
ccaccatacc	catctgggg	gcctgaaggg	cccgggagaag	actcggtgag	catgcgcgg	3120
cctgaaatca	ccgggcaggt	ctctctgcct	cctggtaaaa	ggacaaactt	gcttaaaaact	3180
ggctcagagc	gtatcgctca	tggaaatgggg	atttgaccc	tttactgtca	tttactgtca	3240
gattcgctt	tggagggaga	atttgaccc	gtacagagaa	ttatttatga	ggttgcgtac	

5	ccaaggctgc	ccaatgatga	aggcatcag	gctttcaca	atgctgtgt	tgcaggccac	3300
	acagaaatcg	ttaagttcct	ggtacagtt	gggttaaatg	taaatgtgc	tgatagtgt	3360
	ggatggactc	cattacattg	tgctgcctca	tgtacaac	tccaatgtg	taagttttg	3420
	gtggagtcag	gagccgtgt	gtttgcctat	acctacatgt	acatgcagac	tgctgcagat	3480
	aagtgcgagg	aatggagga	aggctacact	cagtgcctcc	aatttcttta	tggagttcag	3540
	gagaagatgg	gcataatgaa	taaaggagtc	atttatgcgc	tttgggattta	tgaacctca	3600
	aatgtatgt	agctgcccatt	gaaagaagga	gactgcata	caatcatcca	cagggaagac	3660
	gaagatgaaa	tgcataatgg	gtgggcgcgc	cttaatgata	aggaggata	tgttccacgt	3720
10	aacttgctgg	gactgtaccc	aagaataaa	ccaaagacaaa	ggagcttggc	ctgaaacttc	3780
	cacacagaat	tttagtcaat	gaagaattaa	tctctgtta	gaagaagtaa	tacgattatt	3840
	tttggcaaaa	atttcacaag	acttatttt	atgacaatgt	agcttggaaag	cgatgaagaa	3900
	tgtctctaga	agagaatgaa	ggattgaaga	attcaccatt	agaggacatt	tagcgtgt	3960
	aaataaagca	tctacgtcag	caggccatac	tgtgttgggg	caaagtgtc	ccgtgtagca	4020
	ctcagataag	tatacagcga	caatctgtt	ttctacaaga	atcctgtcta	gtaaatagga	4080
	tcatttattt	ggcagttggg	aaatcagctc	tctgtcctgt	tgagtgttt	cagcagctgc	4140
	tcctaaacca	gtccctctgc	cagaaaggac	cagtgcgcgc	acatcgtgt	ctctgattt	4200
	ccccggcacc	agcaggcctt	ggggctcaact	gaaggtctga	aggcactgca	caccttgtat	4260
	attgtcagt	aagaacgtt	gttggttgtc	agtggaaat	aacttattt	tatgagttt	4320
	tgttagcatt	taagaattat	acatatgtt	gaaatattga	aactaaatgt	cagtaccgt	4380
	aatttagatgt	agaatcttgc	ttttaggtgt	aattttaatc	tgtatttatt	gtcttttgta	4440
	tctcagaaat	tagaaacttg	ctacagactt	acccgtataa	tttgcataaga	tcatagctga	4500
20	ctttaaaaac	agttgtataa	aacttttga	tgtc			4534

25 <210> 26
<211> 4660
<212> DNA
<213> *Homo sapiens*

	agggttagccc	ctcagatatac	accactttgt	ctgtcgagcc	tgataaaaaag	gacagtgcac	2340
	ctacttctgt	gtcagtgact	ggacaggtac	aaggaaactc	cagtataaaa	ctagaactgg	2400
	atgcttcaa	aaaaaaagaa	tcaaaagacc	attagctct	acgctatctt	ttagataaaag	2460
	atgagaaaga	tttaagatca	actccaaacc	tgagcctgga	tgatgtaaag	gtgaaagttgg	2520
5	aaaagaaga	acagatggat	ccatgtataa	caaaccacac	cccaatgacc	aaaccacactc	2580
	ctgagggaaat	aaaactggag	gcccgagagcc	agtttacagc	tgaccttgac	cagtttgatc	2640
	agttactgcc	cacgctggag	aaggcagcac	agttgccagg	tttatgtgag	acagacagga	2700
	tggatgggtc	ggtcacca	gtaccatca	aatcgaggat	cctgcccagct	tcacttcagt	2760
	ccggcactgc	cagacccact	tccaggctaa	atagattacc	tgagctggaa	ttggaaagccaa	2820
10	ttgataacca	attggacaa	ccaggaacag	gcgatcagat	tccatggaca	ataataacag	2880
	tgacagctat	aaatcagagt	aaatcagaag	accagtgtat	tagctcacaa	tttagatgagc	2940
	ttctctgtcc	accacacaaca	gtagaagggg	gaaatgtatg	gaaggctt	cttgaacacgc	3000
	tggtatcctt	ccttagtggc	aaagatggaa	ctgagcttagc	tgaactagac	agagctctgg	3060
15	gaattgacaa	acttgttag	gggggtggat	tagatgtatt	atcagagaga	ttccacccac	3120
	aacaagcaac	gccacccccc	atcatgaaag	aaagacccaa	cctttattcc	cagcccttaact	3180
	cttctccccc	tcctactgccc	aatctcccta	gccctttccca	aggcatggtc	aggccaaaac	3240
	cttcactggg	gacatgcct	gttcaagtaa	caccccccgg	aggtgcttt	tcacctggca	3300
	tgggcatgca	gcccaggca	actctaaaca	gaccccccggc	tgcacccaa	cagttcgcac	3360
20	ttcaactaca	gcagcgat	cagggacaac	agcagttgtat	acacccaaat	cgcaagcta	3420
	tcttaaacc	gttgcagca	actgctctg	ttggcatcaa	tatgagatca	gcatgcac	3480
	agcaaattac	acccatcgca	ccccctgaat	ctcaaatgtt	ggcacaacgt	cagcgggaac	3540
	tgtacatgc	acagcaccga	cagaggcagc	taatacagca	gcaaaagagcc	atgcttatga	3600
	ggcagcaaa	cttggggaa	aacccctc	cctcatctg	actaccagtt	caaatgggg	3660
25	accccccgtt	tcctcagggt	gctccacagc	aattccctca	tccacccaaac	tatgttacaa	3720
	atccaggaac	cccacctgt	tctaccagcc	cgttttcaca	actagcagca	aatccctgaag	3780
	catccttggc	caacccgaac	agcatgtga	gcagaggcat	gacaggaaac	ataggaggac	3840
	agtttggcac	tggaaatca	cctcagatgc	agcagaatgt	cttccagtt	ccaggagcag	3900
	gaatggttcc	ccaaaggtag	gccaacttt	ctccatctc	aagccctggg	agctccatgg	3960
30	tgccgatgca	aatccctct	cctcagagtt	ctctgctcca	gcaaactcca	ctgcctccg	4020
	ggtatcagt	accagacatg	aaggccttgc	agcaaggagc	gataggaaac	aacaatgtgt	4080
	tcagtcaagc	tgtccagaa	cagccca	ctgcacagcc	aggagtatac	aacaacatga	4140
	gcatcacccgt	ttccatggca	ggtggaaata	cgaatgttca	gaacatgaac	ccaatgatgg	4200
	cccagatgca	gatgagctt	ttgcagatgc	caggaatgaa	cactgtgtc	cttgagcaga	4260
35	taaaatgatc	cgcactgaga	cacacagggc	tctactgca	ccagctctca	tccactgtacc	4320
	ttctcaaaa	agaagcagat	ggaacccagg	tgcacacagg	tcaggtttt	gtgtacgtcc	4380
	agtgtacatg	gaatctggta	ggcggggacc	cttacctgaa	ccagcttgg	ccacttgggaa	4440
	ctcaaaaagcc	cacgtcagga	ccacagaccc	cccaggccca	gcagaagagc	ctccttcagc	4500
	agctactgac	tgaataacca	cttttaaagg	aatgtgaaat	ttaaataata	gacatacaga	4560
40	gatatacaca	tatattat	attttctga	gattttgtat	atctcaatct	gcagccattc	4620
	ttcaggtcgt	agcatttgg	gcaaaaaaaa	aaaaaaaaaa			4660

<210> 27
<211> 6773
<212> DNA
<213> Human

45 <212> DNA
<213> *Homo sapiens*

<400> 27

50	tcgttttaccc agttttttttt gggaccggga aatcttaagaa ttggagaaag aaattgaaga 120 actccatgtca aaaaaccttta ctgaaggaaac tggtttatattt attaaggccat taactgaacg 180 tctggatgtc cttcttctgg aaaaaggcaga gactgagccaa cagttctttt ctctgaaaaaa 240 ggaaaatataa aaaatgaagc aagaggttga ggattctgtaa acaaagatgg gagatgcaca 300 taaggagttt gaaacatcac atataaacta tggaaagaa attgaaaattt tgaaaaatgtaa 360 gttggatggca gtacgttcca aatacagtgaa agacaaagct aacttacaaa agcagctggaa 420 55 agaaagcaatg aatacgtcaat tagaactttc agaacaactt aaatttcaga acaactctga 480 agataatgtt aaaaaactac aagaagagat tgagaaaattt aggccaggct ttgaggagca 540 aattttatata ctgcaaaagc aatttagacgc taccactgtat gaaaagaagg aaacagttac 600 tcaactccaa aatatcatttgg aggctaattc tcagcattac caaaaaaata ttaatagttt 660 60 gcaggaagag cttttacagt tgaaaagctat acaccaagaa gaggtgaaag agttgtatgt 720 ccagatggaa gcatcagctaa aggaaacatga agcagagata aataagtgtaa acgagctaaa 780 agagaacttga gtaaaacaatgttggaccaag tgaaaaaaac atcccagaaga aatatgaatg 840 tgagtttagaa aattttaagga aaggccatcc aaaaatgtaa acagacaatc agatatgttc 900 tattctcttg caagaaaata catttgtaga acaagtagta caagacaatc aatggaaaaag tcaaaacactt 960 65 agaagatatacc ttaaaagaac ttgaatctca acacagtatac aatggaaaaag tcaaaagatg aggttaacttta 1020 tatgaataat cttaaatgtt aacttggaaat ggatgtctaa catataaagg atgagttttt 1080 tcatgaacgg gaagacttag agttttaaaat taatgtaaattt ttactagcta aagaagaaca 1140 ggctgtgtta attgaaaaat taaaatctga gctagcaggt taaaataaac agttttgcta 1200
----	---

5	tgtgatttcc catgcatgct gccagaataa aaccaccagg aatgaattca ctccccactt	5280
	ctctggAAC tcaggACCG cccatttctc ggcagtactg tgaatttga agttaaacta	5340
	aattttggta ccataccaaC tggaaatttag gctttaaaaa taatgttca aggccaggTG	5400
	tggtattca tgcctgaaat cccactactt tgggaggcTG aggctggaga attgttgag	5460
	gctagtggc tggactccc actgcactcc agctcgggga acagagcgaG accttgcTc	5520
	taaaaataat agtaataaaa taaaaataac gtttatgac tatttattgc aaggcagAG	5580
	ttacagattt ttataaattt ttgagaaatt tttgtgatta gaatatgaag gaaaaagctt	5640
10	tggtggaaa agtgacatgt taaggggcTA tgaagtaat atgctgcagt taatgtgct	5700
	aagttaaaat acagtttagt tatttgcTT aaaaataact cttctttt tctttaaagt	5760
	atactatctc aaaactcatt atgttgcaG agcccttagag ctggcttagt taacactgac	5820
	tatgagtagg tgggcccacc acttgagttt aggtgatttC atgggtcTT tccaggcTc	5880
	tgatagggtg tcactgcAT caagccatga atctgtttt agaatcctt ccatttccc	5940
15	aaataaaaac ctatcacaac agtgactata tcactcagca ttggatctaa atataaaagt	6000
	ggtgcttca gtgttttgg cagatagtgt tccataagct ttccatcaga aggatttta	6060
	gacaccttag aggtccgtc tacatcgtca cagttccTc gaataacctt aggtggtagt	6120
	gttacttgcc ttgacaccc ctgcataatgt tttaaatgact agatccaaac tgggttgc	6180
	ttaaatcaaa aattggataa ttgtataat ttatgttta atcacacagt atgctctg	6240
	aagttcttC aagccttcag ttatactct taatttaatt ttctttctga gctggagaac	6300
20	tggcttgc ctttggttac acagaacattt ggtttcaat tcaGtttaac tggaaatttgc	6360
	tgtgtatg ttgagtttgc tttttaaaaaa atagtcata tatctcatct ttccctctgt	6420
	cttagaagaa cagaccaac tagtgaatgtt attaatgaaa atgcatactt ttcaGagctg	6480
	acatgaagag tttagtttt ttactttata aactgtgaat atgatgtc cagctgcata	6540
	cgatgttaact aatcatattt aatatattt cactttctt ttgactttt accttttggaa	6600
25	gtctgtataa acttgtttgg aatatatagtc tctgcttacG aatgtcataaa caaaaataatt	6660
	ttttgcataa taaaaatta cttgattac aaaaggcgtA ttctttcatg gtttctgcaa	6720
	tgagaggaag tggatgtt atttaataat ttcttattaa tatgtttaac tgt	6773

30 <210> 28
 <211> 2619
 <212> DNA
 <213> Homo sapiens

35	<400> 28	
	atggccacag cttgtaaaag atcaggagaa cctcagtctg acgacattga agctagccga	60
	atgaagcgaG cagctgcaaa gcatctaata gaacgctact accaccagg aactgaggGC	120
	tgtggaaatg aaggctgcac gaatgagtt tggcttccT gtccaaCTt tcttcgtatg	180
40	gataataatg cagcagctat taaaggccctc gagctttata agattaatgc aaaactctgt	240
	gatcctcatc cctccaaagaa aggagcaagc tcagcttacc ttgagaactc gaaagggtgc	300
	cccaacaact cctgctctga gataaaaatg aacaagaaag ggcgctagaat tggatttAA	360
	gatgtgactt acttaacaga agagaaggta tatgaaatttC ttgattatg tagagaaaga	420
	gaggattattt cccctttaat ccgtgttattt ggaagagttt ttcttagtgc tgaggcattG	480
45	gtcagagct tccggaaatg taataacac accaagaag aactgaaatc tcttcaagca	540
	aaagatgtaa acaaaagatga agatgaaaag gggaaagctg catgttctgc tgctgtatg	600
	gaagaagact cagaagcattc ttccctcaagg atagggtata gctcacagg agacaacaat	660
	ttgcaaaaat taggcctga tggatgtctt gtggatattt atgcatttgc aagggtctac	720
	accagatttgc tctctaatga aaaaatttga actgccttC tcaatgcact tggatatttgc	780
50	tcacctaacc ttggatgtga cttgacgtat cacaatgtat actctcgaga tcctaattat	840
	ctgaatttgc tcattatcgG aatggagaat agaaatcttC acagtcttgc atatctggaa	900
	atggctttgc cattatttgc caaaggcgtG agcaagctac cccttgcagc ccaaggaaaa	960
	ctgatcagac tgggtctaa atacaatgca gaccaggattt ggagaatgtt ggagacattt	1020
55	cagcaactt ttacttataa agtctataaC aatgtataaC aatgttta acagtcgaaa tctgtatgt	1080
	gatgtatgtt ccatttgc tggcttgc tggatgttggaaatggatgttacta tgcaatgt	1140
	gtgggggggg aagtggacac aaatccaaat gaagaagatg atgaagagcc catccctgag	1200
	tccagcggc tgacacttca ggaactttt ggagaagaaa gaagaaacaa gaaaggctt	1260
	cgagtggacc ccctggaaac tgaacttggt ttggatgttgc aaaaacactt	1320
60	atccctttt aagatgtttaatgtacca ctgtatgggg ttcttagaaat ggataaaagat	1380
	tatactttt tcaaagtata aacagagaaC aaatttcttC ttatgtacatg tcccttata	1440
	ttgaatgttgc tcacaaagaa ttgggatC tattatgaca atagaatttgc catgtacagt	1500
	gaacgaagaa tcactgttctt ctacagcttC gttcaaggac agcagttgaa tccatatttgc	1560
	agactcaaag tttagacgtga ccatatcata gatgtatgttgc ttgtccggc agagatgtc	1620
	gctatggaaa atcctgcaga cttgaaagaa agtggatgttgc tggatgttgc aggagaacaa	1680
65	ggagttgttgc agggaggtgt ttccaaagaa ttgttgc tggatgttgc gggaaatcttC	1740
	aatccagata ttggatgttgc cacaatcgtat gatgtatgttgc tggatgttgc tggatgttgc	1800
	tcttcttttC aaactgaggG tcagtttact ctgtatggca tagtacttgg tctggctatt	1860
	tacaataact gtataacttgc tggatgttgc cccatgggtt cttacaggaa gctaattgggg	1920

aaaaaaggaa	ctttcgtga	cttgggagac	tctcacccag	ttctatata	ca gat tttaaa	1980
gatttattgg	aqtatgaagg	gaatgtggaa	gatgacatga	tgatcactt	ccagatata	2040
cagacagatc	tttttggtaa	cccaatgatg	tatgatctaa	aggaaaatgg	tgataaaatt	2100
ccaattacaa	ataaaacacag	gaaggaaattt	gtcaatctt	attctgacta	cattctcaat	2160
5 aaatcagtat	aaaaacacgtt	caaggcttt	cggagaggtt	ttcatatgtt	gaccatgaa	2220
tc tcccttaa	agtacttatt	cagaccagaa	gaaattgaat	tgcttata	tggagccgg	2280
aatctagatt	tccaaagact	agaagaaact	acagaatatg	acggtggtca	taccaggac	2340
tctgttctga	ttaggaggtt	ctgggaaatc	gttcattcat	ttacagatga	acagaaaaga	2400
ctcttcttgc	agtttacaac	gggcacagac	agagcacctg	tgggaggact	agggaaaatta	2460
10 aagatgatta	tagccaaaaa	ttggccagac	acagaaaggt	tacctacatc	tcatacttgc	2520
ttaatgtgc	tttacttcc	ggaatactca	agcaaagaaa	aacttaaaga	gagattgttg	2580
aaggccatca	cgtatgccaa	aggatttggc	atgctgtaa			2619
15 <210> 29						
<211> 4263						
<212> DNA						
<213> Homo sapiens						
20 <400> 29						
ggccgttccc	ctctccctcag	cagtagctct	atggtttcag	ggcggcaacg	tgca	60
ttaccttgcag	cctgtcagt	tgccctcacc	ccggaatcca	tagtca	ctgt	120
gaggacttgg	gcgacaggt	gcctcccagt	cccacacgct	gcgggtccgc	gcctggccaa	180
gcccacccctcga	cctgtgaagt	ttggggcgtt	acccagcaac	tccccctgtt	cagccgcgt	240
ttccaaagggg	tcaaggaaaccg	ctgtgtttgt	ttcg	tcgc	gggtcgcgga	300
25 gtactgtgc	tgaccgcacg	gtggcaagtc	tgacgcgtca	gccagagacc	ggtgcccgg	360
gtaggagtcg	cagccgttgc	tggtgacgc	tgctgggtag	acagactgc	tttcttta	420
agcatgtcat	ttccaaaatg	catcggtgtt	ttctgcctt	aagtctata	ggaagacact	480
gcccgcacta	gaccgggtct	tatgtcgc	actgttattt	tgactca	cccg	540
30 tagcatatg	tatgaaaatg	ccttaggagg	gaaccatgga	gaagtatgt	tgcat	600
agattggaga	agtttcat	gaaaaagctt	ttcttgc	atcgac	atgc	660
attatgtcat	caaggaaattt	aacatctcaa	aatgtctga	taaagaaagg	caagaatcaa	720
ggagagaagt	tgctgtattt	gcaaacatg	agcatccaa	tattgtccaa	tataaagaat	780
catttgaaga	aatggctct	ctctacatag	taatggatta	ctgt	gatgtt	840
ttaaacgaat	aatgtc	aaaggcgctc	tg	ttca	gg	900
35 ttgtcgat	atgttggct	ctgaagcatg	ta	catgat	tttt	960
taaagtca	gaacatattt	ctaaacaaag	atggacatg	gcag	cttgg	1020
ttgctcgat	tcttaatagt	actgtagagc	ttgctcgaa	tt	catgg	1080
acttgtcacc	tgaaatctgt	gaaaacaagg	cttataacaa	taaaatgt	gg	1140
40 tggctgtgt	cctttatgag	ttgtgtacac	ttaa	acatgc	tttt	1200
aaaaccttgg	actgaagata	atctccggat	cctttc	actgtc	cc	1260
atgatctccg	cagcttgc	tctcagttat	ttaa	aggat	ttt	1320
tcaactccat	attggagaaa	ggtttata	ctaa	acgat	ttt	1380
45 agcttattgc	agaagaattt	tgtctaaaaa	cactt	tttgg	cc	1440
caggtaaaag	accagcatca	ggacaagg	tc	tttgc	cc	1500
caaaggctgc	tgctaaatac	ggagtgc	tttgc	tttgc	cc	1560
tacttggagaa	aaaaccaccc	ccaaaacata	aa	cg	tttgc	1620
tgaatttctgg	agaagaaaagg	agaaaaatgt	ct	gg	tttgc	1680
aatttattga	gaaagaaaagg	aagcaaaagg	atc	gg	tttgc	1740
50 tgaagcggca	agagaagcag	cggttggaga	ggataa	at	tttgc	1800
ggaatgtttt	aagggttgg	ggaagcggt	aa	tttgc	tttgc	1860
gggctgtctc	tccatcacc	tgttctc	gggg	tttgc	tttgc	1920
ttgaccaat	gcagcggcta	agagcaga	at	tttgc	tttgc	1980
atgtcgat	gttccc	aggcaaaag	gac	tttgc	tttgc	2040
tggaaagaatt	cctacagcg	aaacgaga	ct	tttgc	tttgc	2100
55 acgtggttt	tttggcaaga	ctgaggc	aa	tttgc	tttgc	2160
agattaaagc	caaacttcgt	gg	tttgc	tttgc	tttgc	2220
caacttgc	gactgacat	gg	tttgc	tttgc	tttgc	2280
cacgtgtgc	tgtactaaa	gaa	tttgc	tttgc	tttgc	2340
60 aaaagaaatgt	atgggaa	gg	tttgc	tttgc	tttgc	2400
cttggaaact	tcttggaa	gg	tttgc	tttgc	tttgc	2460
ctgtgacttc	agcttggaaa	gg	tttgc	tttgc	tttgc	2520
aagaaatgg	aaagagaac	gg	tttgc	tttgc	tttgc	2580
atgaaatct	taaagctaa	gg	tttgc	tttgc	tttgc	2640
65 agaccgttgg	tcacaaagat	gg	tttgc	tttgc	tttgc	2700
gcaagaagt	ggagatggg	gg	tttgc	tttgc	tttgc	2760
catccttctc	tgcaacc	aa	tttgc	tttgc	tttgc	2820
gctctcca	aaaagtctgg	gg	tttgc	tttgc	tttgc	2880

	aagctgaatt	acagctata	acagaactac	tagaaaaacac	atctttaaa	agtgagg	ttt	2940
	atgctgaaga	ggagaactac	aaacccttac	ttactgaaga	agagaatctg	cagtgcatt		3000
	caaaagaaat	aatccatca	gctactgtt	attctactga	aacaaaaagt	ccaaagtta		3060
	ctgagggtgc	tccacaaatg	tcagaaggaa	atgtggaaaga	acctgatgt	ttggaaacag		3120
5	aagttctaca	agagccaa	agcacacaca	cagatgggag	tttgcacact	tttcttaatg		3180
	atgtgtggac	tagagagaag	gaagcagcta	aggaaactga	tttggaaagat	aagggtgcgt		3240
	tgcagcagag	tgaagtttg	gaagatagaa	ttccagggaa	cgtggacca	tcctgtaa		3300
	atcagagaga	tcctgcgat	gacgattctc	cgcagtcgtt	ctgtgatgt	gagaagtca		3360
	tacagccaga	atcgatttc	cagaaagtgg	ttcattctaa	ggacttgaac	ttatcagg		3420
10	cagttcattt	ctcaccagaa	gaaccaattt	caatttcgatc	tcactctgt	tctccaccaa		3480
	aaactaaagag	caagaattcc	ttactgtt	gacttcaac	ttgtctgtt	gtgcaaaaca		3540
	atccaaatgg	gctggggacc	tgctcactt	cagatcttc	caagctgtt	agaaccctaa		3600
	tggacgttcc	cactgtgggg	gacgttcatc	aagacagtct	tgaaatcgat	gagctggaaag		3660
15	atgaaccaat	taaaaagggg	ccttctgtt	ccgaagacac	tgtatttga	gaaactgaca		3720
	cagatttaca	agagcttc	tctgtttaa	agcagctgt	tagggagca	ccaggtgacg		3780
	aatacagtg	ggagggagag	tctgtttaa	aaagcagcga	tgtggagca	acagcaagag		3840
	ggacagatgc	cccagacgag	gaggacaacc	ccagcagcga	aagccctga	acgaggaatg		3900
	gcactcagat	aatagtgc	ctgagaccac	tagtgaatgt	gaatatgaca	gtgtctttaa		3960
20	ccatTTtagag	gaactaaagac	ttcacttgg	gcaagaaatg	ggctttga	agttctttga		4020
	ggTTtatgag	aaagtaaagg	ctattcatg	ggatgaagat	gaaaatattt	aaatttgttc		4080
	aacaatagt	gagaatattt	tgggcaatg	gcaccagcat	ctctatgca	agattctgca		4140
	tttagtcatg	gcagatggag	cctatcagga	agataatgtat	gaataatctt	caggacattc		4200
	ttaaatatgc	aactgtaa	acacatttga	acttggctca	taatacaagc	ttcctggaa		4260
25	ata							4263
	<210> 30							
	<211> 1756							
	<212> DNA							
	<213> Homo sapiens							
30	<400> 30							
	tcggggcgca	ccgcgaagat	gccgttggaa	ctgacgcaga	gccgagtgc	gaagatctgg		60
	gtgccccgtt	accacaggcc	ctcggttccc	agatcctgt	ggccaaagct	gaccaactcc		120
	cccccgtca	tcgtcatgtt	gggcctcccc	gcccggggca	agacctacat	ctccaagaag		180
35	ctgactcgt	acctcaact	gattggcg	cccacaaaag	tgttcaacgt	cgggagttat		240
	cgcccgggg	ctgtgaagca	gtacagctcc	tacaacttct	tccgccccga	caatgaggaa		300
	gcccataaa	tccggaaagca	atgtccctt	gctgccttga	gagatgtcaa	aagctacactg		360
	gcgaaagaag	ggggacaat	tgcgtttt	gatgccacca	atactactag	agagaggaga		420
	cacatgatcc	ttcattttgc	caaaagaaaat	gactttaaag	cggttttcat	cgagtgcgtt		480
40	tgcgacgacc	ctacagtgt	ggcctccaa	atcatggaa	ttaaaatctc	cagccccggat		540
	tacaaagact	gcaactcg	agaagccat	gacgacttca	tgaagaggat	cagtgtctat		600
	gaagccagct	accagccct	cgaccccgac	aaatgcgaca	gggacttgc	gctgatcaag		660
	gtgattgacg	tggccggag	gttccctgtt	aaccgggtgc	aggaccacat	ccagagccgc		720
45	atcggtact	acctgtatgaa	catccacgt	cagccgcgt	ccatctacat	gtgccccggac		780
	ggcgagaacg	agcacaac	ccagggccgc	atcgggggcg	actcagccct	gtccagccgg		840
	gcaagaagt	ttgcctagt	tctgagca	ttcggtggagg	agcagaacat	gaaggacactg		900
	cgcgtgtgt	ccagccat	gaagagcacc	atccagacgg	ccgaggccgt	gcccgtgccc		960
50	tacgagca	ggaaggcg	caatgagatc	gacggggcg	tctgtgagga	gctgacctac		1020
	gaggagatca	gggacacc	cccttgagag	tatcgctgc	gggagcagg	caagtactat		1080
	taccgctacc	ccacccggga	gtccttacc	gacccgttcc	agcgttgg	gccagtgtatc		1140
	atggagctgg	agcggcagga	aatgtgtgt	gtcatctgc	accaggccgt	cctgcgttgc		1200
55	ctgcttgct	acttcttgg	taagagtgc	gaggagatgc	cctacctgaa	atgccttctt		1260
	cacaccgtcc	tgaaaactgac	gcctgtcg	tatggctgc	gtgtggaaatc	catctacat		1320
	aacgtggagt	ccgtctgcac	acaccggag	aggtcagagg	atgcaaaagaa	gggaccta		1380
	ccgctcatga	gacgcaatag	tgtcacc	ctagccagcc	ccgaaccac	caaaaagcct		1440
	cgcatcaaca	gctttgagga	gcatgtggcc	tccacactcg	ccgcctcgcc	cagctgcctg		1500
60	ccccccgggg	tgcccacgca	gctgccttga	caaaacatga	aaggctcccg	gagcagcgct		1560
	gactcttcca	ggaaacactg	aggcagacgt	gtcggttca	ttccatttcc	atttctgcag		1620
	cttagtctt	gtcccttcc	ccggccggagg	caaaacgtat	cctgaggact	tcttccggag		1680
	agggtgggg	ggagcagcg	gggagcctt	gccgaagaga	accatgttgc	gcaccgtctg		1740
	tgtccctctcg	ggcgct						1756
65	<210> 31							
	<211> 1661							
	<212> DNA							
	<213> Homo sapiens							

<400> 31

5	tgctgcagcc	gctgccgccc	attccggatc	tcattgccac	gcccggccg	cgaccgccc	60
	acgtgcattc	ccgattcctt	ttggttccaa	gtccaatatg	gcaactctaa	aggatcagct	120
	gatttataat	cttctaaagg	aagaacagac	ccccagaat	aagattacag	ttgttgggt	180
10	tggtgtgtt	ggcatggcct	gtgccatca	tatcttaatg	aaggacttg	cagatgaact	240
	tgcctctgtt	gatgtcatcg	aagacaaaatt	gaaggagag	atgatggatc	tccaacatgg	300
	cagcccttcc	cttagaacad	caaagattgt	ctctggcaa	gactataatg	taactgcaaa	360
	ctccaagctg	gtcattatca	cggctgggg	acgtcagca	gagggagaaa	gccgtcttaa	420
	tttggtccag	cgtaacgtg	acatattttaa	attcatcatt	cctaattgtt	taaaatacag	480
15	cccaactgc	aagtgttta	ttgtttccaa	tccagtgat	atcttgacat	acgtggcttg	540
	gaagataagt	ggtttccca	aaaaccgtgt	tattgaaatg	ggttgcata	tggattcagc	600
	ccgattccgt	tacctgatgg	gggaaaggct	gggagttcac	ccattaatgt	gtcatgggtg	660
	ggtccttggg	gaacatggag	atccagtg	gcctgtatgg	agtggaaatg	atgttgctgg	720
20	tgtctctctg	aagactctgc	acccagattt	agggactgtat	aaagataagg	aacagtggaa	780
	agagggtcac	aagcaggtgg	ttgagagtgc	ttatgaggtg	atcaaactca	aaggtcacac	840
	atccctggct	atggactct	ctgttagcaga	tttggcagag	agtataatg	agaatcttag	900
	gcgggtgcac	ccagttcca	ccatgattaa	gggtcttac	gaaataaaagg	atgatgtctt	960
25	ccttagtgtt	ccttgcattt	tggacagaaa	tggaatctca	gacctgtgt	aggtgactct	1020
	gacttctgag	gaagaggccc	gttgaagaaa	gagtgcagat	acactttggg	ggatccaaaa	1080
	ggagctgcaa	tttaaagt	ttctgatgtc	atatcatttc	actgtctagg	ctacaacagg	1140
	attcttagtg	gagggtgtc	atgttgcctt	ttttatctga	tctgtgat	aaggactaat	1200
	atttaaatg	ggactggaa	aaacatcaac	tcctgaatgt	agaaataaaga	atggttgt	1260
	aaatccacag	ctatattctg	atgctggatg	gtatataatct	tgttagtct	tcaactgtt	1320
30	agtgtgaat	agttctgcca	cctctgacgc	accactgcca	atgctgtacg	tactgcattt	1380
	gccctttag	ccaggtggat	gttaccgtg	tgttatataa	cttcctgggt	ccttcactga	1440
	acatgcctag	tccaacattt	tttcccagtg	agtcacatcc	tgggatccag	tgtataaaatc	1500
	caatatcatg	tcttgtgcat	aatttttcca	aaggatctt	ttttgtgaac	tatatcagta	1560
	gtgtacatta	ccatataatg	taaaaagatc	tacataaaaa	caatgcaccc	aactatccaa	1620
	gtgttataacc	aactaaaacc	cccaataaaac	cttgcacatgt	g		1661

30 <210> 32

<211> 4169

<212> DNA

<213> Homo sapiens

35 <400> 32

40	ggccgcttcc	agggtggcgc	gcaaggccgt	ggtcctgctt	tgtgcctctg	acctgtgt	60
	gctgctgcta	ctgctaccac	cgcctgggtc	ctgcggggcc	gaaggctcgc	ccggggacgccc	120
	cgacgagtc	accccaccc	cccgaaagaa	gaagaaggat	attcgcgatt	acaatgtatgc	180
45	agacatggcg	cgtcttctgg	agcaatggg	gaaagatgtat	gacattgaag	aaggagatct	240
	tccagagcac	aagagacattt	cagcacctgt	cgacttctca	aatagatgacc	caagaagcc	300
	tgaagcata	ttgaaaatga	cggaaaaaagg	gaagactctc	atgtatgtt	tcactgtatc	360
	aggaagccct	actgagaagg	agacagaggg	aattacgac	ctctggcagg	gcagcccttt	420
50	caatgccaac	tatgacgtcc	agagggttcat	tgtggatca	gaccgtgtca	tcttcatgt	480
	tcgcgatggg	agctacgcct	gggagatcaa	ggacttttg	gtcgggtca	acagttgtgc	540
	tgtatgtact	ctggaggggcc	aggtgttacc	cgccaaaggaa	ggagggaaagca	aagagaaaaaa	600
	taaaacaaatg	caagacaagg	gcaaaaaaaaaa	gaagggagga	gatctgaaat	ctcggttttc	660
	caagggaaagaa	aatcgagctg	ggaataaaaag	agaagacctg	tgtatggggca	gcagtgcacgc	720
	gctgtggggg	gacaggtgga	cgtggagagc	tctttggcca	gctctgggg	tgggagttgt	780
55	ctcaaggcaac	tgcacacccgg	atgacattct	agtgttttct	agaaagggtc	tgccacatga	840
	ccagtttgc	gtcaaaagat	tactgtttaa	taggttca	gtaagaagac	agatgttttc	900
	taatttataac	tggacactga	caaattcatg	tttactataa	aatctcttca	catgaaatgt	960
	tgactgttt	gttttttcc	atttacactt	ggtgatgtat	caactctact	gagattccac	1020
60	tccctccaa	gcacctgt	tgattgggt	gcctgtctg	atcagatagc	aaattctgtat	1080
	cagagaagac	tttaaaactc	tttactgtat	tgatgttact	tttcatgtc	tatacatcat	1140
	tttcattatg	ttttaaggtaa	aatatgtttt	gtgaaatcg	atgttgcgt	ccagaaagcc	1200
	agggtgtgt	aatccaaat	ctatgcacca	aatggggaga	atagaaaata	tgtcaacttga	1260
	aatcttaagt	agttttgtat	ttctttgact	tgaactttac	tcatcagtaa	gagaactctt	1320
	ggtgtctgtc	aggttttatg	tgttctgtaa	agttagggt	tctgttttgc	ttcccttattt	1380
65	aggaaaagagt	actgctgggt	tcgagggggtt	atatgttcca	ttaatgttgc	cagttttaaa	1440
	ggatttaagt	aggaaatcg	agtcctttgc	agagtgtgac	agacgactca	ataacccat	1500
	ttgtttctaa	acatttttct	ttgataaaatg	gcctaaatct	gtcttttgc	atagagtaac	1560
	atgtatgtgt	actgttgcatt	tctgttttgc	ccgttcatgt	tagggctac	tgtgaataag	1620
	agttagaaaca	tttataataca	gtgttgcattt	ctaaagacta	aaattcttgc	ggaaaaaacc	1680
	tcaattgtgt	tttataataaa	ttaaaagtag	cacattacat	gtttagaaaa	tgtcaacttgc	1740
	aaagaatgtgt	acaaagtgaa	aagtgtatcc	ctctcttgc	gcccgggtgt	gtttgtccca	1800
	gtgaaagctg	ctgttaacaa	tttgcaccc	cacatcccc	ttccctggcca	tccacccaaaa	1860

aaaagtacat ttacttatgt	aatgtactt atggtgatgt	atgtttgtt tggcctcaca	1920
5 gcatctgtt cccctaatt	tggtagctgc tcacatttc	ctcgaaagaa ccacaccctc	1980
tgcatctca gttctttgc	tggatggga cattgcct	gcagtcggcc caccctccag	2040
gccatgcct ctccagggtg	aggcctgtgt gatctaccgt	actagggtac taggcctga	2100
aagaggctt tcttgcctt	cctgcatttt	gaacctggag cggagactgt	2160
gcccctggag aagagaactg	tctgacagtg gggagagagc	gccacaccct ggtggcataa	2220
5 acgagtcct gaatcatgcc	gtggctgaac caagccctgt	ctgtggctt tttctgtgt	2280
actcaggcc gtttgcgtgg	gttactgtcc tgcatagcca	taatggccca gtataaagca	2340
10 gctgtttga tgagataatt	gcttttaattt	agcaaaaggta agcaaagctt	2400
ctgtaccc tcgttccaat	taggacctt cccatgtcag	aatgtgcaga tctgtctcat	2460
tgtttctgt gcagtgtgcc	cccacttcac ccagtagtt	ctgtgtgtct gttatgtact	2520
aggtaactaca aggtgcagg	acggtgtaga tacacccct	gctatcgtaa aactcaatga	2580
ttcgggtggg gaagacaaat	gtcagtaatg tacaaagtaa	aatggcagct gttagaagta	2640
15 tgaaaggggc agggtagggg	gaggtagaat cttccctgac	caggtaaga aaaccagagg	2700
ccttcctcga gggcaagagg	aggagaggag aaatagagta	aggcaggcag agggaaacagt	2760
ctgagctaag accctgtggc	tagaagtggc agagggagag	gcagcaggaa ggccagcggg	2820
gaggctgggg cccagtgca	gcccagggtt gaggagcgt	gcacatggag tttgttagga	2880
gttgggacg ccctgggtgg	tcttaattgt gatgggggtgg	gtgtgaaagg cagtcagggt	2940
20 tgcactgggt gcacaggaga	agtgtatcaga agaggacccc	agcagggtgt agccgtgagc	3000
tgggagggtc ttcaagtatgt	caggccatag ctgaaggtgt	cctacatcag caggtgtatg	3060
gtgagggtt aaccactgtt	tcactgcata gtcctctgt	atggacactt gaggtttag	3120
atttttgtc ggtatattca	gtgctgcgtt ggacatttc	ataacaaaata tttcggtaca	3180
cttttggta tatctgaaag	gtaaatttc acgactagaa	ttattagagc aaacggaaatt	3240
taacattttg gtgtgtattt	ccaaatttgc cttccaaatgt	gttttagtcg cttacccttg	3300
25 ccaacaatag atctatcctt	gccagcctt ggcacatcacat	ttaccatgtt aatagattgt	3360
aaaaccatat cttaaatttggc	taccctgaag ccaccatact	ggagaggctg cgtacagtgt	3420
ttcacgtaga gagagggtt	cccaggaggc ccacctgtctc	caaccccaacg tgcatagtc	3480
ttcccagccc aggcacagac	atgtggataa gattaaaca	tttccagccc cagccttcaa	3540
30 gcaatccatg ttgacactga	ggggagccaa cataagctga	gctgagaaac agtctgccc	3600
gtctgcagat tcatgagcaa	aagaaatgtt gggctggta	cagtggctca cgctgtat	3660
cccaactt tgggaggccg	aggtgggtgg atcagtttag	gtcaggagtt tgagaccagc	3720
ctggccaaaca tggtaagcc	ctgtctctac taaaatttag	ccgagtggtgg tggcggggc	3780
ctgttaatccc agtactatcg	ctggctgagg caggagaatg	gttgaaccc gggaggcgg	3840
35 gtttgactgt agccaagatc	aggccactgc actccagcct	gatgacgggg atgagactct	3900
gtctcaaaaa aacgaaacaa	aaatttttt agaaaatgtt	cattgtttt tggttttag	3960
acagggtctc actctgttgc	cctcaactaga gtgacttagg	gtcacggct cactgaagtc	4020
tctacctacc ggctcaattt	atcttccac cacagcctcc	caaataagctg ggagaaatgt	4080
cctgtttta atgaattttgt	tttcctttt gtctgtttt	tttaataatc tagtgatcta	4140
40 ataaattttgg atgatatctt	ttgactatc		4169

<210> 33

<211> 859

<212> DNA

<213> Homo sapiens

45 <400> 33			
catgccatgc agtttaccaa ccatcgagtc tgggactatg	ctggagataa ctatgttcat	60	
cgactgggtt caagtaaaac agatggaaaa atagtagatgt	atgaatgtga ggggataact	120	
50 tgccaggaag agaaaataga tgccttacag ttagagtatt	cataatttact aacaagccag	180	
ctggaatctc agcgaatcta ctggaaaac aagatagttc	ggatagagaa ggacacagca	240	
gaggaaatta acaacatgaa gaccaagttt aaagaaacaa	ttgagaatgt tgataatcta	300	
gacacaaac taaatgtatct cttaaaagaa aacgactctg	tggaaagaaa gtgcactcg	360	
ctaaacacaa aagtggccaa actcaccacac gagctaaag	aggagcagga aatgaacaaag	420	
55 tggggcgag ccaaccaatgtt cctccctgcag aacaagctaa	aagaggagga gaggtgtctg	480	
aaggagactt gtgacccaaaa agatctgcag atcaccgaga	tccaggagga gctgcgtgac	540	
gtcatgttct acctggagac acgcaggaaatcaaccatc	tgccctggcc gaccggcag	600	
60 gaaatccagg agggacacat caacatcgcc atggcctcg	cctcgagcc tgccctttcg	660	
ggggggcagtg ggaagttgcc ctccaggaag ggcccgagca	agagggccaa gtgacccatca	720	
gagcaacaga catccctgag actgttctcc ctgacactgt	gagagtgtgc tgggaccc	780	
agctaaatgt gagggtggc cctaataagt acaagtgagg	acgaaggccg gccttcgtgg	840	
ccttagagat ggatgaggc		859	

<210> 34

<211> 1070

<212> DNA

<213> Homo sapiens

<400> 34

gcgattgtcg	gggctgcagc	gctgcctccg	agaccgagag	tggttggagc	gggttccct	60
ggaagggtgc	gataaggccg	ggcgagggtgc	ctgggatgt	tctcccttc	cgcgaggaag	120
agatctaatt	ggtagggcg	ggtgtagact	agcctgccg	gccgcccgt	gacactgca	180
gcctccctgg	ccccgcggg	cccgccgaga	aagggtttaa	agggagcgag	gtgggtgtc	240
ctggggtccg	aggcgcgcct	ctcacgcct	gccaacaga	agccgcagtc	ccgtgggtc	300
tggagacgca	gttccttgc	taatgacaat	aaatccctgc	tccctctgcc	tcaagacatct	360
acgcagcgaa	atcgagctg	gccttgaggg	tccacaccgc	gaggaagatg	cgtgcgcca	420
ttccagagcc	taagcctgga	gacctgattt	agattttgc	cccttctac	agacactggg	480
ccatctatgt	tggcgatgg	tatgtggtc	atctggccccc	tccaaatgag	gtcgcaaggag	540
ctgggtcagc	cagtgtcatg	tccgcctga	ctgacaaggc	catcgtaag	aaggaaattgc	600
tgtatgtatgt	ggccgggag	gacaagtacc	agtcacacaa	caaacatgt	gacaagtact	660
cgccgctgcc	ctgcacgaaa	atcatccagc	ggccgggagga	gtgggtgggg	caggagggtgc	720
tctacaagct	gaccagttag	aactgcgagc	actttgtaa	tgagctgcgc	tatggagtcg	780
cccgcaatgt	ccaggtcaga	gatgtcatca	tccgtcgaag	cgttgcagga	atgggcttgg	840
cagccatgag	ccttatttgg	gtcatgttct	caagaaacaa	gcaaaaaaaag	caataactga	900
aaaagactgt	ctgtcagcga	tgactttata	catcaagggg	gtttttttt	gttagagat	960
ttgggggttg	gtttgtggat	ttcattgtga	tttataataa	ggcttattttt	cacagaataa	1020
aataaagcaa	aacgaggggag	gattttattt	ggggaggtqca	qcccaaaaaaa		1070

20

<210> 35

<211> 460

<212> DNA

<213> Homo sapiens

25

<400> 35

cttttcctcc	catgtcgcca	ccgaggtgcc	acgcgtgaga	cttctccgcc	gcctccgccc	60
cagacgcgc	cgcgatgcgc	tacgtcgcc	cctacactgc	ggctgcccta	gggggcaact	120
cctccccccag	cgcgaaggac	atcaagaaga	tcttggacag	cgtgggtatc	gaggcggacg	180
acgaccggct	caacaagggtt	atcagtgagc	tgaatggaaa	aaacattgaa	gacgtcattg	240
cccagggtat	tggcaagctt	gccagtgatc	ctgctggtgg	ggctgttagcc	gtctctgctg	300
ccccaggctc	tgcagccccct	gctgctggtt	ctgccccctgc	tgcagcagag	gagaagaaaag	360
atgagaagaa	ggaggaggtct	gaagagtcag	atgatgacat	gggatttggc	ctttttgatt	420
aaattcctgc	tccctgtcaa	ataaaagcctt	tttacacatc			460

35

<210> 36

<211> 4416

<212> DNA

<213> *Homo sapiens*

40

<400> 36

ggcgcacagg	gttttatagg	atcacattga	caaaagtacc	atggagttt	atgagtcagc	60
atattttatt	gttcttattc	cttcaatagt	tattacagta	attttctct	tcttctggct	120
tttcatgaaa	gaaacattat	atgatgaagt	tcttgcaaaa	cagaaaaagag	aacaaaagct	180
tattcttacc	aaaacagata	aaaagaaagc	agaaaaagaa	aagaataaaa	agaaagaaat	240
ccagaatgga	aacctccatg	aatccgactc	tgagagtgt	cctcgagact	ttaaattatc	300
agatgtttg	gcagtagaaag	atgatcaagt	tgcacctgtt	ccattgaatg	tcgttgaaac	360
ttcaagtagt	gttagggaaa	gaaaaaagaa	ggaaaaagaaa	caaagcctg	tgcttgaaga	420
gcaggatcata	aaaagaaatgt	acgcatcaaa	gatcttgc	aaaaaagtag	aacctgtccc	480
agttactaaa	cagccccacc	ctccctctga	agacgtgc	tgcgaaaga	aaccaggcca	540
gaagaagtct	aaaaatggaa	gcgatgacca	ggataaaaaag	gtggaaactc	tcatggtacc	600
atcaaaaagg	caagaagcat	tgccccctca	ccaaagagact	aaacaagaaa	gtggatcagg	660
gaagaagaaa	gcttcatcaa	agaaaacaaa	gacagaaaaat	gtcttcgtag	atgaacccct	720
tattcatgca	actacttata	ttcctttagt	ggataatgct	gactcaagtc	ctgtggtaga	780
taagagagag	gttattgatt	tgcttaaacc	tgaccaagta	gaagggatcc	agaaatctgg	840
gactaaaaaa	ctgaagaccg	aaactgacaa	agaaaaatgct	gaagtgaagt	ttaaagatt	900
tcttctgtcc	ttgaagacta	tgatgtttc	tgaagatgag	gctctttagt	ttgttagactt	960
gctaaaggag	aagtctggtg	taatacaaga	tgctttaaag	aagtcaagta	agggagaatt	1020
gactacgctt	atacatcagc	ttcaagaaaa	ggacaaagtta	ctcgctgctg	tgaaggaaga	1080
tgctgtgtct	acaaaaggatc	ggtgtaaagca	gttaacccag	gaaatgatga	cagagaaaaga	1140
aagaaggcaat	gtggttataa	caaggatgaa	agatcgaatt	ggaacattag	aaaaggaaca	1200
taatgtattt	caaaaacaaa	tacatgtcag	ttatcaagag	actcaacaga	tgcagatgaa	1260
gtttcagcaa	gttcgtgagc	agatggaggc	agagatagct	cacttgaagc	agggaaaatgg	1320
tatactgaga	gatgcgtca	gcaacactac	aaatcaactg	gaaagaaagc	agtctgcaga	1380
actaaataaa	ctacgcccagg	attatgctag	gttggtaat	gagctgactg	agaaaaacagg	1440
aaagctacag	caagagggaaag	tccaaaagaa	gaatgctgag	caagcagcta	ctcagttgaa	1500
ggttcaacta	caaaaqactq	aqaaaaqgtq	qqaqaaqagt	cagactaca	tcaagggaaq	1560

	aacagccgaa catgaggcag cacagcaaga tttacagagt aaatttggc ccaaagaaaa	1620
5	tgaagtacag agtctgcata gtaagcttac agatacctt gtatcaaaac aacagttgg a	1680
	gcaaagacta atgcagttaa tggatcaga gcagaaaagg gtgaacaaag aagagtctct	1740
	acaaatgcag gttcaggata tttggagca gaatgaggct ttgaaagctc aatttcgca	1800
	gttccattcc cagatagcag cccagaccc cgcttcgtt ctagcagaag aatttcataa	1860
	agtgattgca gaaaaggata agcagataaa acagactgaa gattcttag caagtgaacg	1920
10	tgatcggtt acaagtaaaag aagaggaact taaggatata cagaatatga atttcttatt	1980
	aaaagctgaa gtgcagaaat tacaggccct ggcaaattgag caggctgctg ctgcacatga	2040
	attggagaag atgcaacaaa gtgttatgt taaagatgt aaaataagat tgctggaaa	2100
	gcaactacaa catgaaattt caaacaaaat ggaagaattt aagattctaa atgaccaaa	2160
	caaagccataa aatcagaag ttcagaagct acagactctt gttctgaac agcctaataa	2220
	ggatgttgg gaacaaatgg aaaaatgcattcaagaaaaa gatgagaagt taaagactgt	2280
15	ggaagaattt ctgaaaactg gacttattca ggtggcaact aaagaagagg agctgaatgc	2340
	aataagaaca gaaaattcat ctctgacaaa agaagttcaa gacttaaaag ctaagcaaaa	2400
	tgatcagggt tctttgcct ctcttagtga agaactttaag aaggtatcc atgagaaaaga	2460
	tggaaagatc aagtctgttag aagagcttct ggaggcagaa cttctcaag ttgctaaca	2520
	ggagaaaaact gttcaggatt tggaaacagga aataaaggctt ctaaaaagaa aataggaaa	2580
20	tgtccagtt gaaaaggctc aacagttatc tattcacttcc aaagttcagg agcttcagaa	2640
	cttattaaaa gggaaaagagg aacagatgaa taccatgaa gctgtttgg aagagaaaaga	2700
	gaaagaccta gccaatacag ggaagtggtt acaggatctt caagaagaaa atgaatctt	2760
	aaaagcacat gttcaggaa tagcacaaca taacttgaaa gggcctt ctgcacatcaca	2820
	gtttgaagaa ctggagattt tggtgaaaga aaggaaaaat gaatttgaaga gtttggaa	2880
25	catgctaaaaa gagagggaga gtgtatcttc tagcaaaaaca cagctgttac aggtgtaca	2940
	agataaaaac aaattgtttt agtccaaat tggcagctt aaacaacaaa actaccaaca	3000
	ggcatcttct tttccccctc aataagtgtt ctctggaaatgatc aatggaaaaga	3060
	gaaaaacaaat gaaaggcagc aacaggttga agtgtttagt ttgaggat gcaatgttac	3120
	caaaaaattt tttccaaagg tgcgttccc ttcttaattt agttatgtt aatgggttgc	3180
30	tggatttggaa aaaaaggcaa aagaatgtat ggctggact tcagggttac aggggtttaa	3240
	ggttcttagag cacaagttga aagaagctga tggaaatgcac acatttttac agttaggt	3300
	tgaaaaatac aaatccgtcc ttgcagaaac agaaggaaattt ttcacatggc tacagagaa	3360
	tgttgagcaaa gaagaaaata aatggaaatgt taaggtcgat gaatcacaca agactattaa	3420
	acagatgcag tcattcatttta catcttcaga acaagagctt gaggcattaa gaagcgaaaa	3480
35	taaggatatt gaaaatctga gaagagaaacg agaacattt gaaatggaaac tagaaaaggc	3540
	agagatggaa cgatcttccct atgttacaga agttagagat ttgaggccac agttaaatgt	3600
	aacacttcacaa aacttttagaa ctgaaacaaaat tggaaagacag aaggtatctg gtgtttgg	3660
	taaggctcaaa cgtcaactgg agcttattccca gtcaaaaataa tggaaatgtt ctggagacac	3720
	tactgttatt gaaaatgtt gatgttttttccca agaaacggag tttctgttca agggagacat	3780
40	gtctgttattt ctaaatcaga ctgttacaca gtttacagtg ttgttttccagg cggttacca	3840
	acagctcaca aaggagaaaag agcacttacca ggtgttagag tggaaatgtt aatggaaaactgt	3900
	tcatttgagg ataaaaaaaatg cattgttattt tattttgcctt aatggaaatgtt ttatgtt	3960
	tttcacccctt tctactttgt tagactactg attttaaagaa ggaaaaaaaatg aatggaaatgtt	4020
	atgtttataa taaaaactgtt tggaaatattt agacctttac attcctgtt aatggaaatgtt	4080
45	aatcttttat cttatgttgc tcaataaaat tggcagatgg atcaaaatgtt taaaagacaaat	4140
	gtaaaattt acatttat actgtatgtt tacactgtt tacttaacat ttggggaaat	4200
	aactgcctt gacttcaactt caagaaaaca cttttttgtt gctaattgtt tgggttttgc	4260
	taatggcgctc agcaaaaaaa aggtatgttta ttatc	4320
		4380
		4416
50	<210> 37	
	<211> 628	
	<212> DNA	
	<213> Homo sapiens	
55	<220>	
	<221> unsure	
	<222> 284..284	
	<223> n = a, c, g or t	
60	<220>	
	<221> unsure	
	<222> 594..594	
	<223> n = a, c, g or t	
65	<220>	
	<221> unsure	
	<222> 597..597	

5 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 607...607
 <223> n = a, c, g or t
 <400> 37
 10 ggcacgagaa gaagtctaaa aatggaaagcg atgaccaggg ataaaaaagggt ggaaactctc
 atggtagccat caaaaaggca agaagcattg cccctccacc aagagactaa acaagaaaagt
 15 ggatcaggg aagaagaaaagc ttcatcaaag aacaaaaga cagaaaaatgt cttcgtagat
 gaacccctta ttcatgcaac tacttatatt cctttgatgg ataatgctga ctcaagtcct
 gtggtagata agagagaggt tatttattt cttaaacctg accnagtaga agggatccag
 20 aaatctggga ctaaaaaaact gaagacccaa actgacaaag aaaatgctga agtgaagtt
 aaagatttc ttctgtcctt taagactatg atgtttctg aagatgaggc tctttgtgtt
 gtagacttgc taaaggagaa gtctcggtatacacaatgatg ctttaaagaa gtcaagtaag
 ggagaattga ctacgcttat acatcagctt caagaaaagg accaagttac tcgctgctgt
 gaaggaagat gctgctgcta caaaggatcc gtgtaagcag ttacccagg aatnatncca
 25 aagaaaanaca gagcaattt gatatcaa 628
 <210> 38
 <211> 730
 <212> DNA
 <213> Homo sapiens
 30 <220>
 <221> unsure
 <222> 127..127
 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 260..260
 <223> n = a, c, g or t
 35 <220>
 <221> unsure
 <222> 307..307
 <223> n = a, c, g or t
 40 <220>
 <221> unsure
 <222> 329..329
 <223> n = a, c, g or t
 45 <220>
 <221> unsure
 <222> 336..336
 <223> n = a, c, g or t
 50 <220>
 <221> unsure
 <222> 473..473
 <223> n = a, c, g or t
 55 <220>
 <221> unsure
 <222> 487..487
 <223> n = a, c, g or t
 60 <220>
 <221> unsure
 <222> 487..487
 <223> n = a, c, g or t
 65 <220>
 <221> unsure
 <222> 494..494
 <223> n = a, c, g or t
 70 <220>
 <221> unsure

<222> 563..563
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 640..640
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 681..681
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 689..689
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 708..708
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 714..714
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 728..728
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 730..730
 <223> n = a, c, g or t

40 <400> 38
 aaagaattcg gcacgagtga agaccgaaac tgacaaaagaa aatgctgaag tgaagttaa 60
 agatttgccttcttgc agactatgtat gttttctgaa gatgaggctc tttgtgtgt 120
 agactyncta aaggagaagt ctgggttaat acaagatgtct taaaagaagt caagtaaggg 180
 agaatttgact acgcttatac atcagcttca agaaaaggac aagtyactcg ctgctgtgaa 240
 ggaagatgtct gctgcyacan aggatcggtt taagcagtta acccaggaaa ttagtacacaga 300
 gaaaganaga agcaatgtgg ttataacang gatganagay cgaatygaa cattagaaaa 360
 ggracataat gatyyccaa acaaataaca tgtcagtyat caagagacac aacagatgca 420
 gatgaagttt cagcaagttt gtgagcagat ggaggcagag atagcycact tgnagcagga 480
 aatatggnata ctngnagaat gcagtcagca acactacaaa tcaactggaa agcaagcagt 540
 ctgcagaact aaataaacta cgnccaggatt atgcttagttt ggtgaatgag cctgactgag 600
 aaacaggaaa gctacacgaa gaggaaatca aagaagaatn ctgagcaagc agctactcag 660
 ttgaaggttc caactacacg nacgccttngn agaaggtggg ggaggcgntt cagngcctac 720
 atcagggnngn 730

55 <210> 39
 <211> 571
 <212> DNA
 <213> Homo sapiens

60 <220>
 <221> unsure
 <222> 37..37
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 42..42
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 64..64
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 67..67
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 73..73
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 86..99
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 106..107
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 117..117
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 139..139
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 153..153
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 243..243
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 257..257
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 264..264
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 319..319
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 337..337
 <223> n = a, c, g or t

 <220>

5 <221> unsure
 <222> 341..341
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 353..353
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 373..373
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 379..379
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 384..385
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 419..419
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 427..427
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 433..433
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 440..442
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 444..444
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 448..448
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 450..450

<223> n = a, c, g or t
<220>
<221> unsure
<222> 455..455
<223> n = a, c, g or t

5 <220>
<221> unsure
<222> 486..486
<223> n = a, c, g or t

10 <220>
<221> unsure
<222> 488..489
<223> n = a, c, g or t

15 <220>
<221> unsure
<222> 493..493
<223> n = a, c, g or t

20 <220>
<221> unsure
<222> 496..497
<223> n = a, c, g or t

25 <220>
<221> unsure
<222> 500..500
<223> n = a, c, g or t

30 <220>
<221> unsure
<222> 504..504
<223> n = a, c, g or t

35 <220>
<221> unsure
<222> 506..507
<223> n = a, c, g or t

40 <220>
<221> unsure
<222> 515..515
<223> n = a, c, g or t

45 <220>
<221> unsure
<222> 520..520
<223> n = a, c, g or t

50 <220>
<221> unsure
<222> 523..523
<223> n = a, c, g or t

55 <220>
<221> unsure
<222> 525..526
<223> n = a, c, g or t

60 <220>
<221> unsure
<222> 538..538
<223> n = a, c, g or t

65 <220>

5	ayacaatgc cttttttatc ctcaaata tggagnagct ctnctcctt tgcgrnnnn taactgtgtt acagtctgnt ttaggcttac ttctggggga acatcaactt tttcaataac tgnctggata agtcnngtg actnttgagc ttcattttgt tcagttctna gttttgtggg gncttcgtta acntagggng gtcnntccct ntctcgntct cnccccagn nngncaanan gcccncnnc cgnagnngn aaangnngc catcgccctt tacctttccc tttattttct t	120 180 240 300 360 420 480 540 571
10	<400> 39	
15	<210> 40 <211> 644 <212> DNA <213> Homo sapiens	
20	<220> <221> unsure <222> 415..415 <223> n = a, c, g or t	
25	<220> <221> unsure <222> 525..526 <223> n = a, c, g or t	
30	<400> 40 atattttgga gcagaatgag gctttgaaaag ctcaaattca gcagttccat tcccat cagccccagac ctccgcttca gttctagcag aagaattaca taaaatgtatt ataaggcagat aaaacagact gaagattttt tagcaagtga acgtgatcgt ttaacaagta aagaagagga acttaaggat atacagaata tgaattttttt attaaaagct gaatgtcaga aattacaggc cctggcaat gagcaggctg ctgctgcaca tgaattttggg aagatgcaac acagtgtta tggtaaagat gataaaataa gattgcttga agagcaacta caacatgaca tttcaaacaa aatggaaagaa tttaaatgattc taaaatgacca aaacaaagca ttaanatca aagttcagaa gctacagact cttgtttctg aacagcctaa taaggatgtt gtggacaca tggaaaaatg cattcaagaa aagatgagaa gttaaagact gtggnnngatt acttgacact ggacttattc aggtggcaac taaagagagg agctgatgca tagacagaca ttcatctctg acaaagagtt caagacttac agcttagcaaa tgatcagggtt ctgg	60 120 180 240 300 360 420 480 540 600 644
35	<210> 41 <211> 566 <212> DNA <213> Homo sapiens	
40	<220> <221> unsure <222> 47.47 <223> n = a, c, g or t	
45	<220> <221> unsure <222> 47.47 <223> n = a, c, g or t	
50	<220> <221> unsure <222> 59..59 <223> n = a, c, g or t	
55	<220> <221> unsure <222> 91..91 <223> n = a, c, g or t	
60	<220> <221> unsure <222> 104..104 <223> n = a, c, g or t	
65	<220> <221> unsure	

5 <222> 441..441
 <223> n = a, c, g or t
 <220>
 <221> unsure
 <222> 448..448
 <223> n = a, c, g or t
 10 <220>
 <221> unsure
 <222> 457..457
 <223> n = a, c, g or t
 15 <220>
 <221> unsure
 <222> 525..525
 <223> n = a, c, g or t
 20 <220>
 <221> unsure
 <222> 539..539
 <223> n = a, c, g or t
 25 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t
 30 <400> 41
 caacacaatc tcaaggctt caaactggga tgcagaagag gcctctntca agttatgtng 60
 tgctacttcc tgaacaaggg ctggaaaaga ntcaatggct tctngaagag cccgtAACCA
 ctcccccgta ttggcttaggg ctttctcttt ctcttccaaa acagccttca tgggattcat
 ctgtgcctct ttccctttta ataagttcyg aagctcctga actttggaaag tgatagataa
 cygttgagcc ttttcaagct ggacatttcc tattttttct ttagagcct ttatccccg
 35 tttccaaatcc cgaacagttt ttcaccccttc tcatggatca ctctcttaag gtcttcaact
 ctcttcttca gacttgatct ttcccttgc agcaacattt agaagtgcgg cctccaggaaag
 agagaggcaa aagaacccga ncatttgnta gttttangct cgaacttctt ttgtcagaga
 tgaattttct gttcttattt catttagctc ctcttcttta ggtgnccacca gaataaggnc
 40 agtgtcaaga aattcttcca cagnct 566
 <210> 42
 <211> 878
 <212> DNA
 <213> Homo sapiens
 45 <220>
 <221> unsure
 <222> 595..595
 <223> n = a, c, g or t
 50 <220>
 <221> unsure
 <222> 756..756
 <223> n = a, c, g or t
 55 <220>
 <221> unsure
 <222> 766..766
 <223> n = a, c, g or t
 60 <220>
 <221> unsure
 <222> 815..815
 <223> n = a, c, g or t
 65 <220>
 <221> unsure

5 <220> 818..818
 <223> n = a, c, g or t

 <220>
 10 <221> unsure
 <222> 827..827
 <223> n = a, c, g or t

 <220>
 15 <221> unsure
 <222> 831..831
 <223> n = a, c, g or t

 <220>
 20 <221> unsure
 <222> 866..866
 <223> n = a, c, g or t

 <400> 42
 25 accttaaacct cctctgacct gaagttccag ccatacattc ttttgccttt ttttcaatcc 60
 atgcaaccat tcaccataaac tcaaattaga agggacagac acctttggaa ataatttttt 120
 gagaacttct ttagcctcca actcaacagc ttccacctgt tgctgccttt cattgttttt 180
 ctctctctgg tggtaactg catccttcaa agaatctaac tcattccaga gaccacttat 240
 ttcttctctt ctttctgaaa ttactttaa taattctca tgagggggaa aagaagatgc 300
 ctgttggtag ttttggtag taagctgctc aatttggac taaaacaatt tgtttcatc 360
 ttgtacatcc tggtaacagct gtgtttgtct agaaagatca ctctccctct cttttagcat 420
 ggcttctaac ctcttcaatt ctcttccatt ttcttcaac acaatctcaa gttcttcaaa 480
 ctgtgtatgca gaagaggcct ttcttcaagg tattcatctg ccctgttattt gctangtctt 540
 35 taaaagattc attttcttct tgaagatcct gtaaccactt ccctgttattt gctangtctt 600
 tctctttctc ttccaaaaca gccttcaagg tattcatctg ccctgttattt gctangtctt 660
 agttctgaag ctcttgaact ttggaaagtga tagataactg ttgagccctt tcaagcctgg 720
 acattcctaa ttccctctt aaaaggctta attccngttt caaaancgg aacagtttc 780
 ccccttgtaa gcaacttga gaaattcggc tccanaancc ctcctanaga nttgatctt 840
 40 caactttcc aanggattac ttccnnaag ttcttaa 878

 <210> 43
 <211> 620
 <212> DNA
 <213> Homo sapiens
 45 <220>
 <221> unsure
 <222> 391..391
 <223> n = a, c, g or t

 50 <220>
 <221> unsure
 <222> 400..400
 <223> n = a, c, g or t

 55 <220>
 <221> unsure
 <222> 411..411
 <223> n = a, c, g or t

 60 <220>
 <221> unsure
 <222> 414.. 414
 <223> n = a, c, g or t

 65 <220>
 <221> unsure

5 <222> 418..418
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 427..428
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 446..446
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 454..455
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 463..463
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 465..465
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 471..471
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 480..480
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 484..484
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 493..493
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 500..500
 <223> n = a, c, g or t

5 <220>
<221> unsure
<222> 514..515
<223> n = a, c, g or t

10 <220>
<221> unsure
<222> 524..524
<223> n = a, c, g or t

15 <220>
<221> unsure
<222> 539..539
<223> n = a, c, g or t

20 <220>
<221> unsure
<222> 568..568
<223> n = a, c, g or t

25 <220>
<221> unsure
<222> 573..574
<223> n = a, c, g or t

30 <220>
<221> unsure
<222> 581..581
<223> n = a, c, g or t

35 <220>
<221> unsure
<222> 600..600
<223> n = a, c, g or t

40 <220>
<221> unsure
<222> 604..604
<223> n = a, c, g or t

45 <220>
<221> unsure
<222> 608..608
<223> n = a, c, g or t

50 <220>
<221> unsure
<222> 616..616
<223> n = a, c, g or t

55 <220>
<221> unsure
<222> 619..619
<223> n = a, c, g or t

60 <400> 43
accttaacct cctctgaccc tgaattccag ccatacattc ttttgccctt ttttcaaatac
catgcaacca ttcaaccataa ctcaaattag aaggacaga caccttgcga aataattttt
tgagaacttc tttagcctcc aactcaacag cttccacccg ttgcgcctt tcattgtttt
tcttcctctg gtgtcaact gcacccctca aagaatctaa ctcattccag agaccactta
tttctttctc tctttctgaa attacttttataattcttc atgagggggaa aaagaagatg
cctgttggta gtttgggtt ttaagctgct caatttggga cttaaacaaat ttgtttccat
cctgtacatc ctgtAACAGC tgggtttgc naagaaaatn actccccctc nccnttanca
65 nggggtnca acctncttaa atacantcc tttnnctta aananaatct naggttccn
caangggta tgnaaaaaan gccccttca agtnnggttgc tgcnacttcc tgaacatgng
ctttaagatc atttctctg aagatccngt acnntcccg nattggtagg cttcccttcn
600
120
180
240
300
360
420
480
540
600

ttcnaanag cttcangng

620

5 <210> 44
 <211> 623
 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> unsure
 <222> 25..25
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 409..409
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 412..412
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 414..414
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 423..423
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 426..426
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 435..435
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 444..444
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 450..450
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 454..454
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 459..459
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 490..490
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 508..508
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 511..511
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 515..515
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 545..545
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 555..555
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 564..564
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 600..600
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 611..611
 <223> n = a, c, g or t

50 <400> 44

acctaacct	cctctgaccc	tgaantccag	ccatacattc	ttttgccttt	tttcaaatc	60
catgcaacca	ttcaccataa	ctcaaattag	aaggacaga	caccccttgg	aataattttt	120
tgagaacttc	tttagcctcc	aactcaacag	cttccacctg	ttgctgcctt	tccttggaaag	180
tcttggtcac	tttgtccctgc	agcatttttt	cagtgtatgc	caatgcttcc	attgcttccc	240
agtttttctc	ccgaaggctca	ttgtttttct	tcctctggtg	ttcaactgca	tccttcaaag	300
aatctaactc	attccagaga	ccacttattt	ctttctctct	ttctgaaatt	acttttaata	360
attcttcatg	agggggaaaa	gaagatgcct	ggtggaaatt	tggtggttna	ancngccaa	420
ttnggnacct	aaaanatttgc	gttncaactn	gtanaccng	taaaaaactgt	gttttgctaa	480
55 aaagataacn	ccccctctct	ttaagcangg	nttcaacct	cttnatttcat	ttcctttct	540
tcaanaaaatc	tcagntctca	aacngggatg	caaaagaggc	tcttcaagtt	aaggtgggc	600
acttccggaa	natggccttt	aaa				623

60 <210> 45
 <211> 625
 <212> DNA
 <213> Homo sapiens

65 <220>
 <221> unsure
 <222> 392..392
 <223> n = a, c, g or t

5 <220>
 <221> unsure
 <222> 408..408
 <223> n = a, c, g or t

10 <220>
 <221> unsure
 <222> 417..417
 <223> n = a, c, g or t

15 <220>
 <221> unsure
 <222> 421..421
 <223> n = a, c, g or t

20 <220>
 <221> unsure
 <222> 424..425
 <223> n = a, c, g or t

25 <220>
 <221> unsure
 <222> 437..437
 <223> n = a, c, g or t

30 <220>
 <221> unsure
 <222> 439..439
 <223> n = a, c, g or t

35 <220>
 <221> unsure
 <222> 456..456
 <223> n = a, c, g or t

40 <220>
 <221> unsure
 <222> 467..467
 <223> n = a, c, g or t

45 <220>
 <221> unsure
 <222> 469..469
 <223> n = a, c, g or t

50 <220>
 <221> unsure
 <222> 473..473
 <223> n = a, c, g or t

55 <220>
 <221> unsure
 <222> 475..475
 <223> n = a, c, g or t

60 <220>
 <221> unsure
 <222> 496..496
 <223> n = a, c, g or t

65 <220>
 <221> unsure
 <222> 499..500
 <223> n = a, c, g or t

 <220>

5 <221> unsure
 <222> 516..516
 <223> n = a, c, g or t

 10 <220>
 <221> unsure
 <222> 524..524
 <223> n = a, c, g or t

 15 <220>
 <221> unsure
 <222> 535..535
 <223> n = a, c, g or t

 20 <220>
 <221> unsure
 <222> 560..560
 <223> n = a, c, g or t

 25 <220>
 <221> unsure
 <222> 582..582
 <223> n = a, c, g or t

 30 <220>
 <221> unsure
 <222> 592..592
 <223> n = a, c, g or t

 35 <220>
 <221> unsure
 <222> 594..594
 <223> n = a, c, g or t

 40 <220>
 <221> unsure
 <222> 604..604
 <223> n = a, c, g or t


 45 <400> 45
 accttaacct cctctgaccc tgaagtccag ccatacattc ttttgccttt tttcaaatc 60
 catgcaacca ttacccataa ctcaaattag aaggcacaga cacctttgga aataattttt 120
 tgagaacttc tttagccctcc aactcaacag cttcacctg ttgctgcctt tcattgttt 180
 tcttcctctg gtgttcaact gcataccttca aagaatctaa ctcattccag agaccactta 240
 ttctttctc tctttctgaa attacttttataatcttc atgaggggga aaagaagatg 300
 cctgttggta gttttgtt ttaagctgtt caatttggga cttaaacaat ttgttttcat 360
 ctgtacatc ctggtaacag ctgtgtttt cntagaaaag attactcncc ctctctnttt 420
 ncanngggtt caaccctnta aattacattt cccttntctt aaacaanant ctnangttct 480
 tcaaactgtg atgcanaann ggctcttca agttangttg tgcnacttcc tgaanatntg 540
 55 ctttaaagat catttcttcn tgaatccgt aaccacttcc cngtatggc angncttccc 600
 ttcncttcaa aaaagccctca aggtta 625

 60 <210> 46
 <211> 4416
 <212> DNA
 <213> Homo sapiens

 <400> 46
 65 gccccacagg gttttatagg atcacattga caaaagtacc atggagttt atgagtcagc 60
 atattttattt gttcttattt cttcaatagt tattacagta attttccttct tcttctggct 120
 tttcatgaaa gaaacattat atgatgaagt tcttgcaaaa cagaaaagag aacaaaagct 180
 tattccttacc aaaacagata aaaagaaaagc agaaaaagaaa aagaataaaaa agaaagaaaat 240

5	ccagaatgga aacccatcg aatccgactc tgagagtgtc cctcgagact ttaaattatc agatgcttg gcagtagaag atgatcagt tgcacctgtt ccattgaatg tcgttgaac 300 ttcaagtagt gttagggaaa gaaaaaaagaa gaaaaagaaa caaaaggctg tgcttgaaga 360 gcaggtcatc aaagaaaatg acgcatcaaa gattcctggc aaaaaagtag aacctgtccc 420 agttactaaa cagcccaccc ctccctctga agcagctgcc tcgagaaga aaccaggca 480 gaagaagtct aaaaatggaa gcgatgacca ggataaaaag gtggaaactc tcatggtacc 540 atcaaaaagg caagaagcat tgcccttcca ccaagagact aaacaagaaa gtggatcagg 600 gaagaagaaa gcttcatcaa agaaacaaaa gacagaaaat gtggaaactc tcatggtacc 660 tattcatgca actactata ttcccttgat ggataatgtc gactcaagtc ctgtggtaga 720 taagagagag gttatttgatt tgcttaaacc tgaccaagta gaaggatcc agaaatctgg 780 gactaaaaaa ctgaagaccg aaactgacaa agaaaatgtc gactcaagtc ctgtggtaga 840 tcttcgtcc ttgaagacta tgatgtttc tgaagatgag gtaatgttgc gaaatgttgc 900 gctaaaggag aagtctgggtaatacacaaga tgctttaaag gaaatgttgc 960 gactacgctt atacatcagc ttcaagaaaa ggacaagtt aagtcaagta agggagaatt 1020 tgctgctgtc acaaaggatc ggtgtaaagca gttaaacccag ctcgctgctg tgaaggaaga 1080 aagaagcaat gttgtataa caaggatgaa agatcgatt gaaatgttgc cagagaaaaga 1140 taatgttattt caaaacaaaa tacatgttag ttatcaagag gaaatgttgc 1200 gtttcagcaa gttcgtgagc agatggggc agagatagct actcaacaga tgcagatgaa 1260 tatactgaga gatgcagtc gcaacactac aaatcaactg cacttgaagc agggaaaatgg 1320 actaaataaa ctacgccagg attatgttag gttggtagat gaaatgttgc 1380 aaagctacag caagaggaag tccaaaagaa gaatgttag gttcaacta caaggatgttgc 1440 ggttcaacta caagaagctg agagaagggtt ggaagaagtt aacagcggaa catgaggcag 1500 cacagcggaa ttacagatgaa gatgttgc 1560 tgaagttacag agtctgcata gtaagcttac agatacctt gaaatgttgc 1620 gcaaaagacta atgcagttaa ttgaatcaga gcaagaaaagg gttcaacta aacagtttgc 1680 acaaatgcag gttcaggata ttttggagca gaatgttag gttccatttc 1740 gttccatttc cagatagcag cccagaccc tcgttgcattt 1800 agtgattgca gaaaaggata agcagataaa acagactgaa ctagcagata aatttcagca 1860 tgatgttta acaagtaaaag aagaggaact taagatata gttcttagt 1920 aaaagctgaa gtgcagaaat tacaggccct ggcaatgtg ctagtgcata aatttcataa 1980 atggagaaatg atgcaacaaa gtgtttatgt taaagatgtt gttcttagt 2040 gcaactacaa catgaaattt caaacaaaaat ggaagaattt aagattctaa atgaccaaaa 2100 caaagcatta aaatcagaag ttcaagatc acagactttt gttctgaac agctataaa 2160 ggatgttgc gaaacaaatgg aaaaatgtc tcaagaaaaa cagaatgttgc 2220 ggaagaattt cttgaaactg gacttattca ggtggcaact aaaaataagat tgcttggaga 2280 aataagaaca gaaaattcat ctctgacaaa agaagttcaa gttcttagt 2340 tgatcagggtt tctttgcct ctcttagttgaa agaacttaag aagatgttgc atgagaaaga 2400 tgaaagatc aagtctgttgc aagagcttgc ggaggcagaa cttctcaag ttgttcaacaa 2460 ggagaaaaact gttcaggatt tgaaacagaa aataaaaggctt cttatgttgc 2520 tgtccagctt gaaaaggctc aacagtttac tatcatcttcc 2580 cttattaaaaa gggaaagagg aacagatgaa taccatgaa gtttgcattt 2640 gaaagaccta gccaatacag ggaagtggg acagatctt 2700 aaaagcacat gttcaggaag tagcacaaca taacttggaa gggctctt ctgcattcaca 2760 gtttgaagaa cttgagattt ttttggaaatgaa aagggaaaat gtttgcattt 2820 catgtctaaa gagagggaga gtgtatcttcc tagcaaaaaca cagctgttac aggatgtaca 2880 agatgaaaac aaattgttta agtcccaat tgacgcattt aaacaacaaa actaccaaca 2940 ggcatcttct tttcccccattc atgaaagattt atttcaatgttgc 3000 aataagtgtt ctctggaaatg agttagattt ttttggggat gtttgcattt 3060 gaaaacaaat gaaaggcagc aacagggttgc agtctgttgc ttggaggctt aagaagttct 3120 caaaaaattt tttccaaagg tttctgtccc ttcttatttgc agttatgttgc aatgttgc 3180 tggatttgaa aaaaaggcaaa aagaatgttgc ggttgcattt 3240 gtttcttagatg cacaagttgaa aagaagctgaa tgaaatgttgc acattgttac agcttagatgt 3300 tgaaaaatac aaatccgtcc ttgcagaaac agaaggaaattt ttacagaagc tacagagaag 3360 tgttgagcaaa gaagaaaaata aatggaaatg taaggctcatttgc gtttgcattt 3420 acagatgcag tcatcatttgc catcttgcatttgc acaagagcttgc 3480 taaggatattt gaaaatgttgc gtttgcatttgc 3540 agagatggaa cgtatctacatc atgttacaga agtctgttgc gtttgcatttgc 3600 aacactcaca aaacttagaa ctgcacaaaaa tgaaagacag aaggttagcttgc 3660 taaggctcatttgc cgttgcatttgc agtctgttgc gtttgcatttgc 3720 tacttttattt gaaaatgttgc atgttccccc agaaacgggat gtttgcatttgc 3780 gtctgttgc gtttgcatttgc 3840 acagctcaca aaggagaaatg agcacttacca ggttgcatttgc ttttgcatttgc 3900 tcatttgcatttgc attttttttttgc ttttgcatttgc 3960 tttcaccctt tctacttttgc cagaaacacttgc gtttgcatttgc 4020 tagactactg atttaaagaa gggaaaaaaa aagccaaactc ttttgcatttgc 4080 agttttataa taaaaactgttgcataatatttgc agaccttac attccttgc 4140 aatcttttat ctttttttgc tcaataaaaat ttttgcatttgc 4200 tttttttgc tcaataaaaat ttttgcatttgc 4260
---	--

gtaaaattta acatttaat actgatgtt tacactgtt tacttaacat ttgggaagt 4320
aactgcctct gactcaact caagaaaaca ctttttgtt gctaatgtaa tcggtttttg 4380
taatggcgtc agcaaataaa aggatgctta ttattc 4416





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, C07K 14/47, A61K 31/70, 35/12, 38/17, C07K 16/18, G01N 33/574, C12Q 1/68		A3	(11) International Publication Number: WO 00/20587
			(43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/22873			(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
(22) International Filing Date: 4 October 1999 (04.10.99)			
(30) Priority Data: 09/166,300 5 October 1998 (05.10.98) US 09/166,350 5 October 1998 (05.10.98) US			(81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).			Published <i>With international search report.</i>
(72) Inventors: OBATA, Yuichi; Chikusa-Ku, Nagoya 464 (JP); GOUT, Ivan; 91 Riding House Street, London W1P 8BT (GB); TURECI, Ozlem; Innere Medizin I, D-66421 Homburg/Saar (DE); SAHIN, Ugar; Innere Medizin I, D-66421 Homburg/Saar (DE); PFREUNDSCHEU, Michael; Innere Medizin I, D-66421 Homburg/Saar (DE); SCANLAN, Matthew, J.; 1275 York Avenue, New York, NY 10021 (US); STOCKERT, Elisabeth; 1275 York Avenue, New York, NY 10021 (US); CHEN, Yao-Tseng; 525 East 68th Street, New York, NY 10021 (US); OLD, Lloyd, J.; 605 Third Avenue, New York, NY 10158 (US); JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE); KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE).			(88) Date of publication of the international search report: 12 October 2000 (12.10.00)

(54) Title: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

(57) Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in renal cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with renal cancer. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No.
PCT/US 99/22873

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 7	C12N15/12	C07K14/47	A61K31/70	A61K35/12
	C07K16/18	G01N33/574	C12Q1/68	A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>Database EMBL Entry AA858164; Accession number AA858164 13.03.1998 National Cancer Institute, Cancer Genome Anatomy Project; of66h01.s1 NCI_CGAP_Co8 Homo sapiens clone IMAGE:1435345; in relation to SEQ ID Nos. 1 and 12 XP002132221 see the abstract</p> <p>---</p> <p>-/-</p>	55, 56, 60, 68, 69, 71, 72, 75

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 June 2000

Date of mailing of the international search report

14.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Alt, G

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA10936; Accession number 188593 20.01.1997 The WashU-Merck EST Project zp75e04.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 626046; in relation to SEQ ID Nos. 1 and 12 XP002132222 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry AI139112; Accession number AI139112 25.09.1998 National Cancer Institute, Cancer Genome Anatomy Project; qc27h04.x1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:1710871; in relation to SEQ ID Nos. 1 and 12 XP002132223 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	Database EMBL Entry MM1210701; Accession number AA415243 09.05.1997 The WashU-HHMI Mouse EST Project; vd25e08.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone 793574; in relation to SEQ ID Nos. 1 and 12 XP002132224 see the abstract ---	68,69
X	Database EMBL Entry HS437322, Accession number W00437 19.04.1996 The WashU-Merck EST Project yz99c04.r1 Homo sapiens cDNA clone 291174; in relation to SEQ ID Nos. 1 and 12 XP002132225 see the abstract ---	68,69
A	KAWAHARA, K. ET AL.: "Review: Potassium transport and potassium channels in the kidney tubules" JAPANESE JOURNAL OF PHYSIOLOGY, vol. 47, 1997, pages 1-10, XP000881680 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1
A	WANG, W. ET AL.: "Renal K ⁺ channels: Structure and function" ANNUAL REVIEW OF PHYSIOLOGY, vol. 59, 1997, pages 413-436, XP000881688 see the whole document; in relation to SEQ ID Nos. 1 and 12 ---	1

-/-

INTERNATIONAL SEARCH REPORT

Int'l. Application No
PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL Entry HSAA24402; Accession number AA211485 02.02.1997 zn55c06.s1 Stratagene muscle 937209 Homo sapiens cDNA clone IMAGE:562090 3' similar to TR:E245548 E245548 Chromosome XII Reading frame ORF YLR097C Hillier, L. et al.; in relation to SEQ ID No. 4 XP002140895 see the abstract ---	55,56, 60,68, 69,71, 72,75
X	SEMENKOVICH C F ET AL: "Human fatty acid synthase mRNA: tissue distribution, genetic mapping and kinetics of decay after glucose deprivation" JOURNAL OF LIPID RESEARCH, US, BETHESDA, MD, vol. 36, no. 7, July 1995 (1995-07), pages 1507-1521-1521, XP002105049 ISSN: 0022-2275 see Figure 1; in relation to SEQ ID No. 5 ---	55,56, 60,68, 69,71, 72,75
X	US 5 665 874 A (KUHAJDA FRANCIS P ET AL) 9 September 1997 (1997-09-09) see cDNA and protein OA-519 (SEQ ID No. 9) corresponding to columns 43-60; in relation to SEQ ID Nos. 5 and 16 ---	55,56, 60,68, 69,71, 72,75
A	GANSLER, T. S. ET AL.: "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival" HUMAN PATHOLOGY, vol. 28, 1997, pages 686-692, XP000909948 related to SEQ ID No. 5 ---	1
P, X	WO 99 18989 A (BAYLOR COLLEGE MEDICINE) 22 April 1999 (1999-04-22) see page 109, SEQ ID No. 41; in relation to SEQ ID No. 15 ---	48,49
P, X	WO 98 48020 A (FIORE PIER PAOLO DI ISTITUTO EUROPEO DI ONCOLOGIA S (IT); CAPRA MAR) 29 October 1998 (1998-10-29) see pages 42-48 corresponding to SEQ ID Nos. 3 and 4; in relation to SEQ ID Nos. 7 and 18 ---	55,56, 60,68, 69,71, 72,75

-/-

INTERNATIONAL SEARCH REPORT

Inte Application No
PCT/US 99/22873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAMURA, T. ET AL.: "A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells" ONCOGENE, vol. 7, 1992, pages 733-741, XP000670282 see Figure 3; in relation to SEQ ID NOS. 7 and 18	55, 56, 60, 68, 69, 71, 72, 75
X	RICH, B.E. AND STEITZ, J.A. : "Human acidic ribosomal phosphoproteins P0, P1 and P2: Analysis of cDNA clones in vitro synthesis and assembly" MOLECULAR AND CELLULAR BIOLOGY, vol. 7, 1987, pages 4065-4074, XP000909977 see Figure 1C; phosphoprotein P2; in relation to SEQ ID No. 35	55, 56, 60, 68, 69, 71, 72, 75
X	SEKI, T. ET AL.: "Cloning of the cDNA encoding a novel importin alpha homologue, Qip1: Discrimination of Qip1 and Rch1 from hSrpl by their ability to interact with DNA helicase A1/RecQL" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, 1997, pages 48-53, XP000910159 see Figure 1 & Database EMBL; 10.04.1997; Entry HSAB2533; Accession number AB002533; in relation to SEQ ID No. 35.	55, 56, 60, 68, 69, 71, 72, 75
A	JIANG, C. ET AL.: "Characterization of colorectal cancer related cDNA clones obtained by subtractive hybridization screening" JOURNAL OF CANCER RESEARCH AND ONCOLOGY, vol. 123, 1997, pages 447-451, XP000909986 see the whole document as far as related to phosphoprotein P2	1
A	WO 96 29409 A (UNIV LEIDEN ;LUDWIG INST CANCER RES (US)) 26 September 1996 (1996-09-26) the whole document	1
A	SAHIN ET AL: "Human neoplasms elicit multiple specific immune responses in the autologous host" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, 1 December 1995 (1995-12-01), pages 11810-11813, XP002091914 ISSN: 0027-8424 cited in the application the whole document	1

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22873

C:(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	SCANLAN, M.J. ET AL.: "Antigens recognized by autologous antibody in patients with renal-cell carcinoma" INTERNATIONAL JOURNAL OF CANCER, vol. 83, 12 November 1999 (1999-11-12), pages 456-464, XP000867569 see whole document in relation to SEQ ID Nos. 1, 4, 5, 7, 12, 15, 16, 18 and 35 of the application	1
P, X	& Database EMBL, 06.July 1999; Entry AF155110; Accession number AF155110 Scanlan, M.J. et al.; in relation to SEQ ID Nos. 1 and 12 & Database EMBL, 06.July, 1999; Entry AF155114; Accession number AF155114; Scanlan, M.J. et al.; in relation to SEQ ID Nos. 4, 5, 15 and 16 & Database EMBL; 06.07.1999; Entry AF155116; Accession number AF155116; in relation to SEQ ID No. 7 -----	55-60, 68,69, 71,72,75
2		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/22873

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 78, 79, 81-88, 90-107 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-116 (subject 1, 4, 6 and 22 of non-unity motivation)

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-4, 14-17, 20, 30-35, 39-41, 57-59, 75, 78, 79, 81, 83, 84, 98-101, 104, 109, 110, 112-114

1. The terms NA group 1, NA group 2, etc. and PP group 1, PP group 2, etc. are applicants own reference signs and have therefore no recognised meaning. Consequently, all claims in which these terms are used are unclear within the meaning of Article 6 PCT. For the purposes of the search the terms have been interpreted as shown in the description, pages 14 and 15.

2. Present claims 1, 2 (as far as points (g) - (i) are concerned), 3, 4, 14-17, 20, 30, 39-41, 57-59, 75, 78, 79, 81, 98-101, 104, 109, 110, 112-114 relate to an extremely large number of products and methods defined inter alia by reference to a desirable characteristic or property, namely in the case of
1) claims 1-4: "specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule"
2) claims 14-17 and 20, 78, 79, 81, 83, 84 and claims 98-101 as far as they relate to claims 14-17: "enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen"
3) claims 30-35, 39-41: "binds selectively to a..... polypeptide"
4) claims 57-59 and 75: "of sufficient length to represent a sequence unique within the human genome"
5) claim 104: "inhibits the expression or activity of the protein"
6) claims 109, 110, 112-114: "bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein"

The above mentioned claims cover all products and methods having or using a compound having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a few or even none of these compounds or methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the complete claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound or method inter alia by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely:
group 1) of claims: antibodies reacting with a peptide encoded by SEQ ID 1 and nucleic acids hybridizing to SEQ ID No. 1
group 2) of claims: polypeptides encoded by SEQ ID No. 1, host cells expressing them, complexes of said polypeptide with HLA, nucleic acid having SEQ ID No. 1.
group 3 of claims: antibodies and fragments thereof reacting with polypeptides encoded by SEQ ID No. 1
group 4 of claims: complete SEQ ID No. 1
group 5 of claims: antibodies reacting with a polypeptide encoded by SEQ

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

ID No. 1

group 6 of claims: no search

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-
116 all partially as far as they relate to SEQ ID N.
os. 1 and 12

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID No. 1 (cl. 42, 43, 55) or the corresponding protein (cl. 48, 68) and HLA binding fragments (cl. 56, 71, 72, 109), an expression vector comprising said DNA molecule (cl. 61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID No. 1 which are long enough to represent a sequence unique within the human genome (cl. 57, 75).
Kit for detecting the presence of a SEQ ID No. 1 molecule using nucleotide fragments of SEQ ID NO.1 (cl. 76)
Method of treatment consisting essentially of increasing the immune response to a molecule encoded by SEQ ID NO. 1 (cl. 78, 85, 88, 102) or in the administration of an antibody to such a molecule (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID No. 1 or encoded molecules, fragments, etc. (cl.5)

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules with polypeptides encoded by SEQ ID No. 1 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to a polypeptide encoded by SEQ ID No. 1 molecule and fragments (cl. 30-34) or a conjugate thereof (cl. 39).

Method of treatment by inhibiting expression of a polypeptide encoded by SEQ ID No. 1 molecule (cl. 104).

Method of diagnosing using an agent binding to SEQ ID No. 1 or encoded molecule (cl.1)

2. Claims: 1-10, 12, 14-17, 19-22, 24, 26-33, 35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-
116 all partially as far as they relate to SEQ ID N.
os. 2 and 13

essentially idem as for subject 1, but related to SEQ ID Nos. 2 and 13

3. Claims: 1-10, 12, 14-17, 19-22, 24, 26-33, 35, 37-44, 46-50, 52-69, 71-79, 81-88, 90-107, 109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
os. 3 and 14

essentially idem as for subject 1, but related to SEQ ID
Nos. 3 and 14

4. Claims: 1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,
109-

116 all partially as far as they relate to SEQ ID N
os. 4, 5, 15 and 16

essentially idem as for subject 1, but related to SEQ ID
Nos. 4, 5, 15 and 16

5. Claims: 1-10, 12, 14-17, 19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-

116 all partially as far as they relate to SEQ ID N
os. 6 and 17

essentially idem as for subject 1, but related to SEQ ID
Nos. 6 and 17

6. Claims: 1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,
109-

116 all partially as far as they relate to SEQ ID N
os. 7 and 18

essentially idem as for subject 1, but related to SEQ ID
Nos. 7 and 18

7. Claims: 1-10, 12, 14-17, 19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-

116 all partially as far as they relate to SEQ ID N
os. 8, 9, 19, 20

essentially idem as for subject 1, but related to SEQ ID
Nos. 8, 9, 19 and 20

8. Claims: 1-10, 12, 14-17, 19-22, 24, 26-33, 35, 37-44, 46-50,
52-69, 71-79, 81-88, 90-107,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
o. 10, 11, 21

essentially idem as for subject 1, but related to SEQ ID
Nos. 10, 11 and 21

9. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 22

essentially idem as for subject 1, but related to SEQ ID No.
22

10. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 23

essentially idem as for subject 1, but related to SEQ ID No.
23

11. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 24

essentially idem as for subject 1, but related to SEQ ID No.
24

12. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 25

essentially idem as for subject 1, but related to SEQ ID No.
25

13. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
o. 26

essentially idem as for subject 1, but related to SEQ ID No.
26

14. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 27

essentially idem as for subject 1, but related to SEQ ID No.
27

15. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 28

essentially idem as for subject 1, but related to SEQ ID No.
28

16. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 29

essentially idem as for subject 1, but related to SEQ ID No.
29

17. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 30

essentially idem as for subject 1, but related to SEQ ID No.
30

18. Claims: 1-9,12,14-16,19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

116 all partially as far as they relate to SEQ ID N
o. 31

essentially idem as for subject 1, but related to SEQ ID No.
31

19. Claims: 1-9, 12, 14-16, 19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 32

essentially idem as for subject 1, but related to SEQ ID No.
32

20. Claims: 1-9, 12, 14-16, 19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 33

essentially idem as for subject 1, but related to SEQ ID No.
33

21. Claims: 1-9, 12, 14-16, 19-22, 24, 26, 28-31, 35, 37-42, 44,
46-48, 50, 52-54, 69, 71-79, 81-88, 90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 34

essentially idem as for subject 1, but related to SEQ ID No.
34

22. Claims: 1-9, 11, 12, 14-16, 19-22, 24, 26, 28-31, 34, 35,
37-42, 44, 46-48, 50, 52-54, 69, 71-79, 81-88,
90-106,
109-

116 all partially as far as they relate to SEQ ID N
o. 35

essentially idem as for subject 1, but related to SEQ ID No.
35

23. Claims: 1-12, 14-17, 19-22, 24, 26-35, 37-44, 46-50, 52-69,
71-79, 81-88, 90-107,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

109-

116 all partially as far as they relate to SEQ ID N
os. 36-46

Pharmaceutical compositions or isolated molecules comprising a molecule having the sequence of SEQ ID Nos. 36-46 (cl. 42) or the corresponding protein (cl. 48, 70) and HLA binding fragments (cl. 71, 72, 109), an expression vector comprising said DNA molecule (cl. 61) and host cells comprising the expression vector (cl. 64) as well as related antibodies (cl. 115).

Fragments of SEQ ID Nos. 36-36 which are long enough to represent a sequence unique within the human genome (cl. 57). Kit for detecting the presence of a SEQ ID Nos. 36-46 molecule using nucleotide fragments of SEQ ID Nos. 36-46 (cl. 76)

Method of treatment consisting essentially in increasing the immune response to proteins encoded by SEQ ID Nos. 36-46 (cl. 78, 85, 88, 102) or in the administration of an antibody binding to the protein encoded by SEQ ID No. 36-46 (cl. 95)

Methods for determining regression, progression or onset of a condition characterized by monitoring SEQ ID Nos. 36-46 molecules or encoded fragments, etc. (cl. 5).

Pharmaceutical compositions comprising an agent that enriches selectively the presence of complexes of HLA molecules and molecules encoded by SEQ ID NOS. 36-46 (cl. 14) and use in a method of treatment (cl. 98)

Composition comprising an agent binding to proteins encoded by SEQ ID Nos. 36-46 (cl. 30, 32, 34) or a conjugate thereof (cl. 39)

Method of treatment by inhibiting expression of a protein encoded by SEQ ID Nos. 36-46 (cl. 104)

Method of diagnosing using an agent binding to SEQ ID Nos. 36-46 molecule or protein encoded (cl. 1)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No

PCT/US 99/22873

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 5665874	A 09-09-1997	US 5759791 A			02-06-1998
		US 5872217 A			16-02-1999
		US 5864011 A			26-01-1999
		US 5759837 A			02-06-1998
		AU 682007 B			18-09-1997
		AU 4786493 A			14-02-1994
		CA 2140866 A			03-02-1994
		EP 0651636 A			10-05-1995
		JP 7509470 T			19-10-1995
		MX 9304501 A			29-04-1994
		WO 9402108 A			03-02-1994
		AT 151882 T			15-05-1997
		AU 632535 B			07-01-1993
		AU 5040690 A			13-08-1990
		CA 2045552 A			26-07-1990
		DE 69030494 D			22-05-1997
		DE 69030494 T			07-08-1997
		DK 454782 T			27-10-1997
		EP 0454782 A			06-11-1991
		ES 2101695 T			16-07-1997
		JP 2959837 B			06-10-1999
		JP 4504110 T			23-07-1992
		KR 174528 B			15-05-1999
		WO 9008324 A			26-07-1990
WO 9918989	A 22-04-1999	AU 1088399 A			03-05-1999
WO 9848020	A 29-10-1998	IT MI970905 A			19-10-1998
		AU 7077998 A			13-11-1998
WO 9629409	A 26-09-1996	US 5939526 A			17-08-1999
		AU 705768 B			03-06-1999
		AU 5429896 A			08-10-1996
		CA 2211448 A			26-09-1996
		EP 0815229 A			07-01-1998
		JP 11506904 T			22-06-1999
		NZ 306122 A			29-06-1999
		ZA 9602280 A			28-08-1996

